WO1999016419A9 - Perforated microparticles and methods of use - Google Patents

Perforated microparticles and methods of use

Info

Publication number
WO1999016419A9
WO1999016419A9 PCT/US1998/020602 US9820602W WO9916419A9 WO 1999016419 A9 WO1999016419 A9 WO 1999016419A9 US 9820602 W US9820602 W US 9820602W WO 9916419 A9 WO9916419 A9 WO 9916419A9
Authority
WO
WIPO (PCT)
Prior art keywords
powder
perforated
perforated microstructures
particles
agents
Prior art date
Application number
PCT/US1998/020602
Other languages
French (fr)
Other versions
WO1999016419A1 (en
Inventor
Thomas E Tarara
Jeffry G Weers
Alexey Kabalnov
Ernest G Schutt
Luis A Dellamary
Original Assignee
Alliance Pharma
Thomas E Tarara
Jeffry G Weers
Alexey Kabalnov
Ernest G Schutt
Luis A Dellamary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999016419(A9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2000513557A priority Critical patent/JP5372306B2/en
Priority to CA002304819A priority patent/CA2304819C/en
Priority to EP98953220A priority patent/EP1019022B2/en
Priority to BR9812693-8A priority patent/BR9812693A/en
Priority to NZ503464A priority patent/NZ503464A/en
Priority to AT98953220T priority patent/ATE238035T1/en
Priority to DK98953220.5T priority patent/DK1019022T4/en
Priority to AU10644/99A priority patent/AU757337C/en
Application filed by Alliance Pharma, Thomas E Tarara, Jeffry G Weers, Alexey Kabalnov, Ernest G Schutt, Luis A Dellamary filed Critical Alliance Pharma
Priority to ES98953220T priority patent/ES2195408T5/en
Priority to DE69813853T priority patent/DE69813853T3/en
Priority to MEP-2008-41A priority patent/ME00003B/en
Priority to MEP-41/08A priority patent/MEP4108A/en
Priority to EA200000375A priority patent/EA002562B1/en
Priority to SK449-2000A priority patent/SK285068B6/en
Priority to KR1020007003367A priority patent/KR100589926B1/en
Priority to IL13512698A priority patent/IL135126A0/en
Priority to EEP200000194A priority patent/EE04628B1/en
Priority to PL98339732A priority patent/PL195212B1/en
Priority to US09/219,736 priority patent/US6565885B1/en
Priority to AU35469/99A priority patent/AU760537B2/en
Priority to CA002335940A priority patent/CA2335940A1/en
Priority to EP99917320A priority patent/EP1091755A1/en
Priority to JP2000556800A priority patent/JP2003535017A/en
Priority to KR1020007015026A priority patent/KR100796220B1/en
Publication of WO1999016419A1 publication Critical patent/WO1999016419A1/en
Publication of WO1999016419A9 publication Critical patent/WO1999016419A9/en
Priority to IL135126A priority patent/IL135126A/en
Priority to IS5415A priority patent/IS2154B/en
Priority to HR20000175A priority patent/HRP20000175B1/en
Priority to NO20001618A priority patent/NO340149B1/en
Priority to HK01100524A priority patent/HK1031680A1/en
Priority to US09/886,296 priority patent/US8168223B1/en
Priority to US10/096,780 priority patent/US7306787B2/en
Priority to US10/612,393 priority patent/US20050074498A1/en
Priority to US10/616,448 priority patent/US20040105820A1/en
Priority to US11/317,839 priority patent/US20060165606A1/en
Priority to US11/317,523 priority patent/US20060159629A1/en
Priority to US12/774,540 priority patent/US9554993B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926Topical chemical, e.g. cosmetic or sunscreen

Definitions

  • the present invention relates to formulations and methods for the production of perforated microstructures which comprise an active agent
  • the active agent will comprise a bioactive agent.
  • the perforated microstructures will preferably be used in conjunction with inhalation devices such as a metered dose inhaler, dry powder inhaler or nebulizer for both topical and systemic delivery via pulmonary or nasal routes.
  • Targeted drug delivery means are particularly desirable where toxicity or bioavailabi ty of the pharmaceutical compound is an issue.
  • Specific drug delivery methods and compositions that effectively deposit the compound at the site of action potentially serve to minimize toxic side effects, lower dosing requirements and decrease therapeutic costs.
  • the development of such systems for pulmonary drug delivery has long been a goal of the pharmaceutical industry.
  • MDIs dry powder inhalers
  • MDIs metered dose inhalers
  • nebulizers the most popular method of inhalation administration, may be used to deliver medicaments in a solubilized form or as a dispersion.
  • MDIs comp ⁇ se a Freon or other relatively high vapor pressure propellant that forces aerosolized medication into the respiratory tract upon activation of the device.
  • DPIs generally rely entirely on the patient's inspiratory efforts to introduce a medicament in a dry powder form to the lungs.
  • nebulizers form a medicament aerosol to be inhaled by imparting energy to a liquid solution. More recently, direct pulmonary delivery of drugs du ⁇ ng liquid ventilation or pulmonary lavage using a fluorochemical medium has also been explored. While each of these methods and associated systems may prove effective in selected situations, inherent drawbacks, including formulation limitations, can limit their use.
  • the MDI is dependent on the propulsive force of the propellant system used in its manufacture.
  • the propellant system has consisted of a mixture of chiorofluorocarbons (CFCs) which are selected to provide the desired vapor pressure and suspension stability.
  • CFCs such as Freon 11, Freon 12, and Freon 114 are the most widely used propellents in aerosol formulations for inhalation administration.
  • the selected bioactive agent is typically incorporated in the form of a fine particulate to provide a dispersion.
  • surfactants are often used to coat the surfaces of the bioactive agent and assist in wetting the particles with the aerosol propellant.
  • While selected compounds in these classes may function effectively as biocompatible propellants, many of the surfactants that were effective in stabilizing drug suspensions in CFCs are no longer effective in these new propellant systems.
  • solubility of the surfactant in the HFA decreases, diffusion of the surfactant to the interface between the drug particle and HFA becomes exceedingly slow, leading to poor wetting of the medicament particles and a loss of suspension stability. This decreased solubility for surfactants in HFA propellants is likely to result in decreased efficacy with regard to any incorporated bioactive agent.
  • drug suspensions in liquid fluorochemtcais comprise heterogeneous systems which usually require redispersion prior to use. Yet, because of factors such as patient compliance obtaining a relatively homogeneous distribution of the pharmaceutical compound is not always easy or successful.
  • prior art formulations comprising micronized particulates may be prone to aggregation of the particles which can result in inadequate delivery of the drug Crystal growth of the suspensions via Ostwald ripening may also lead to particle size heterogeneity and can significantly reduce the shelf life of the formulation
  • Another problem with conventional dispersions comprising micronized dispersants is particle coarsening.
  • Coarsening may occur via several mechanisms such as flocculatio ⁇ , fusion, molecular diffusion, and coalescence Over a relatively short period of time these processes can coarsen the formulation to the point where it is no longer usable.
  • conventional systems compnsi ⁇ g fluorochemical suspensions for MDIs or liquid ventilation are certainly a substantial improvement over p ⁇ or art non fluorochemical delivery vehicles, the drug suspensions may be improved upon to enable formulations with improved stability that also offer more efficient and accurate dosing at the desired site
  • conventional powdered preparations for use in DPIs often fail to provide accurate, reproducible dosing over extended periods In this respect, those skilled in the art will appreciate that conventional powders (i.e.
  • micronized tend to aggregate due to hydrophobic or electrostatic interactions between the fine particles
  • These changes in particle size and increases in cohesive forces over time tend to provide powders that give undesirable pulmonary distribution profiles upon activation of the device.
  • fine particle aggregation disrupts the aerodynamic properties of the powder, thereby preventing large amounts of the aerosolized medicament from reaching the deeper airways of the lung where it is most effective
  • the methods and associated compositions of the present invention provide, in a broad aspect, for the improved delivery of agents to a desired site. More particularly, the present invention may provide for the delivery of bioactive agents to selected physiological target sites using perforated microstructure powders In preferred embodiments, the bioactive agents are in a form for administration to at least a portion of the pulmonary air passages of a patient in need thereof To that end, the present invention provides for the formation and use of perforated microstructures and delivery systems comprising such powders, as well as individual components thereof.
  • the disclosed powders may further be dispersed in selected suspension media to provide stabilized dispersions Unlike prior art powders or dispersions for drug delivery, the present invention preferably employs novel techniques to reduce attractive forces between the particles As such, the disclosed powders exhibit improved flowability and dispersibilty while the disclosed dispersions exhibit reduced degradation by flocculation, sedimentation or creaming. Moreover, the stabilized preparations of the present invention preferably comp ⁇ se a suspension medium (e g a fluorochemical) that further serves to reduce the rate of degradation with respect to the incorporated bioactive agent. Accordingly, the dispersions or powders of the present invention may be used in conjunction with metered dose inhalers, dry powder inhalers atomizers, nebulizers or liquid dose instillation (LDI) techniques to provide for effective drug delivery
  • LDDI liquid dose instillation
  • the hollow and/or porous perforated microstructures substantially reduce attractive molecular forces, such as van der Waals forces, which dominate p ⁇ or art powdered preparations and dispersions.
  • the powdered compositions typically have relatively low bulk densities which cont ⁇ bute to the flowability of the preparations while providing the desired characteristics for inhalation therapies.
  • the use of relatively low density perforated (or porous) microstructures or microparticulates significantly reduces attractive forces between the particles thereby lowe ⁇ ng the shear forces and increasing the flowability of the resulting powders.
  • the relatively low density of the perforated microstructures also provides for supenor aerodynamic performance when used in inhalation therapy.
  • select embodiments of the invention provide for powders having increased dispersibility compnsing a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm 3 wherein said perforated microstructure powder compnses an active agent.
  • the perforated microstructures may be formed of any biocompatible matenal providing the desired physical characte ⁇ stics or morphology.
  • the perforated microstructures will preferably comp ⁇ se pores, voids, defects or other interstitial spaces that act to reduce attractive forces by minimizing surface interactions and decreasing shear forces Yet, given these constraints, it will be appreciated that any material or configuration may be used to form the microstructure matrix.
  • the selected mate ⁇ als it is desirable that the microstructure incorporates at least one surfactant.
  • this surfactant will comp ⁇ se a phospho pid or other surfactant approved for pulmonary use.
  • the microstructures incorporate at least one active agent which may be a bioactive agent
  • the microstructures incorporate at least one active agent which may be a bioactive agent
  • the perforated microstructures will further comprise a bioactive agent
  • the present invention provides for the use of a bioactive agent in the manufacture of a medicament for pulmonary delivery whereby the medicament comp ⁇ ses a plurality of perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament compnsing said bioactive agent wherein said aerosolized medicament is administered to at least a portion of the nasal or pulmonary air passages of a patient in need thereof.
  • the present invention compnses methods for forming perforated microstructures that exhibit improved dispersibility.
  • the disclosed perforated microstructures reduce attractive molecular forces, such as van der Waals forces, which dominate p ⁇ or art powdered preparations. That is, unlike pnor art preparations comprising relatively dense, solid particles or nonporous particles (e.g. micronized), the powdered compositions of the present invention exhibit increased flowability and dispersibility due to the lower shear forces. In part, this reduction in cohesive forces is a result of the novel production methods used to provide the desired powders.
  • preferred embodiments of the invention provide methods for forming a perforated microstructure compnsing the steps of: providing a liquid feed stock compnsing an active agent; atomizing said liquid feed stock to produce dispersed liquid droplets; drying said liquid droplets under predetermined conditions to form perforated microstructures compnsing said active agent; and collecting said perforated microstructures.
  • the particles will be spray d ⁇ ed using commercially available equipment.
  • the feed stock will preferably compnse a blowing agent that may be selected from fiuo ⁇ nated compounds and nonfluo ⁇ nated oils.
  • the fluo ⁇ nated compounds will have a boiling point of greater than about 60°C.
  • the fluo ⁇ nated blowing agent may be retained in the perforated microstructures to further increase the dispersibility of the resulting powder or improve the stability of dispersions incorporating the same.
  • nonfluo ⁇ nated oils may be used to increase the solubility of selected bioactive agents (e.g. steroids) in the feed stock, resulting in increased concentrations of bioactive agents in the perforated microstructures.
  • the dispersibility of the perforated microstructure powders may be increased by reducing, or minimizing, the van der Waals attractive forces between the constituent perforated microstructures
  • the present invention further provides methods for increasing the dispersibility of a powder compnsing the steps of: providing a liquid feed stock compnsing an active agent; and spray drying said liquid feed stock to produce a perforated microstructure powder having a bulk density of less than about 0.5 g/cm 3 wherein said powder exhibits reduced van der Waals attractive forces when compared to a relatively non porous powder of the same composition
  • the perforated microstructures will compnse hollow, porous microspheres.
  • the blowing agent may be dispersed in the earner using techniques known in the art for the production of homogenous dispersions such a sonication, mechanical mixing or high pressure homogenization.
  • Other methods contemplated for the dispersion of blowing agents in the feed solution include co mixing of two fluids p ⁇ or to atomization as described for double nebulization techniques.
  • the atomizer can be customized to optimize the desired particle characte ⁇ stics such as particle size.
  • a double liquid nozzle may be employed.
  • the blowing agent may be dispersed by introducing the agent into the solution under elevated pressures such as in the case of nitrogen or carbon dioxide gas.
  • the present invention provides systems for the pulmonary administration of a bioactive agent to a patient comprising: an inhalation device compnsing a reservoir; and a powder in said reservoir wherein said powder compnses a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm 3 wherein said perforated microstructure powder compnses a bioactive agent whereby said inhalation device provides for the aerosolized administration of said powder to at least a portion of the pulmonary air passages of a patient in need thereof.
  • an inhalation device may comp ⁇ se an atomizer, a sprayer, a dry powder inhaler, a metered dose inhaler or a nebulizer.
  • the reservior may be a unit dose container or bulk reservior.
  • the perforated microstructure powders may be dispersed in an appropnate suspension medium to provide stabilized dispersions for delivery of a selected agent.
  • Such dispersions are particularly useful in metered dose inhalers and nebulizers
  • particularly preferred suspension mediums comp ⁇ se fiuorochemicals (e.g. perfluorocarbo ⁇ s or fluorocarbons) that are liquid at room temperature.
  • fiuorochemicals e.g. perfluorocarbo ⁇ s or fluorocarbons
  • fiuorochemicals may be able to provide for the dispersion of particles deeper into the lung, thereby improving systemic delivery
  • fiuorochemicals are also bacte ⁇ ostatic thereby decreasing the potential for microbial growth in compatible preparations
  • bioactive agent refers to a substance which is used in connection with an application that is therapeutic or diagnostic in nature, such as methods for diagnosing the presence or absence of a disease in a patient and/or methods for treating disease in a patient
  • bioactive agent may be selected from the group consisting of antiallergics, bronchodilators, bro ⁇ choco ⁇ st ⁇ ctors, pulmonary lung surfactants, analgesics, antibiotics, leukot ⁇ ene inhibitors or antagonists, anticholinergics, mast cell inhibitors, antihistamines, antii ⁇ flammato ⁇ es, antineoplastics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material,
  • the present invention provides methods for the pulmonary delivery of one or more bioactive agents compnsing the steps of: providing a powder compnsing a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm 3 wherein said perforated microstructure powder comp ⁇ ses a bioactive agent; aerosolizing said perforated microstructure powder to provide an aerosolized medicament; and admiraste ⁇ ng a therapeutically effective amount of said aerosolized medicament to at least a portion of the nasal or pulmonary passages of a patient in need thereof.
  • aerosolized shall be held to mean a gaseous suspension of fine solid or liquid particles unless otherwise dictated by contextual restraints. That is, an aerosol or aerosolized medicament may be generated, for example, by a dry powder inhaler, a metered dose inhaler, an atomizer or a nebulizer.
  • the selected agent or bioactive agent, or agents may be used as the sole structural component of the perforated microstructures.
  • the perforated microstructures may compnse one or more components (i e. structural mate ⁇ als, surfactants, excipients, etc ) in addition to the incorporated agent.
  • the suspended perforated microstructures will comprise relatively high concentrations of surfactant (greater than about 10% w/w) along with an incorporated bioactive agent(s).
  • particulate or perforated microstructure may be coated, linked or otherwise associated with an agent or bioactive agent in a non integral manner Whatever configuration is selected, it will be appreciated that any associated bioactive agent may be used in its natural form, or as one or more salts known in the art
  • the powders or stabilized dispersions of the present invention are particularly suitable for the pulmonary administration of bioactive agents, they may also be used for the localized or systemic administration of compounds to any location of the body. Accordingly, it should be emphasized that, in preferred embodiments, the formulations may be administered using a number of different routes including, but not limited to, the gastrointestinal tract, the respiratory tract, topically, intramuscularly, intrape ⁇ toneally, nasally, vagmally, rectaily, aurally, orally or ocularly.
  • Figs. 1 A1 to 1 F2 illustrate changes in particle morphology as a function of va ⁇ ation in the ratio of fluorocarbon blowing agent to phosphohpid (PFC/PC) present in the spray dry feed.
  • the micrographs produced using scanning electron microscopy and transmission electron microscopy techniques, show that in the absence of FCs, or at low PFC/PC ratios, the resulting spray dried microstructures comprising gentamicin sulfate are neither particularly hollow nor porous. Conversely, at high PFC/PC ratios, the particles contain numerous pores and are substantially hollow with thin wails.
  • Fig. 2 depicts the suspension stability of gentamicin particles in Perflubron as a function of formulation PFC/PC ratio or particle porosity. The particle porosity increased with increasing PFC'PC ratio.
  • Fig. 3 is a scanning electron microscopy image of perforated microstructures comprising cromolyn sodium illustrating a preferred hollow/porous morphology.
  • Figs. 4A to 4D are photographs illustrating the enhanced stability provided by the dispersions of the present invention over time as compared to a commercial cromolyn sodium formulation (Intaf, Rhone-Poulenc- Rorer). In the photographs, the commercial formulation on the left rapidly separates while the dispersion on the right, formed in accordance with the teachings herein, remains stable over an extended period.
  • Fig. 5 presents results of in-vitro Andersen cascade impactor studies comparing the same hollow porous albuterol sulfate formulation delivered via a MDI in HFA-134a, or from an exemplary DPI. Efficient delivery of particles was observed from both devices. MDI delivery of the particles was maximized on plate 4 corresponding to upper airway delivery. DPI delivery of the particles results in substantial deposition on the later stages in the impactor corresponding to improved systemic delivery in-vivo.
  • the present invention provides methods, systems and compositions that comprise perforated microstructures which, in preferred embodiments, may advantageously be used for the delivery of bioactive agents.
  • the disclosed perforated microstructure powders may be used in a dry state (e.g. as in a DPI) or in the form of a stabilized dispersion (e.g. as in a MDI, LDI or nebulizer formulation) to deliver bioactive agents to the nasal or pulmonary air passages of a patient.
  • the perforated microstructures disclosed herein comprise a structural matrix that exhibits, defines or comprises voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes.
  • the absolute shape (as opposed to the morphology) of the perforated microstructure is generally not critical and any overall configuration that provides the desired characteristics is contemplated as being within the scope of the invention. Accordingly, preferred embodiments can comprise approximately microspherical shapes. However, collapsed, deformed or fractured particulates are also compatible. With this caveat, it will further be appreciated that, particularly preferred embodiments of the invention comprise spray dried hollow, porous microspheres. In any case the disclosed powders of perforated microstructures provide several advantages including, but not limited to, increases in suspension stability, improved dispersibility, superior sampling characteristics, elimination of carrier particles and enhanced aerodynamics.
  • the present invention provides unique methods and compositions to reduce cohesive forces between dry particles, thereby minimizing paniculate aggregation which can result in an improved delivery efficiency.
  • the disclosed preparations provide a highly flowable, dry powders that can be efficiently aerosolized, uniformly delivered and penetrate deeply in the lung or nasal passages.
  • the perforated microstructures of the present invention result in surprisingly low throat deposition upon administration.
  • the perforated microstructure powders have relatively low bulk density, allowing the powders to provide superior sampling properties over compositions known in the art.
  • many commercial dry powder formulations comprise large lactose particles which have micronized drug aggregated on their surface.
  • the lactose particles serve as a carrier for the active agents and as a bulking agent, thereby providing means to partially control the fine particle dose delivered from the device.
  • the lactose particles provide the means for the commercial filling capability of dry particles into unit dose containers by adding mass and volume to the dosage form.
  • the present invention uses methods and compositions that yield powder formulations having extraordinarily low bulk density, thereby reducing the minimal filling weight that is commercially feasible for use in dry powder inhalation devices. That is, most unit dose containers designed for DPIs are filled using fixed volume or gravimetric techniques. Contrary to prior art formulations, the present invention provides powders wherein the active or bioactive agent and the incipients or bulking agents make-up the entire inhaled particle. Compositions according to the present invention typically yield powders with bulk densities less than 0.5 g/cm 3 or 0.3 g/cm 3 , preferably less 0.1 g/cm 3 and most preferably less than
  • the minimum powder mass that can be filled into a unit dose container is reduced, which eliminates the need for carrier particles. That is, the relatively low density of the powders of the present invention provides for the reproducible administration of relatively low dose pharmaceutical compounds. Moreover, the elimination of carrier particles will potentially minimize throat deposition and any "gag" effect, since the large lactose particles will impact the throat and upper airways due to their size.
  • the perforated microstructures will preferably be provided in a "dry" state. That is the microparticles will possess a moisture content that allows the powder to remain chemically and physically stable during storage at ambient temperature and easily dispersibie. As such, the moisture content of the microparticles is typically less than 6% by weight, and preferably less 3% by weight. In some instances the moisture content will be as low as 1 % by weight.
  • the moisture content is, at least in part, dictated by the formulation and is controlled by the process conditions employed, e.g., inlet temperature, feed concentration, pump rate, and blowing agent type, concentration and post drying
  • the composition of the structural matrix defining the perforated microstructures may be formed of any mate ⁇ al which possesses physical and chemical characte ⁇ stics that are compatible with any incorporated active agents. While a wide va ⁇ ety of matenals may be used to form the particles, in particularly preferred pharmaceutical embodiments the structural matrix is associated with, or comp ⁇ ses, a surfactant such as phosphohpid or fluonnated surfactant.
  • the incorporation of a compatible surfactant can improve powder flowability, increase aerosol efficiency, improve dispersion stability, and facilitate preparation of a suspension.
  • structural mat ⁇ x or “microstructure mat ⁇ x” are equivalent and shall be held to mean any solid atenal forming the perforated microstructures which define a plurality of voids, apertures, hollows, defects, pores, holes, fissures, etc. that provide the desired characte ⁇ stics.
  • the perforated microstructure defined by the structural mat ⁇ x comp ⁇ ses a spray dned hollow porous microsphere incorporating at least one surfactant. It will further be appreciated that, by altering the matrix components, the density of the structural matrix may be adjusted.
  • the perforated microstructures preferably comp ⁇ se at least one active or bioactive agent.
  • the perforated microstructures of the present invention may optionally be associated with, or comp ⁇ se, one or more surfactants.
  • miscible surfactants may optionally be combined in the case where the microparticles are formulated in a suspension medium liquid phase
  • surfactants while not necessary to practice the instant invention, may further increase dispersion stability, powder flowability, simplify fomiulation procedures or increase efficiency of delivery
  • combinations of surfactants including the use of one or more in the liquid phase and one or more associated with the perforated microstructures are contemplated as being within the scope of the invention
  • associated with or comp ⁇ se it is meant that the structural mat ⁇ x or perforated microstructure may incorporate, adsorb, absorb, be coated with or be formed by the surfactant.
  • surfactants suitable for use in the present invention include any compound or composition that aids in the formation of perforated microparticles or provides enhanced suspension stability, improved powder dispersibility or decreased particle aggregation.
  • the surfactant may comp ⁇ se a single compound or any combination of compounds, such as in the case of co surfactants.
  • Particularly preferred surfactants are nonfluonnated and selected from the group consisting of saturated and unsaturated lipids, no ⁇ ionic detergents, nomonic block copolymers, ionic surfactants and combinations thereof. In those embodiments comprising stabilized dispersions, such nonfluonnated surfactants will preferably be relatively insoluble in the suspension medium.
  • suitable fluonnated surfactants are compatible with the teachings herein and may be used to provide the desired preparations.
  • Lipids, including phospholipids, from both natural and synthetic sources are particularly compatible with the present invention and may be used in varying concentrations to form the structural mat ⁇ x.
  • Generally compatible lipids comprise those that have a gel to liquid crystal phase transition greater than about 40°C.
  • the incorporated lipids are relatively long chain d e C, B C 22 ) saturated pids and more preferably comprise phospholipids.
  • Exemplary phospholipids useful in the disclosed stabilized preparations compnse, dipalmitoylphosphatidylchohne, disteroylphosphatidylchohne, diarachidoylphosphatidylcholine dibehenoylphosphatidylchohne, short chain phosphatidylcholmes, long-chain saturated phosphatidylethanolamines, long chain saturated phosphatidylserines, long chain saturated phosphatidylglycerols, long chain saturated phosphatidyhnositols, glyco pids, ganghoside GM1, sphingomyelin, phosphatidic acid, cardiolipin; lipids bearing polymer chains such as polyethylene glycol, chitin, hyaluromc acid, or polyvinylpyrrohdo ⁇ e, lipids bearing sulfonated mono , di , and poiysaccha ⁇ des, fatty acids such as palmitic acid, steanc
  • Preferred block copolymers include diblock and tnblock copolymers of polyoxyethylene and polyoxypropylene, including poloxamer 188 (Pluronic * F 68), poloxamer 407 (Pluronic " F 127), and poloxamer 338.
  • Ionic surfactants such as sodium sulfosuccinate, and fatty acid soaps may also be utilized.
  • the microstructures may comprise oleic acid or its alkali salt.
  • cationic surfactants or lipids are preferred especially in the case of delivery or RNA or DMA
  • suitable cationic lipids include: DOTMA, N [1 (2,3 dioleyloxylpropyl] N,N,N t ⁇ methylammo ⁇ ium chloride, DOTAP, 1,2 dioleyloxy 3 (tr ⁇ methylammon ⁇ o)propane, and DOTB, 1,2 dioleyl 3 (4' t ⁇ methylammoniolbutanoyl sn glycerol
  • Polycationic ammo acids such as polylysme, and polyargimne are also contemplated.
  • surfactants compnsing the structural matrix may also be useful in the formation of precursor oil in water emulsions (i ⁇ . spray drying feed stock) used du ⁇ ng processing to form the perforated microstructures.
  • the incorporation of relatively high levels of surfactants may be used to improve powder dispersibility, increase suspension stability and decrease powder aggregation of the disclosed applications. That is, on a weight to weight basis, the structural mat ⁇ x of the perforated microstructures may comp ⁇ se relatively high levels of surfactant.
  • the perforated microstructures will preferably compnse greater than about 1 %, 5%, 10%, 15%, 18%, or even 20% w/w surfactant. More preferably, the perforated microstructures will compnse greater than about 25%, 30%, 35%, 40%, 45%, or 50% w/w surfactant.
  • Still other exemplary embodiments will comp ⁇ se perforated microstructures wherein the surfactant or surfactants are present at greater than about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or even 95% w/w.
  • the perforated microstructures will comp ⁇ se essentially 100% w/w of a surfactant such as a phosphohpid.
  • a surfactant such as a phosphohpid.
  • surfactant levels are preferably employed in perforated microstructures, they may be used to provide stabilized systems compnsing relatively nonporous, or substantially solid, particulat ⁇ s. That is, while preferred embodiments will comp ⁇ se perforated microstructures associated with high levels of surfactant, acceptable microspheres may be formed using relatively low porosity particulates of the same surfactant concentration (i.e greater than about 20% w/w). In this respect such high surfactant embodiments are specifically contemplated as being within the scope of the present invention.
  • the structural mat ⁇ x defining the perforated microstructure optionally comp ⁇ ses synthetic or natural polymers or combinations thereof.
  • useful polymers comp ⁇ se polylactides, polylactide-glycolides, cyclodext ⁇ ns, polyacrylates, methylcellulose, carboxymethylcellulose, polyvinyl alcohols, polyanhydndes, polylactams, polyvinyl pyrrolidones, polysacchandes (dextrans, starches, chitin, chitosan, etc.), hyaluronic acid, proteins, (albumin, collagen, gelatin, etc.).
  • polymeric resins that would be useful for the preparation of perforated ink microparticles include: styrene butadiene, styre ⁇ e-isoprene, styrene acrylo ⁇ itnle, ethylene-vmyl acetate, ethylene-acrylate, ethylene-acry c acid, ethylene methylacrylatate, ethylene ethyl acrylate, vinyl methyl methacrylate, acrylic acid methyl methacrylate, and vinyl chloride-vinyl acetate.
  • the delivery efficiency of the perforated microparticles and/or the stability of the dispersions may be tailored to optimize the effectiveness of the active or bioactive agent.
  • excipients include, but are not limited to- coloring agents, taste masking agents, buffers, hygroscopic agents, a ⁇ tioxida ⁇ ts, and chemical stabilizers.
  • excipients may be incorporated in, or added to, the paniculate matrix to provide structure and form to the perforated microstructures (i.e. microspheres such as latex particles).
  • the ⁇ gidifying components can be removed using a post-production technique such as selective solvent extraction.
  • ngidifying excipients may include, but are not limited to, carbohydrates including monosaccha ⁇ des, disaccha ⁇ des and polysacchandes.
  • monosacchandes such as dextrose (anhydrous and monohydrate), galactose, mannitol, D-mannose, sorbitol, sorbose and the like; disacchandes such as lactose, maltose, sucrose, trehalos ⁇ , and the like; trisacchandes such as raffmose and the like; and other carbohydrates such as starches (hydroxyethylstarch), cyclodext ⁇ s and maltodext ⁇ ns.
  • Ammo acids are also suitable excipients with glycine preferred. Mixtures of carbohydrates and ammo acids are further held to be within the scope of the present invention.
  • inorganic e.g. sodium chloride, calcium chloride, etc.
  • organic salts e.g. sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluco ⁇ ate, tromethamine hydrochloride, etc.
  • buffers e.g. sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluco ⁇ ate, tromethamine hydrochloride, etc.
  • salts and organic solids such as ammonium carbonate, ammonium acetate, ammonium chloride or camphor are also contemplated
  • Yet other preferred embodiments include perforated microstructures that may comp ⁇ se, or may be coated with, charged species that prolong residence time at the point of contact or ⁇ nhanc ⁇ penetration through mucosae.
  • anionic charges are known to favor mucoadhesion while cationic charges may be used to associate the formed microparticulate with negatively charged bioactive agents such as genetic matenal.
  • the charges may be imparted through the association or incorporation of polyaniomc or polycationic mate ⁇ als such as polyacry c acids, polylysine, polylactic acid and chitosan.
  • the perforated microstructures will preferably comp ⁇ se at least one active or bioactive agent
  • active agent simply refers to a substance that enables the perforated microstructures to perform the desired function.
  • bioactive agent shall be held inclusive of the term “bioactive agent” unless otherwise dictated by contextual restraints As to the term “bioactive agent” it shall be held to comp ⁇ se any substance that is used in connection with the diagnosis or treatment of a disease, condition or physiological abnormality in a patient
  • bioactive agent it shall be held to comp ⁇ se any substance that is used in connection with the diagnosis or treatment of a disease, condition or physiological abnormality in a patient
  • bioactive agents for use in accordance with the invention include anti allergies, peptides and proteins, pulmonary lung surfactants, bronchodilators and anti inflammatory steroids for use in the treatment of respiratory disorders such as asthma by inhalation therapy.
  • Preferred active agents for use in accordance with the present invention include pigments, dyes, inks, paints, detergents, food sweeteners, spices, adsorbants, absorbents, catalysts, nucleating agents, thickening agents, polymers, resins, insulators, fillers, fertilizers, phytohormones, insect pheromones, insect repellents, pet repellents, antifou ng agents, pesticides, fungicides, disinfectants, perfumes, deodorants, and combinations of thereof.
  • the perforated microstructures of the present invention may exclusively comp ⁇ se one or more active or bioactive agents (i.e. 100% w/w). However, in selected embodiments the perforated microstructures may incorporate much less bioactive agent depending on the activity thereof. Accordingly, for highly active matenals the perforated microstructures may incorporate as little as 0.001 % by weight although a concentration of greater than about 0.1 % w/w is preferred. Other embodiments of the invention may comp ⁇ se greater than about 5%, 10%, 15%, 20%, 25%, 30% or even 40% w/w active or bioactive agent.
  • the perforated microstructures may comprise greater than about 50%, 60%, 70%, 75%, 80% or even 90% w/w active or bioactive agent.
  • the precise amount of active or bioactive agent incorporated in the perforated microstructures of the present invention is dependent upon the agent of choice, the required dose, and the form of the agent actually used for incorporation. Those skilled in the art will appreciate that such determinations may be made by using well-known pharmacological techniques in combination with the teachings of the present invention.
  • any bioactive agent that may be formulated in the disclosed perforated microstructures is expressly held to be within the scope of the present invention.
  • the selected bioactive agent may be administered in the form of an aerosolized medicaments.
  • particularly compatible bioactive agents comprise any drug that may be formulated as a flowable dry powder or which is relatively insoluble in selected dispersion media
  • the formulated agents are subject to pulmonary or nasal uptake in physiologically effective amounts.
  • bioactive agents comp ⁇ se hydrophi c and Iipophi c respiratory agents, pulmonary surfactants, bronchodilators, antibiotics, antivirals, anti-infiammatones, steroids, antihistaminics, leukot ⁇ ene inhibitors or antagonists, anticholinergics, antineoplastics, anesthetics, enzymes, cardiovascular agents, genetic matenal including DNA and RNA, viral vectors, immu ⁇ oactive agents, imaging agents, vaccines, immunosuppressive agents, peptides, proteins and combinations thereof.
  • Particularly preferred bioactive agents for inhalation therapy comprise mast cell inhibitors (anti allergies), bronchodilators, and anti inflammatory steroids such as, for example, cromoglycate (e.g. the sodium salt), and albuterol (e.g. the sulfate salt).
  • exemplary medicaments or bioactive agents may be selected from, for example, analgesics, e g. codeine, dihydromorphine, ergotamine, f ⁇ ntanyl, or morphine; anginal preparations, e.g. diltiazem; mast c ⁇ ll inhibitors, e.g. cromolyn sodium; antimfectives, e.g. cephalospo ⁇ ns, macrohdes, quinolines, penicillins, streptomycin, sulphona ides, tetracyclines and pentamidme; antihistami ⁇ es, e g methapy ⁇ lene; anti-inflammato ⁇ es, e.g.
  • analgesics e g. codeine, dihydromorphine, ergotamine, f ⁇ ntanyl, or morphine
  • anginal preparations e.g. diltiazem
  • mast c ⁇ ll inhibitors e.g
  • fluticaso ⁇ e propionate beclomethasone dipropionate, flunisolide, budesomde, t ⁇ pedane, cortisone, predmsone, predmsilone, dexamethasone, beta ethasone, or t ⁇ amcinolone acetomde; a ⁇ titussives, e.g. ⁇ oscapine; bronchodilators, e.g.
  • ephednne adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, salbuta ol, albuterol, salmeterol, terbutaline; diuretics, e.g amilo ⁇ de; anticholinergics, e.g. ipatropium, atropine, or oxitropium; lung surfactants e.g. Surfaxi ⁇ , Exosurf, Survanta; xanthi ⁇ es, e.g. aminophylline, theophylhne, caffeine; therapeutic proteins and peptides, e g.
  • bioactive agents that comp ⁇ se an RNA or DNA sequence particularly those useful for gene therapy, genetic vaccination, genetic tolenzation or antisense applications, may be incorporated in the disclosed dispersions as desc ⁇ bed herein.
  • ONA plasmids include, but are not limited to pCMV ⁇ (available from Genzyme Corp, Framington, MA) and pCMV- ⁇ -gal (a CMV promotor linked to the E. coli Lac-Z gene, which codes for the enzyme ⁇ galactosidasel.
  • the selected active or bioactive agent(s) may be associated with, or incorporated in, the perforated microstructures in any form that provides the desired efficacy and is compatible with the chosen production techniques.
  • the terms "associate” or “associating” mean that the structural matrix or perforated microstructure may comp ⁇ se, incorporate, adsorb, absorb, be coated with or be formed by the active or bioactive agent.
  • the actives may be used in the form of salts (e g. alkali metal or amine salts or as acid addition salts) or as esters or as solvates (hydrates).
  • the form of the active or bioactive agents may be selected to optimize the activity and/or stability of the actives and/or to minimize the solubility of the agent in the suspension medium and/or to minimize particle aggregation.
  • the perforated microstructures according to the invention may, if desired, contain a combination of two or more active ingredients.
  • the agents may be provided in combination in a single species of perforated microstructure or individually in separate species of perforated microstructures.
  • two or more active or bioactive agents may be incorporated in a single feed stock preparation and spray dried to provide a single microstructure species comprising a plurality of active agents.
  • the individual actives could be added to separate stocks and spray dried separately to provide a plurality of microstructure species with different compositions
  • These individual species could be added to the suspension medium or dry powder dispensing compartment in any desired proportion and placed in the aerosol delivery system as described below.
  • the perforated microstructures (with or without an associated agent) may be combined with one or more conventional (e.g. a micronized drug) active or bioactive agents to provide the desired dispersion stability or powder dispersibility
  • perforated microstructures of the present invention various components may be associated with, or incorporated in the perforated microstructures of the present invention.
  • several techniques may be used to provide particulates having the desired morphology (e.g. a perforated or hollow/porous configuration), dispersibility and density.
  • perforated microstructures compatible with the instant invention may be formed by techniques including spray drying, vacuum drying, solvent extraction, emulsification or lyophilization, and combinations thereof. It will further be appreciated that the basic concepts of many of these techniques are well known in the p ⁇ or art and would not, in view of the teachings herein, require undue expenmentation to adapt them so as to provide the desired perforated microstructures.
  • spray drying is a one-step process that converts a liquid feed to a d ⁇ ed paniculate form.
  • spray drying has been used to provide powdered material for various administrative routes including inhalation. See, for example, M. Sacchetti and M.M. Van Oort in' Inhalation
  • Aerosols Physical and Biological Basis for Therapy, A.J. Hickey, ed Marcel Dekkar, New York, 1996, which is incorporated herein by reference.
  • spray drying consists of bringing together a highly dispersed liquid, and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets.
  • the preparation to be spray dried or feed (or feed stock) can be any solution, course suspension, slurry, colloidal dispersion, or paste that may be atomized using the selected spray drying apparatus.
  • the feed stock will comprise a colloidal system such as an emulsion, reverse emulsion, microemulsion, multiple emulsion, paniculate dispersion, or slurry.
  • the feed is sprayed into a current of warm filtered air that evaporates the solvent and conveys the dried product to a collector. The spent air is then exhausted with the solvent.
  • Those skilled in the art will appreciate that several different types of apparatus may be used to provide the desired product. For example, commercial spray dryers manufactured by Buchi Ltd. or Niro Corp. will effectively produce particles of desired size.
  • these spray dryers may be modified or customized for specialized applications, i.e. the simultaneous spraying of two solutions using a double nozzle technique. More specifically, a water in oil emulsion can be atomized from one nozzle and a solution containing an anti-adherent such as mannitol can be co atomized from a second nozzle. In other cases it may be desirable to push the feed solution though a custom designed nozzle using a high pressure liquid chromatography (HPLC) pump.
  • HPLC high pressure liquid chromatography
  • the resulting spray dried powdered particles typically are approximately spherical in shape, nearly uniform in size and frequently are hollow, there may be some degree of irregularity in shape depending upon the incorporated medicament and the spray drying conditions.
  • dispersion stability and dispersibility of the perforated microstructures appears to be improved if an inflating agent (or blowing agent) is used in their production.
  • Particularly preferred embodiments may compnse an emulsion with the inflating agent as the disperse or continuous phase.
  • the inflating agent is preferably dispersed with a surfactant solution, using, for instance, a commercially available microfluidizer at a pressure of about 5000 to 15,000 psi.
  • This process forms an emulsion, preferably stabilized by an incorporated surfactant, typically compnsing submicron droplets of water immiscible blowing agent dispersed in an aqueous continuous phase.
  • the blowing agent is preferably a fluonnated compound (e.g. perfluorohexane, perfiuorooctyl bromide, perfluorodecalin, perfluorobutyl ethane) which vaporizes during the spray drying process, leaving behind generally hollow, porous aerodynamically light microspheres.
  • liquid blowing agents include nonfluonnated oils, chloroform, Freons, ethyl acetate, alcohols and hydrocarbons Nitrogen and carbon dioxide gases are also contemplated as a suitable blowing agent.
  • inorganic and organic substances which can be removed under reduced pressure by sublimation in a post production step are also compatible with the instant invention.
  • These sublimating compounds can be dissolved or dispersed as micronized crystals in the spray drying feed solution and include ammonium carbonate and camphor.
  • Other compounds compatible with the present invention comprise ⁇ gidifying solid structures which can be dispersed in the feed solution or prepared in-situ. These structures are then extracted after the initial particle generation using a post production solvent extraction step. For example, latex particles can be dispersed and subsequently dried with other wall forming compounds, followed by extraction with a suitable solvent
  • the perforated microstructures are preferably formed using a blowing agent as described above, it will be appreciated that, in some instances, no additional blowing agent is required and an aqueous dispersion of the medicament and/or excipients and surfactant(s) are spray dried directly
  • the formulation may be amenable to process conditions (e.g., elevated temperatures) that may lead to the formation of hollow, relatively porous microparticles
  • the medicament may possess special physicochemical properties (e.g., high crystallmity, elevated melting temperature, surface activity, etc.) that makes it particularly suitable for use in such techniques.
  • the degree of porosity and dispersibility of the perforated microstructure appears to depend, at least in part, on the nature of the blowing agent, its concentration in the feed stock (e.g. as an emulsion), and the spray drying conditions.
  • the use of compounds, heretofore unappreciated as blowing agents may provide perforated microstructures having particularly desirable characteristics. More particularly, in this novel and unexpected aspect of the present invention it has been found that the use of fluonnated compounds having relatively high boiling points (i.e. greater than about 40°C) may be used to produce particulates that are particularly porous.
  • Such perforated microstructures are especially suitable for inhalation therapies.
  • fluonnated or partially fluonnated blowing agents having boiling points of greater than about 40°C, 50°C, 60°C, 70°C, 80°C, 90°C or even 95°C.
  • Particularly preferred blowing agents have boiling points greater than the boiling point of water, i.e. greater than 100°C (e.g. perflubron, perfluorodecalin).
  • blowing agents with relatively low water solubility ⁇ 10 6 M are preferred since they enable the production of stable emulsion dispersions with mean weighted particle diameters less than 0.3 ⁇ m.
  • blowing agents will preferably be incorporated in an emulsified feed stock p ⁇ or to spray drying.
  • this feed stock will also preferably comprise one or more active or bioactive agents, one or more surfactants or one or more excipients.
  • active or bioactive agents one or more surfactants or one or more excipients.
  • surfactants one or more excipients.
  • combinations of the aforementioned components are also within the scope of the invention
  • high boiling ( > 100°C) fluonnated blowing agents comprise one preferred aspect of the present invention
  • nonfluonnated blowing agents with similar boiling points > 100°C
  • Exemplary nonfluo ⁇ nated blowing agents suitable for use in the present invention comprise the formula-
  • This migration apparently slows du ⁇ ng the drying process as a result of increased resistance to mass transfer caused by an increased internal viscosity.
  • the migration ceases the particle solidifies, leaving voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes.
  • the number of pores or defects, their size, and the resulting wall thickness is largely dependent on the formulation and/or the nature of the selected blowing agent (e g boiling point), its concentration in the emulsion, total solids concentration, and the spray drying conditions. It can be greatly appreciated that this type of particle morphology in part contributes to the improved powder dispersibility, suspension stability and aerodynamics
  • spray dried perforated microstructures as described herein may comprise as much as 1 %, 3%, 5%, 10%, 20%, 30% or even 40% w/w of the blowing agent.
  • higher production yields were obtained as a result an increased particle density caused by residual blowing agent.
  • retained fluonnated blowing agent may alter the surface characteristics of the perforated microstructures, thereby minimizing particle aggregation du ⁇ g processing and further increasing dispersion stability.
  • Residual fluonnated blowing agent in the particle may also reduce the cohesive forces between particles by providing a barrier or by attenuating the attractive forces produced during manufacturing (e.g., electrostatics). This reduction in cohesive forces may be particularly advantageous when using the disclosed microstructures in conjunction with dry powder inhalers.
  • the amount of residual blowing agent can be attenuated through the process conditions (such as outlet temperature), blowing agent concentration, or boiling point If the outlet temperature is at or above the boiling point, the blowing agent escapes the particle and the production yield decreases.
  • Preferred outlet temperature will generally be operated at 20, 30, 40, 50, 60, 70, 80, 90 or even 100°C less than the blowing agent boiling point.
  • the temperature differential between the outlet temperature and the boiling point will range from 50 to 150°C
  • particle porosity, production yield, electrostatics and dispersibility can be optimized by first identifying the range of process conditions (e g., outlet temperature) that are suitable for the selected active agents and/or excipients
  • the preferred blowing agent can be then chosen using the maximum outlet temperature such that the temperature differential with be at least 20 and up to 150°C
  • the temperature differential can be outside this range such as, for example, when producing the particulates under supercritical conditions or using lyophilization techniques.
  • the preferred concentration of blowing agent can be determined experimentally without undue experimentation using techniques similar to those described in the Examples herein.
  • residual blowing agent may be advantageous in selected embodiments it may be desirable to substantially remove any blowing agent from the spray dried product.
  • the residual blowing agent can easily be removed with a post production evaporation step in a vacuum oven.
  • post production techniques may be used to provide perforations in the particulates For example, pores may be formed by spray drying a bioactive agent and an excipient that can be removed from the formed particulates under a vacuum.
  • blowing agent concentrations in the feed stock are between 2% and 50% v/v, and more preferably between about 10% to 45% v/v In other embodiments blowing agent concentrations will preferably be greater than about 5%, 10%, 15%, 20%, 25% or even 30% v/v. Yet other feed stock emulsions may comprise 35%, 40%, 45% or even 50% v/v of the selected high boiling point compound.
  • another method of identifying the concentration of blowing agent used in the feed is to provide it as a ratio of the concentration of the blowing agent to that of the stabilizing surfactant (e g. phosphatidylcholine or PC) in the precursor or feed emulsion
  • the stabilizing surfactant e g. phosphatidylcholine or PC
  • the typical PFC/PC ratio will range from about 1 to about 60 and more preferably from about 10 to about 50.
  • the ratio will generally be greater than about 5, 10, 20, 25, 30, 40 or even 50.
  • FIG. 1 shows a series of pictures taken of perforated microstructures formed of phosphatidylcholine (PC) using various amounts of perfluorooctyl bromide (PFC), a relatively high boiling point fluorocarbon as the blowing agent.
  • PC phosphatidylcholine
  • PFC perfluorooctyl bromide
  • the PFC/PC ratios are provided under each subset of pictures, i.e. from 1A to 1 F. Formation and imaging conditions are discussed in greater detail in Examples I and II below.
  • the column on the left shows the intact microstructures while the column on the right illustrates cross sections of fractured microstructures from the same preparations
  • XII illustrates a preferably porous morphology obtained by using higher boiling point blowing agents (in this case perfluorodecalin).
  • blowing agent comprises any volatile substance, which can be incorporated into the feed solution for the purpose of producing a perforated foam like structure in the resulting dry microspheres.
  • the blowing agent may be removed during the initial drying process or during a post production step such as vacuum drying or solvent extraction. Suitable agents include:
  • Dissolved low-boiling (below 100 C) agents irascible with aqueous solutions such as methylene chlo ⁇ de, acetone, ethyl acetate, and alcohols used to saturate the solution.
  • a gas such as C0 2 or N 2 ,or liquid such as Freons, CFCs, HFAs, PFCs, HFCs, HFBs, fiuoroalkanes, and hydrocarbons used at elevated pressure.
  • Emulsions of immiscible low-boiling (below 100 C) liquids suitable for use with the present invention are generally of the formula: R'-X R 2 or R' X wherein: R' or R 2 ⁇ s hydrogen, alkyl, alkenyl, alkynl, aromatic, cyclic or combinations thereof, X is any groups containing carbon, sulfur, nitrogen, halogens, phosphorus, oxygen and combinations thereof. .
  • Such liquids include: Freons, CFCs, HFAs, PFCs, HFCs, HFBs, fiuoroalkanes, and hydrocarbons.
  • Dissolved or dispersed salts or organic substances which can be removed under reduced pressure by sublimation in a post-production step such as ammonium salts, camphor, etc.
  • Dispersed solids which can be extracted after the initial particle generation using a post-production solvent extraction step such particles include latex, etc
  • these lower boiling point inflating agents they are typically added to the feed stock in quantities of about 1 % to 40% v/v of the surfactant solution. Approximately 15% v/v inflating agent has been found to produce a spray dned powder that may be used to form the stabilized dispersions of the present invention.
  • the inlet temperature and the outlet temperature of the spray drier are not critical but will be of such a level to provide the desired particle size and to result in a product that has the desired activity of the medicament.
  • the inlet and outlet temperatures are adjusted depending on the melting characteristics of the formulation components and the composition of the feed stock.
  • the inlet temperature may thus be between 60°C and 170°C, with the outlet temperatures of about 40°C to 120°C depending on the composition of the feed and the desired paniculate characteristics.
  • these temperatures will be from 90°C to 120°C for the inlet and from 60°C to 90°C for the outlet
  • the flow rate which is used in the spray drying equipment wili generally be about 3 ml per minute to about 15 ml per minute
  • the atomizer air flow rate will vary between values of 25 liters per minute to about 50 liters per minute.
  • Commercially available spray dryers are well known to those in the art, and suitable settings for any particular dispersion can be readily determined through standard empi ⁇ cal testing, with due reference to the examples that follow. Of course, the conditions may be adjusted so as to preserve biological activity in larger molecules such as proteins or peptides
  • nonfluonnated oils may be used to increase the loading capacity of active or bioactive agents without compromising the microstructure.
  • selection of the nonfluo ⁇ nated oil is based upon the solubility of the active or bioactive agent, water solubility, boiling point, and flash point.
  • the active or bioactive agent will be dissolved in the oil and subsequently emulsified in the feed solution.
  • the oil will have substantial solubihzation capacity with respect to the selected agent, low water solubility ( ⁇ 10 3 M), boiling point greater than water and a flash point greater than the drying outlet temperature.
  • the addition of surfactants, and co solvents to the nonfluonnated oil to increase the solubihzation capacity is also within the scope of the present invention.
  • nonfluo ⁇ nated oils may be used to solubilize agents or bioactive agents that have limited solubility in aqueous compositions.
  • the use of nonfluonnated oils is of particular use for increasing the loading capacity of steroids such as beclomethasone dipropionate and tnamcinolone acetonide.
  • the oil or oil mixture for solubilizmg these clathrate forming steroids will have a refractive index between 1.36 and 1.41 (e.g. ethyl butyrate, butyl carbonate, dibutyl ether).
  • process conditions such as temperature and pressure, may be adjusted in order to boost solubility of the selected agent. It will be appreciated that selection of an appropnate oil or oil mixtures and processing conditions to maximize the loading capacity of an agent are well within the purview of a skilled artisan in view of the teachings herein and may be accomplished without undue experimentation.
  • compositions compnsing a surfactant such as a phosphohpid and at least one active or bioactive agent.
  • the spray drying preparation may further compnse an excipient comprising a hydrophi c moiety such as, for example, a carbohydrate ( ⁇ .e. glucose, lactose, or starch) in addition to any selected surfactant.
  • a hydrophi c moiety such as, for example, a carbohydrate ( ⁇ .e. glucose, lactose, or starch) in addition to any selected surfactant.
  • various starches and de ⁇ vatized starches suitable for use in the present invention.
  • Other optional components may include conventional viscosity modifiers, buffers such as phosphate buffers or other conventional biocompatible buffers or pH adjusting agents such as acids or bases, and osmotic agents (to provide isotonicity, hyperosmola ⁇ ty, or hyposmola ⁇ ty).
  • buffers such as phosphate buffers or other conventional biocompatible buffers or pH adjusting agents such as acids or bases
  • osmotic agents to provide isotonicity, hyperosmola ⁇ ty, or hyposmola ⁇ ty.
  • suitable salts include sodium phosphate (both monobasic and dibasic), sodium chloride, calcium phosphate, calcium chloride and other physiologically acceptable salts.
  • the first step in paniculate production typically comprises feed stock preparation.
  • the selected drug is dissolved in water to produce a concentrated solution.
  • the drug may also be dispersed directly in the emulsion, particularly in the case of water insoluble agents.
  • the drug may be incorporated in the form of a solid paniculate dispersion.
  • concentration of the active or bioactive agent used is dependent on the amount of agent required in the final powder and the performance of the delivery device employed (e.g., the fine particle dose for a MDI or DPI).
  • cosurfactants such as poloxamer 188 or span 80 may be dispersed into this annex solution. Additionally, excipients such as sugars and starches can also be added.
  • an oil in water emulsion is then formed in a separate vessel.
  • the oil employed is preferably a fluorocarbon (e.g., perfluorooctyl bromide, perfluorodecalin) which is emulsified using a surfactant such as a long chain saturated phosphohpid.
  • a fluorocarbon e.g., perfluorooctyl bromide, perfluorodecalin
  • a surfactant such as a long chain saturated phosphohpid.
  • one gram of phosphohpid may be homogenized in 150 g hot distilled water (e.g., 60°C) using a suitable high shear mechanical mixer (e.g.. Ultra Turrax model T 25 mixer) at 8000 rpm for 2 to 5 minutes.
  • a suitable high shear mechanical mixer e.g.. Ultra Turrax model T 25 mixer
  • 5 to 25 g of fluorocarbon is added dropwise to the dispersed surfactant solution while mixing
  • the resulting perfluorocarbo ⁇ in water emulsion is then processed using a high pressure homogenizer to reduce the particle size.
  • a high pressure homogenizer typically the emulsion is processed at 12,000 to 18,000 psi, 5 discrete passes and kept at 50 to 80°C.
  • the active or bioactive agent solution and perfluorocarbon emulsion are then combined and fed into the spray dryer.
  • the two preparations will be miscible as the emulsion will preferably comprise an aqueous continuous phase.
  • the bioactive agent is solubilized separately for the purposes of the instant discussion it will be appreciated that, in other embodiments, the active or bioactive agent may be solubilized (or dispersed) directly in the emulsion. In such cases, the active or bioactive emulsion is simply spray dried without combining a separate drug preparation.
  • operating conditions such as inlet and outlet temperature, feed rate, atomization pressure, flow rate of the drying air, and nozzle configuration can be adjusted in accordance with the manufacturer's guidelines in order to produce the required particle size, and production yield of the resulting dry microstructures.
  • Exemplary settings are as follows, an air inlet temperature between 60°C and 170°C, an air outlet between 40°C to 120°C; a feed rate between 3 ml to about 15 ml per minute; and an aspiration air flow of 300 L/min. and an atomization air flow rate between 25 to 50 L/min
  • the selection of appropnate apparatus and processing conditions are well within the purview of a skilled artisan in view of the teachings herein and may be accomplished without undue experimentation.
  • the use of these and substantially equivalent methods provide for the formation of hollow porous aerodynamically light microspheres with particle diameters appropriate for aerosol deposition into the lung microstructures that are both hollow and porous, almost honeycombed or foam like in appearance.
  • the perforated microstructures comprise hollow, porous spray dried microspheres
  • perforated microstructures useful in the present invention may be formed by lyophilization.
  • lyophilization is a freeze drying process in which water is sublimed from the composition after it is frozen.
  • bioiogicals and pharmaceuticals that are relatively unstable in an aqueous solution can be dried without elevated temperatures (thereby eliminating the adverse thermal effects), and then stored in a dry state where there are few stability problems.
  • such techniques are particularly compatible with the incorporation of peptides, proteins, genetic matenal and other natural and synthetic macromolecules in particulates or perforated microstructures without compromising physiological activity.
  • lyophilized cake containing a fine foam like structure can be micronized using techniques known in the art to provide 3 to 10 ⁇ m sized particles. Accordingly, to the extent that lyophilization processes may be used to provide microstructures having the desired porosity and size they are conformance with the teachings herein and are expressly contemplated as being within the scope of the instant invention.
  • the perforated microstructures or particles of the present invention may also be formed using a method where a feed solution (either emulsion or aqueous) containing wall forming agents is rapidly added to a reservoir of heated oil (e.g. perflubron or other high boiling FCs) under reduced pressure.
  • heated oil e.g. perflubron or other high boiling FCs
  • the water and volatile solvents of the feed solution rapidly boils and are evaporated This process provides a perforated structure from the wall forming agents similar to puffed ⁇ ce or popcorn.
  • the wall forming agents are insoluble in the heated oil.
  • the resulting particles can then separated from the heated oil using a filtering technique and subsequently dried under vacuum.
  • the perforated microstructures of the present invention may also be formed using a double emulsion method.
  • the medicament is first dispersed in a polymer dissolved in an organic solvent (e.g. methyiene chloride) by somcation or homogemzation.
  • This primary emulsion is then stabilized by forming a multiple emulsion in a continuous aqueous phase containing an emulsifier such as polyvinylalcohol. Evaporation or extraction using conventional techniques and apparatus then removes the organic solvent.
  • the resulting microspheres are washed, filtered and dried prior to combining them with an appropriate suspension medium in accordance with the present invention
  • the resulting powders have a number of advantageous properties that make them particularly compatible for use in devices for inhalation therapies.
  • the physical characteristics of the perforated microstructures make them extremely effective for use in dry powder inhalers and in the formation of stabilized dispersions that may be used in conjunction with metered dose inhalers, nebulizers and liquid dose instillation.
  • the perforated microstructures provide for the effective pulmonary administration of bioactive agents.
  • the mean geometric particle size of the perforated microstructures is preferably about 0.5 50 m, more preferably 1 30 m. It will be appreciated that large particles (i.e. greater than 50 m) may not be preferred in applications where a valve or small o ⁇ fice is employed, since large particles tend to aggregate or separate from a suspension which could potentially clog the device.
  • the mean geometnc particle size (or diameter) of the perforated microstructures is less than 20 m or less than 10 m. More preferably the mean geometnc diameter is less than about 7 m or 5 , and even more preferably less than about 2.5 m.
  • the perforated microstructures will comprise a powder of dry, hollow, porous microsphe ⁇ cal shells of approximately 1 to 10 m or 1 to 5 m m diameter, with shell thicknesses of approximately 0.1 to approximately 0.5 m It is a particular advantage of the present invention that the particulate concentration of the dispersions and structural matrix components can be adjusted to optimize the delivery charactenstics of the selected particle size As alluded to throughout the instant specification the porosity of the microstructures may play a significant part is establishing dispersibility (e.g.
  • the mean porosity of the perforated microstructures may be determined through electron microscopy coupled with modern imaging techniques. More specifically, electron micrographs of representative samples of the perforated microstructures may be obtained and digitally analyzed to quantify the porosity of the preparation. Such methodology is well known in the art and may be undertaken without undue expe ⁇ mentation
  • the mean porosity (i.e. the percentage of the particle surface area that is open to the interior and/or a central void) of the perforated microstructures may range from approximately 0.5% to approximately 80%. In more preferred embodiments, the mean porosity will range from approximately 2% to approximately 40%. Based on selected production parameters, the mean porosity may be greater than approximately, 2%, 5%, 10%, 15%, 20%, 25% or 30% of the microstructure surface area, in other embodiments, the mean porosity of the microstructures may be greater than about 40%, 50%, 60%, 70% or even 80%.
  • the pores themselves, they typically range in size from about 5 nm to about 400 nm with mean pore sizes preferably in the range of from about 20 nm to about 200 nm. In particularly preferred embodiments the mean pore size will be in the range of from about 50 nm to about 100 nm. As may be seen in Figs. 1A1 to 1 F2 and discussed in more detail below, it is a significant advantage of the present invention that the pore size and porosity may be closely controlled by careful selection of the incorporated components and production parameters.
  • the particle morphology and/or hollow design of the perforated microstructures also plays an important role on the dispersibility or cohesiveness of the dry powder formulations disclosed herein That is, it has been surp ⁇ singly discovered that the inherent cohesive character of fine powders can be overcome by lowering the van der Waals, electrostatic attractive and liquid bridging forces that typically exist between dry particles. More specifically, in concordance with the teachings herein, improved powder dispersibility may be provided by engineenng the particle morphology and density, as well as control of humidity and charge To that end, the perforated microstructures of the present invention comp ⁇ se pores, voids, hollows, defects or other interstitial spaces which reduce the surface contact area between particles thereby minimizing interparticle forces. In addition, the use of surfactants such as phospholipids and fluonnated blowing agents in accordance with the teachings herein may contribute to improvements in the flow properties of the powders by tempering the charge and strength of the electrostatic forces as well as moisture content.
  • typical p ⁇ or art dry powder formulations for DPIs comp ⁇ se micronized drug particles that are deposited on large earner particles (e.g., 30 to 90 ⁇ m) such as lactose or agglomerated units of pure drug particles or agglomeration of fine lactose particles with pure drug, since they are more readily fluidized than neat drug particles.
  • large earner particles e.g. 30 to 90 ⁇ m
  • lactose or agglomerated units of pure drug particles or agglomeration of fine lactose particles with pure drug since they are more readily fluidized than neat drug particles.
  • the mass of drug required per actuation is typically less than 100 ⁇ g and is thus prohibitively too small to meter.
  • the larger lactose particles in pnor art formulations function as both a earner particle for aerosolization and a bulking agent for mete ⁇ ng.
  • VDW van der Waals
  • the electrostatic force affecting powders occurs when either or both of the particles are electrically charged. This phenomenon will result with either an attraction or repulsion between particles depending on the similarity or dissimilarity of charge
  • the electric charges can be desc ⁇ bed using Coulomb's Law.
  • One way to modulate or decrease the electrostatic forces between particles is if either or both particles have non conducting surfaces.
  • the present invention provides for the reduction of electrostatic effects in the disclosed powders though the use of relatively non conductive mate ⁇ als.
  • preferred non conductive mate ⁇ als would include halogenated and/or hydrogenated components.
  • Mate ⁇ als such as phospholipids and fluonnated blowing agents (which may be retained to some extent in the spray dried powders) are preferred since they can provide resistance to particle charging It will be appreciated that the retention of residual blowing agent (e g fiuorochemicals) in the particles, even at relatively low levels, may help minimize charging of the perforated microstructures as is typically imparted during spray drying and cyclone separation.
  • the present invention further provides for the attenuation or reduction of hydrogen and liquid bonding.
  • hydrogen bonding and liquid b ⁇ dging can result from moisture that is absorbed by the powder.
  • higher humidities produce higher interparticle forces for hydrophilic surfaces.
  • angles of repose or shear index can be used to assess the flow properties of dry powders.
  • the angle of repose is defined as the angle formed when a cone of powder is poured onto a flat surface Powders having an angle of repose ranging from 45° to 20° are preferred and indicate suitable powder flow. More particularly, powders which possess an angle of repose between 33° and 20° exhibit relatively low shear forces and are especially useful in pharmaceutical preparations for use in inhalation therapies (e.g. DPIs).
  • the shear index though more time consuming to measure than angle of repose, is considered more reliable and easy to determine.
  • the shear index is estimated from powder parameters such as, yield stress, effective angle of internal fnction, tensile strength, and specific cohesion. In the present invention powders having a shear index less than about 0.98 are desirable.
  • powders used in the disclosed compositions, methods and systems will have shear indices less than about 1 1 In particularly preferred embodiments the shear index will be less than about 1 3 or even less than about 1.5 Of course powders having different shear indices may be used provided the result in the effective deposition of the active or bioactive agent at the site of interest
  • the perforated microstructure powders make them particularly useful in preparations for inhalation therapies (e g in inhalation devices such as DPIs, MDIs, nebulizers).
  • inhalation devices e g in inhalation devices such as DPIs, MDIs, nebulizers.
  • the perforated or porous and/or hollow design of the microstructures also plays an important role in the resulting aerosol properties of the powder when discharged.
  • the density of the particles is significantly less than 1.0 g/cm 3 , typically less than 0.5 g/cm 3 , more often on the order of 0.1 g/cm 3 , and as low as 0.01 g/cm 3
  • the mean aerodynamic diameter of the perforated microstructures is preferably less than about 5 ⁇ m, more preferably less than about 3 ⁇ m, and, in particularly preferred embodiments, less than about 2 ⁇ m
  • Such particle distributions will act to increase the deep lung deposition of the bioactive agent whether administered using a DPI, MDI or nebulizer
  • having a larger geometric diameter than aerodynamic diameter brings the particles closer to the wall of the alveolus thus increasing the deposition of small aerodynamic diameter particles.
  • the particle size distribution of the aerosol formulations of the present invention are measurable by conventional techniques such as, for example, cascade impactio ⁇ or by time of flight analytical methods.
  • determination of the emitted dose from inhalation devices were done according to the proposed U S Pharmacopeia method ⁇ Pharmacopeia/ Previews 22(1996) 3065) which is incorporated herein by reference.
  • fine particle fraction refers to the percentage of the total amount of active medicament delivered per actuation from the mouthpiece of a DPI, MDI or nebulizer onto plates 2 7 of an 8 stage Andersen cascade impactor. Based on such measurements the formulations of the present invention will preferably have a fine particle fraction of approximately 20% or more by weight of the perforated microstructures (w/w), more preferably they will exhibit a fine particle fraction of from about 25% to 80% w/w, and even more preferably from about 30 to 70% w/w In selected embodiments the present invention will preferably comprise a fine particle fraction of greater than about 30%, 40%, 50%, 60%, 70% or 80% by weight
  • the formulations of the present invention exhibit relatively low deposition rates, when compared with prior art preparations, on the induction port and onto plates 0 and 1 of the impactor Deposition on these components is linked with deposition in the throat in humans. More specifically, most commercially available MDIs and DPIs have simulated throat depositions of approximately 40 70% (w/w) of the total dose, while the formulations of the present invention typically deposit less than about 20% w/w Accordingly, preferred embodiments of the present invention have simulated throat depositions of less than about 40%, 35%, 30%, 25%, 20%, 15% or even 10% w/w. Those skilled in the art will appreciate that significant decrease in throat deposition provided by the present invention will result in a corresponding decrease in associated local side effects such as throat irritation and candidiasis.
  • MDI propellants typically force suspended particles out of the device at a high velocity towards the back of the throat. Since prior art formulations typically contain a significant percentage of large particles and/or aggregates, as much as two-thirds or more of the emitted dose may impact the throat Moreover, the undesirable delivery profile of conventional powder preparations is also exhibited under conditions of low particle velocity, as occurs with DPI devices. In general, this problem is inherent when aerosolizing solid, dense, particulates which are subject to aggregation. Yet, as discussed above, the novel and unexpected properties of the stabilized dispersions of the present invention result in surprisingly low throat deposition upon administration from inhalation device such as a DPI, MDI atomizer or nebulizer.
  • inhalation device such as a DPI, MDI atomizer or nebulizer.
  • the reduced throat deposition results from decreases in particle aggregation and from the hollow and/or porous morphology of the incorporated microstructures. That is, the hollow and porous nature of the dispersed microstructures slows the velocity of particles in the propellant stream (or gas stream in the case of DPIs), just as a hollow/porous whiffle ball decelerates faster than a baseball. Thus, rather than impacting and sticking to the back of the throat, the relatively slow traveling particles are subject to inhalation by the patient. Moreover, the highly porous nature of the particles allows th propellant within the perforated microstructure to rapidly leave and the particle density to drop before impacting the throat. Accordingly, a substantially higher percentage of the administered bioactive agent is deposited in the pulmonary air passages where it may be efficiently absorbed.
  • DPIs dry powder inhalers
  • a predetermined dose of medicament either alone or in a blend with lactose carrier particles
  • the medicament is fomiulated in a way such that it readily disperses into discrete particles with a size rage between 0.5 to 20 ⁇ m.
  • the powder is actuated either by inspiration or by some external delivery force, such as pressurized air.
  • DPI formulations are typically packaged in single dose units or they employ reservoir systems capable of metering multiple doses with manual transfer of the dose to the device.
  • DPIs are generally classified based on the dose delivery system employed, in this respect, the two major types of DPIs comp ⁇ se unit dose delivery devices and bulk reservoir delivery systems. As used herein, the term
  • unit dose delivery systems require the dose of powder formulation presented to the device as a single unit. With this system, the fomiulation is prefilled into dosing wells which may be foil-packaged or presented in blister strips to prevent moisture ingress. Other unit dose packages include hard gelatin capsules. Most unit dose containers designed for DPIs are filled using a fixed volume technique. As a result, there are physical limitations (here density) to the minimal dose that can be metered into a unit package, which is dictated by the powder flowability and bulk density.
  • the range of dry powder that can be filled into a unit dose container is in the range of 5 to 15 mg which corresponds to drug loading in the range of 25 to 500 ⁇ g per dose.
  • bulk reservoir delivery systems provide a precise quantity of powder to be metered upon individual delivery for up to approximately 200 doses. Again like the unit dose systems, the powder is metered using a fixed volume cell or chamber that the powder is filled into. Thus, the density of the powder is a major factor limiting the minimal dose that can be delivered with this device.
  • bulk reservoir type DPIs can meter between 200 ⁇ g to 20 mg powder per actuation.
  • DPIs are designed to be manipulated such that they break open the capsule/blister or to load bulk powder during actuation, followed by dispersion from a mouthpiece or actuator due to the patient's inspiration.
  • the lactose/drug aggregates are aerosolized and the patient inhales the mist of dry powder.
  • the carrier particles encounter shear forces whereby some of the micronized drug particles are separated from the lactose paniculate surface. It will be appreciated that the drug particles are subsequently carried into the lung.
  • the large lactose particles impact the throat and upper airways due to size and inertial force constraints.
  • the efficiency of delivery of the drug particles is dictated by their degree of adhesion with the carrier particles and their aerodynamic property.
  • Deaggregation can be increased through formulation, process and device design improvements.
  • fine particle lactose FPL
  • coarse lactose carriers wherein the FPL will occupy high-energy binding sites on the carrier particles.
  • This process provides more passive sites for adhesion of the micronized drug particles.
  • This tertiary blend with the drug has been shown to provide statistically significant increases in fine particle fraction.
  • Other strategies include specialized process conditions where drug particles are mixed with FPL to produce agglomerated units.
  • many DPIs are designed to provide deaggregation by passing the dosage form over baffles, or through tortuous channels that disrupts the flow properties.
  • the perforated microstructure powders of the present invention obviate many of the difficulties associated with prior art carrier preparations. That is, an improvement in DPI performance may be provided by engineering the particle, size, aerodynamics, morphology and density, as well as control of humidity and charge.
  • the present invention provides formulations wherein the medicament and the incipients or bulking agents are preferably associated with or comprise the perforated microstructures.
  • preferred compositions according to the present invention typically yield powders with bulk densities less than 0.1 g/cm 3 and often less than 0.05 g/cm 3 .
  • the hollow porous powders of the present invention exhibit superior flow properties, as measured by the angle of repose or shear index methods described herein, with respect to equivalent powders substantially devoid of pores. That is, superior powder flow, which appears to be a function of bulk density and particle morphology, is observed where the powders have a bulk density less than 0.5 g/cm 3 .
  • the powders Preferably have bulk densities of less than about 0.3 g/cm 3 , 0.1 g/cm 3 or even less than about 0.05 g/cm 3 .
  • the perforated microstructures comprising pores, voids, hollows, defects or other interstitial spaces contribute to powder flow properties by reducing the surface contact area between particles and minimizing inte ⁇ article forces.
  • the use of phospholipids in preferred embodiments and retention of fluonnated blowing agents may also contribute to improvements in the flow properties of the powders by tempering the charge and strength of the electrostatic forces as well as moisture content.
  • the disclosed powders exhibit favorable aerodynamic properties that make them particularly effective for use in DPIs. More specifically, the perforated structure and relatively high surface area of the microparticles enables them to be carried along in the flow of gases during inhalation with greater ease and for longer distances than relatively non-perforated particles of comparable size. Because of their high porosity and low density, administration of the perforated microstructures with a DPI provides for increased particle deposition into the peripheral regions of the lung and correspondingly less deposition in the throat. Such particle distribution acts to increase the deep lung deposition of the administered agent which is preferable for systemic administration.
  • the low-density, highly porous powders of the present invention preferably eliminate the need for carrier particles. Since the large lactose carrier particles will impact the throat and upper airways due to their size, the elimination of such particles minimizes throat deposition and any associated "gag" effect associated with conventional DPIs.
  • the perforated microstructures of the present invention may be incorporated in a suspension medium to provide stabilized dispersions.
  • the stabilized dispersions provide for the effective delivery of bioactive agents to the pulmonary air passages of a patient using MDIs, nebulizers or liquid dose instillation (LDI techniques).
  • a bioactive agent using an MDI, nebulizer or LDI technique may be indicated for the treatment of mild, moderate or severe, acute or chronic symptoms or for prophylactic treatment.
  • the bioactive agent may be administered to treat local or systemic conditions or disorders. It will be appreciated that, the precise dose administered will depend on the age and condition of the patient, the particular medicament used and the frequency of administration, and will ultimately be at the discretion of the attendant physician. When combinations of bioactive agents are employed, the dose of each component of the combination will generally be that employed for each component when used alone.
  • the increases in suspension stability may be imparted by engineering perforated microstructures which are then dispersed in a compatible suspension medium
  • the perforated microstructures comprise pores, voids, hollows, defects or other interstitial spaces that allow the fluid suspension medium to freely permeate or perfuse the paniculate boundary
  • Particularly preferred embodiments comprise perforated microstructures that are both hollow and porous, almost honeycombed or foam like in appearance.
  • the perforated microstructures comp ⁇ se hollow, porous spray dried microspheres.
  • the suspension medium i e. propellant
  • the suspension medium is able to permeate the particles, thereby creating a "ho odispersion", wherein both the continuous and dispersed phases are indistinguishable
  • the defined or "virtual" particles i e compnsing the volume circumscribed by the microparticuiate matrix
  • the forces driving particle aggregation are minimized
  • the differences in density between the defined particles and the continuous phase are minimized by having the microstructures filled with the medium thereby effectively slowing particle creaming or sedimentation.
  • the perforated microspheres and stabilized suspensions of the present invention are particularly compatible with many aerosolization techniques, such as MDI and nebulization
  • the stabilized dispersions may be used in liquid dose instillation applications
  • Typical prior art suspensions (e g for MDIs) comprise mostly solid particles and small amounts ( ⁇ 1 % w/w) of surfactant (e g. lecithin, Span 85, oleic acid) to increase electrostatic repulsion between particles or polymers to ste ⁇ cally decrease particle interaction
  • surfactant e g. lecithin, Span 85, oleic acid
  • the suspensions of the present invention are designed not to increase repulsion between particles, but rather to decrease the attractive forces between particles.
  • the principal forces driving flocculation in nonaqueous media are van der Waals attractive forces.
  • VDW forces are quantum mechanical in origin, and can be visualized as attractions between fluctuating dipoles (i e induced dipole induced dipole interactions)
  • Dispersion forces are extremely short range and scale as the sixth power of the distance between atoms When two macroscopic bodies approach one another the dispersion attractions between the atoms sums up. The resulting force is of considerably longer range, and depends on the geometry of the interacting bodies
  • V A the magnitude of the VDW potential
  • R 6 0 ( R , + ⁇ 2 ) accounts for the nature of the particles and the medium, H 0 is the distance between particles, and R and R 2 are the radii of spherical particles 1 and 2.
  • the effective ⁇ amaker constant is proportional to the difference in the pola ⁇ zabihties of the dispersed particles and the suspension medium.
  • a e/f ( y JA SM - * ⁇ P ⁇ RT ) ' , where A and A PART are the ⁇ amaker constants for the suspension medium and the particles, respectively.
  • a ⁇ and A P4RT become closer in magnitude, and A eff and V A become smaller That is, by reducing the differences between the ⁇ amaker constant associated with suspension medium and the ⁇ amaker constant associated with the dispersed particles, the effective ⁇ amaker constant (and corresponding van der Waals attractive forces) may be reduced.
  • the components of the structural matrix (defining the perforated microstructures) will preferably be chosen so as to exhibit a ⁇ amaker constant relatively close to that of the selected suspension medium
  • the components of the structural matrix will preferably be chosen so as to exhibit a ⁇ amaker constant relatively close to that of the selected suspension medium
  • refractive index values of many compounds tend to scale with the corresponding ⁇ amaker constant. Accordingly, easily measurable refractive index values may be used to provide a fairly good indication as to which combination of suspension medium and particle excipients will provide a dispersion having a relatively low effective ⁇ amaker constant and associated stability. It will be appreciated that, since refractive indices of compounds are widely available or easily derived, the use of such values allows for the formation of stabilized dispersions in accordance with the present invention without undue experimentation. For the purpose of illustration only, the refractive indices of several compounds compatible with the disclosed dispersions are provided in Table I immediately below:
  • the formation of dispersions wherein the components have a refractive index differential of less than about 0.5 is preferred. That is, the refractive index of the suspension medium will preferably be within about 0.5 of the refractive index associated with the perforated particles or microstructures. It will further be appreciated that, the refractive index of the suspension medium and the particles may be measured directly or approximated using the refractive indices of the major component in each respective phase.
  • the major component may be determined on a weight percent basis.
  • the major component will typically be derived on a volume percentage basis. In selected embodiments of the present invention the refractive index differential value will preferably be less than about
  • index differentials of less than about 0.28, about 0.25, about 0.2, about 0.15 or even less than about 0.1. It is submitted that a skilled artisan will be able to determine which excipients are particularly compatible without undue experimentation given the instant disclosure. The ultimate choice of preferred excipients will also be influenced by other factors, including biocompatibility, regulatory status, ease of manufacture, cost.
  • the minimization of density differences between the particles and the continuous phase is largely dependent on the perforated and/or hollow nature of the microstructures, such that the suspension medium constitutes most of the particle volume.
  • particle volume corresponds to the volume of suspension medium that would be displaced by the incorporated hollow/porous particles if they were solid, i.e. the volume defined by the particle boundary.
  • these fluid filled particulate volumes may be referred to as "virtual particles.”
  • the average volume of the bioactive agent/excipient shell or matrix i.e. the volume of medium actually displaced by the perforated microstructure
  • the volume of the microparticulate matrix comprises less than about 50%, 40%, 30% or even 20% of the average particle volume. Even more preferably, the average volume of the shell/matrix comprises less than about 10%, 5%, 3% or 1 % of the average particle volume.
  • the excipients used to form the perforated microstructure may be chosen so the density of the resulting matrix or shell approximates the density of the surrounding suspension medium.
  • the use of such microstructures will allow the apparent density of the virtual particles to approach that of the suspension medium substantially eliminating the attractive van der Waals forces.
  • the components of the microparticuiate matrix are preferably selected, as much as possible given other considerations, to approximate the density of suspension medium.
  • the virtual particles and the suspension medium will have a density differential of less than about 0.6 g/cm 3 . That is, the mean density of the virtual particles (as defined by the matrix boundary) will be within approximately 0.6 g/cm 3 of the suspension medium. More preferably, the mean density of the virtual particles will be within 0.5, 0.4, 0.3 or
  • the density differential will be less than about 0.1, 0.05, 0.01, or even less than 0.005 g/cm 3 .
  • the use of hollow, porous particles allows for the formation of free-flowing dispersions comprising much higher volume fractions of particles in suspension. It should be appreciated that, the formulation of prior art dispersions at volume fractions approaching close- packing generally results in dramatic increases in dispersion viscoelastic behavior. Rheological behavior of this type is not appropriate for MDI applications.
  • the volume fraction of the particles may be defined as the ratio of the apparent volume of the particles (i.e. the particle volume) to the total volume of the system. Each system has a maximum volume fraction or packing fraction.
  • the porous structures of the present invention do not exhibit undesirable viscoelastic behavior even at high volume fractions, approaching close packing. To the contrary, they remain as free flowing, low viscosity suspensions having little or no yield stress when compared with analogous suspensions comprising solid particulates.
  • the low viscosity of the disclosed suspensions is thought to be due, at least in large part, to the relatively low van der Waals attraction between the fluid-filled hollow, porous particles.
  • the volume fraction of the disclosed dispersions is greater than approximately 0.3.
  • Other embodiments may have packing values on the order of 0.3 to about 0.5 or on the order of 0.5 to about 0.8, with the higher values approaching a close packing condition.
  • the formation of relatively concentrated dispersions may further increase formulation stability.
  • the methods and compositions of the present invention may be used to form relatively concentrated suspensions, the stabilizing factors work equally well at much lower packing volumes and such dispersions are contemplated as being within the scope of the instant disclosure.
  • dispersions comprising low volume fractions are extremely difficult to stabilize using prior art techniques.
  • dispersions incorporating perforated microstructures comprising a bioactive agent as described herein are particularly stable even at low volume fractions.
  • the present invention allows for stabilized dispersions, and particulariy respiratory dispersions, to be formed and used at volume fractions less than 0.3.
  • the volume fraction is approximately 0.0001 - 0.3, more preferably 0.001 - 0.01.
  • Yet other preferred embodiments comprise stabilized suspensions having volume fractions from approximately 0.01 to approximately 0.1.
  • the perforated microstructures of the present invention may also be used to stabilize dilute suspensions of micronized bioactive agents.
  • the perforated microstructures may be added to increase the volume fraction of particles in the suspension, thereby increasing suspension stability to creaming or sedimentation. Further, in these embodiments the incorporated microstructures may also act in preventing close approach (aggregation) of the micronized drug particles. It should be appreciated that, the perforated microstructures incorporated in such embodiments do not necessarily comprise a bioactive agent.
  • the stabilized suspensions or dispersions of the present invention may be prepared by dispersal of the microstructures in the selected suspension medium which may then be placed in a container or reservoir.
  • the stabilized preparations of the present invention can be made by simply combining the components in sufficient quantity to produce the final desired dispersion concentration.
  • the microstructures readily disperse without mechanical energy, the application of mechanical energy to aid in dispersion (e.g. with the aid of sonication) is contemplated, particularly for the formation of stable emulsions or reverse emulsions.
  • the components may be mixed by simple shaking or other type of agitation. The process is preferably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability. Once formed, the dispersion has a reduced susceptibility to flocculation and sedimentation.
  • the dispersions of the present invention are preferably stabilized.
  • the term "stabilized dispersion” will be held to mean any dispersion that resists aggregation, flocculation or creaming to the extent required to provide for the effective delivery of a bioactive agent.
  • a preferred method for the pu ⁇ oses of the present invention comprises determination of creaming or sedimentation time using a dynamic photosedimentation method. As seen in Example IX and Figure 2, a preferred method comprises subjecting suspended particles to a centrifugal force and measuring absorbance of the suspension as a function of time. A rapid decrease in the absorbance identifies a suspension with poor stability. It is submitted that those skilled in the art will be able to adapt the procedure to specific suspensions without undue experimentation.
  • the creaming time shall be defined as the time for the suspended drug particulates to cream to 1/2 the volume of the suspension medium.
  • the sedimentation time may be defined as the time it takes for the particulates to sediment in 1/2 the volume of the liquid medium.
  • the time necessary for the suspended particulates to cream to 1/2 the volume of the suspension medium i.e., to rise to the top half of the suspension medium), or to sediment within 1/2 the volume (i.e., to settle in the bottom 1 /2 of the medium), is then noted.
  • Suspension formulations having a creaming time greater than 1 minute are preferred and indicate suitable stability. More preferably, the stabilized dispersions comprise creaming times of greater than 1, 2, 5, 10, 15, 20 or 30 minutes. In particulariy preferred embodiments, the stabilized dispersions exhibit creaming times of greater than about 1, 1.5, 2, 2.5, or 3 hours. Substantially equivalent periods for sedimentation times are indicative of compatible dispersions.
  • the stabilized dispersions disclosed herein may preferably be administered to the nasal or pulmonary air passages of a patient via aerosolization, such as with a metered dose inhaler.
  • aerosolization such as with a metered dose inhaler.
  • the use of such stabilized preparations provides for superior dose reproducibility and improved lung deposition as described above.
  • MDIs are well known in the art and could easily be employed for administration of the claimed dispersions without undue experimentation.
  • Breath activated MDIs, as well as those comprising other types of improvements which have been, or will be, developed are also compatible with the stabilized dispersions and present invention and, as such, are contemplated as being with in the scope thereof.
  • the stabilized dispersions may be administered with an MDI using a number of different routes including, but not limited to, topical, nasal, pulmonary or oral. Those skilled in the art will appreciate that, such routes are well known and that the dosing and administration procedures may be easily derived for the stabilized dispersions of the present invention.
  • MDI canisters generally comprise a container or reservoir capable of withstanding the vapor pressure of the propellant used such as, a plastic or plastic-coated glass bottle, or preferably, a metal can or, for example, an aluminum can which may optionally be anoized, lacquer-coated and/or plastic-coated, wherein the container is closed with a metering valve.
  • the metering valves are designed to deliver a metered amount of the formulation per actuation.
  • the valves incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric material such as, for example, low density polyethylene, chlorobutyt, black and white butadiene-acryionitrile rubbers, butyl rubber and neoprene.
  • suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DFIO, DF30, DF 31/50 ACT, DF60), Bespak pic, LTK (e.g. BK300, BK356) and 3M-Neotechnic Ltd., LIK (e.g. Spraymiser).
  • Each filled canister is conveniently fitted into a suitable channeling device or actuator prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient.
  • Suitable channeling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve, to the nose or mouth of a patient e.g., a mouthpiece actuator.
  • Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation such as, for example, in the range of 10 to 5000 micrograms of bioactive agent per actuation.
  • a single charged canister will provide for tens or even hundreds of shots or doses.
  • any biocompatible suspension medium having adequate vapor pressure to act as a propellant may be used.
  • Particulariy preferred suspension media are compatible with use in a metered dose inhaler. That is, they will be able to form aerosols upon the activation of the metering valve and associated release of pressure.
  • the selected suspension medium should be biocompatible (i.e. relatively non-toxic) and non-reactive with respect to the suspended perforated microstructures comprising the bioactive agent.
  • the suspension medium will not act as a substantial solvent for any components incorporated in the perforated microspheres.
  • Selected embodiments of the invention comprise suspension media selected from the group consisting of fluorocarbons (including those substituted with other halogens), hydrofluoroalkanes, perfluorocarbons, hydrocarbons, alcohols, ethers or combinations thereof. It will be appreciated that, the suspension medium may comprise a mixture of various compounds selected to impart specific characteristics.
  • propellants for use in the MDI suspension mediums of the present invention are those propellant gases that can be liquefied under pressure at room temperature and, upon inhalation or topical use, are safe, toxicologically innocuous and free of side effects.
  • compatible propellants may comprise any hydrocarbon, fluorocarbon, hydrogen-containing fluorocarbon or mixtures thereof having a sufficient vapor pressure to efficiently form aerosols upon activation of a metered dose inhaler.
  • Those propellants typically termed hydrofluoroalkanes or HFAs are especially compatible.
  • Suitable propellants include, for example, short chain hydrocarbons, C M hydrogen-containing chlorofluorocarbons such as CH 2 CIF, CCI 2 F 2 CHCIF, CF 3 CHCIF, CHF 2 CCIF 2 , CHCIFCHF 2 , CF 3 CH 2 CI, and CCIF 2 CH 3 ; C M hydrogen-containing fluorocarbons (e.g. HFAs) such as
  • CF 3 CH 2 F, CHF 2 CH 3 , and CF 3 CHFCF 3 perfluorocarbons
  • perfluorocarbons such as CF 3 CF 3 and CF 3 CF 2 CF 3 .
  • a single perfluorocarbon or hydrogen-containing fluorocarbon is employed as the propellant.
  • propellants are 1,1,1,2-tetrafluoroethane (CF 3 CH 2 F) (HFA-134a) and 1,1,1,2,3,3,3- heptafluoro-n-propane (CF 3 CHFCF 3 ) (HFA-227), perfluoroethane, monocnlorodifluoromethane, 1,1-difluoroethane, and combinations thereof. It is desirable that the formulations contain no components that deplete stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbo ⁇ s such as CCI 3 F, CCI 2 F 2 , and CF 3 CCI 3 .
  • fluorocarbons or classes of fluonnated compounds, that are useful in the suspension media include, but are not limited to, fluoroheptane, fiuorocycloheptane, fluoromethylcycloheptane, fluorohexane, fluorocyclohexa ⁇ e, fluoropentane, fluorocyclopentane, fluorometh ⁇ lcyclopentane, fluoro ⁇ imethylcyclopentanes, fluoromethylcyclobutane, fluorodimethylcyclobutane, fluorotrimethylcyclobutane, fluorobutane, fluorocyclobutane, fluoropropane, fluoroethers, fluoropolyethers and fluorotriethylamines.
  • these compounds may be used alone or in combination with more volatile propellants. It is a distinct advantage that such compounds are generally environmentally sound and biologically non-reactive.
  • various chlorofluorocarbons and substituted fluorinated compounds may also be used as suspension mediums in accordance with the teachings herein.
  • FC-11 (CCL3F), FC-11 B1 (CBrCI2F), FC-11B2 (CBr2CIF), FC12B2 (CF2Br2), FC21 (CHCI2F), FC21 B1 (CHBrCIF), FC-21 B2 (CHBr2F), FC-31 B1 (CH2BrF), FC113A (CCI3CF3), FC-122 (CCIF2CHCI2), FC-123 (CF3CHCI2), FC-132 (CHCIFCHCIF), FC-133 (CHCIFCHF2), FC-141 (CH2CICHCIF), FC-141 B (CCI2FCH3), FC-142 (CHF2CH2CI), FC-151 (CH2FCH2CI), FC-152
  • each of these compounds may be used, alone or in combination with other compounds (i.e. less volatile fluorocarbons) to form the stabilized respiratory dispersions of the present invention.
  • the stabilized dispersions of the present invention may also be used in conjunction with nebulizers to provide an aerosolized medicament that may be administered to the pulmonary air passages of a patient in need thereof.
  • Nebulizers are well known in the art and could easily be employed for administration of the claimed dispersions without undue experimentation. Breath activated nebulizers, as well as those comprising other types of improvements which have been, or will be, developed are also compatible with the stabilized dispersions and present invention and are contemplated as being with in the scope thereof.
  • Nebulizers work by forming aerosols, that is converting a bulk liquid into small droplets suspended in a breathable gas.
  • the aerosolized medicament to be administered (preferably to the pulmonary air passages) will comprise small droplets of suspension medium associated with perforated microstructures comprising a bioactive agent.
  • the stabilized dispersions of the present invention will typically be placed in a fluid reservoir operably associated with a nebulizer.
  • the specific volumes of preparation provided, means of filling the reservoir, etc., will largely be dependent on the selection of the individual nebulizer and is well within the purview of the skilled artisan.
  • the present invention is entirely compatible with single-dose nebulizers and multiple dose nebulizers.
  • the present invention overcomes these and other difficulties by providing stabilized dispersions with a suspension medium that preferably comprises a fluonnated compound (i.e. a fluorochemical, fluorocarbon or perfluorocarbon).
  • a fluonnated compound i.e. a fluorochemical, fluorocarbon or perfluorocarbon.
  • Particulariy preferred embodiments of the present invention comprise fiuorochemicals that are liquid at room temperature.
  • the use of such compounds whether as a continuous phase or, as a suspension medium, provides several advantages over prior art liquid inhalation preparations.
  • fiuorochemicals have a proven history of safety and biocompatibility in the lung.
  • fiuorochemicals do not negatively impact gas exchange following pulmonary administration.
  • fiuorochemicals may actually be able to improve gas exchange and, due to their unique wettability characteristics, are able to carry an aerosolized stream of particles deeper into the lung, thereby improving systemic delivery of the desired pharmaceutical compound.
  • the relatively non-reactive nature of fiuorochemicals acts to retard any degradation of an incorporated bioactive agent.
  • many fiuorochemicals are also bacteriostatic thereby decreasing the potential for microbial growth in compatible nebulizer devices.
  • nebulizer mediated aerosolization typically requires an input of energy in order to produce the increased surface area of the droplets and, in some cases, to provide transportation of the atomized or aerosolized medicament.
  • One common mode of aerosolization is forcing a stream of fluid to be ejected from a nozzle, whereby droplets are formed.
  • additional energy is usually imparted to provide droplets that will be sufficiently small to be transported deep into the lungs.
  • additional energy is needed, such as that provided by a high velocity gas stream or a piezoelectric crystal.
  • Two popular types of nebulizers, jet nebulizers and ultrasonic nebulizers rely on the aforementioned methods of applying additional energy to the fluid during atomization.
  • the first category comprises pure piezoelectric single-bolus nebulizers such as those described by M ⁇ tteriein, et. al., (J. Aerosol Med. 1988; 1:231).
  • the desired aerosol cloud may be generated by microchannel extrusion single-bolus nebulizers such as those described in U.S. Pat. No. 3,812,854.
  • a third category comprises devices exemplified by Robertson, et. al., (WO 92/11050) which describes cyclic pressurization single-bolus nebulizers.
  • Robertson, et. al. (WO 92/11050) which describes cyclic pressurization single-bolus nebulizers.
  • Each of the aforementioned references is inco ⁇ orated herein in their entirety. Most devices are manually actuated, but some devices exist which are breath actuated. Breath actuated devices work by releasing aerosol when the device senses the patient inhaling through a circuit.
  • Breath actuated nebulizers may also be placed in-line on a ventilator circuit to release aerosol into the air flow which comprises the inspiration gases for a patient.
  • biocompatible nonaqueous compounds may be used as suspension mediums.
  • they will be able to form aerosols upon the application of energy thereto.
  • the selected suspension medium should be biocompatible (i.e. relatively non-toxic) and non-reactive with respect to the suspended perforated microstructures comprising the bioactive agent.
  • Preferred embodiments comprise suspension media selected from the group consisting of fiuorochemicals, fluorocarbons (including those substituted with other halogens), perfluorocarbons, fluorocarbon/hydrocarbon diblocks, hydrocarbons, alcohols, ethers, or combinations thereof.
  • the suspension medium may comprise a mixture of various compounds selected to impart specific characteristics.
  • the perforated microstructures are preferably insoluble in the suspension medium, thereby providing for stabilized medicament particles, and effectively protecting a selected bioactive agent from degradation, as might occur during prolonged storage in an aqueous solution.
  • the selected suspension medium is bacteriostatic.
  • the suspension formulation also protects the bioactive agent from degradation during the nebulization process.
  • the suspension media may comprise any one of a number of different compounds including hydrocarbons, fluorocarbons or hydrocarbon/fluorocarbon diblocks.
  • the contemplated hydrocarbons or highly fluonnated or perfluorinated compounds may be linear, branched or cyclic, saturated or unsaturated compounds.
  • Conventional structural derivatives of these fiuorochemicals and hydrocarbons are also contemplated as being within the scope of the present invention as well.
  • Selected embodiments comprising these totally or partially fluorinated compounds may contain one or more hetero-atoms and/or atoms of bromine or chlorine.
  • these fiuorochemicals comprise from 2 to 16 carbon atoms and include, but are not limited to, linear, cyclic or polycyclic perfluoroalkanes, bis(perfiuoroalkyl)alkenes, perfluoroethers, perfluoroamines, perfluoroalkyl bromides and perfluoroalkyl chlorides such as dichlorooctane.
  • Particulariy preferred fluorinated compounds for use in the suspension medium may comprise perfluorooctyl bromide C 8 F, 7 Br (PFOB or perflubron), dichlorofluorooctane C 8 F 16 CI ⁇ and the hydrofluoraalkane perfluorooctyl ethane C e F l7 C 2 H 5 (PFOE).
  • perfluorohexane or perfluoropentane as the suspension medium is especially preferred.
  • exemplary fiuorochemicals which are contemplated for use in the present invention generally include halogenated fiuorochemicals (i.e.
  • Fluorocarbons, fiuorocarbon-hydrocarbon compounds and halogenated fiuorochemicals containing other linkage groups, such as esters, thioethers and amines are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • compounds having the general formula, C n F 2 are also suitable for use as suspension media in the present invention.
  • Preferred compounds of this type include C 8 F, 7 C 2 H 5 C 6 F t3 C, 0 H 21 C 8 F, 7 C ⁇ H, 7 C 6 F, 3 CH-CHC 6 H 13 and
  • n F 2n may also be used as well as C n F 2n ,,0- C-,F 2m 0C p H 2p .
  • perfluoroalkyl ated ethers or polyethers may be compatible with the claimed dispersions.
  • Polycyclic and cyclic fiuorochemicals such as C 10 F 18 (F-decalin or perfluorodecalin), perfluoroperhydrophenanthrene, perfluorotetramethylcyclohexane (AP-144) and perfluoro n-butyidecalin are also within the scope of the invention.
  • Additional useful fiuorochemicals include perfluorinated amines, such as F- tripropylamine (“FTPA”) and F-tributylamine (“FTBA”).
  • FMOQ F-4-methyloctahydroquinoiizine
  • FMIQ F-N-methyl- decahydroisoquinoline
  • FHQ F-N-methyldecahydroquinoline
  • FCHP F-N-cyclohexylpyrrolidine
  • FC-75 F-75 or “FC-77”
  • Still other useful fluorinated compounds include perfluorophenanthrene, perfluoromethyldecalin, perfluorodimethylethylcyclohexane, perfluorodimethyldecalin, perfluorodiethyldecalin, perfluoromethyladamantane, perfiuorodimethyladamantane.
  • fiuorochemicals having nonfluorine substituents such as, perfluorooctyl hydride, and similar compounds having different numbers of carbon atoms are also useful.
  • fluorochemicals such as, perfluorooctyl hydride, and similar compounds having different numbers of carbon atoms are also useful.
  • Those skilled in the art will further appreciate that other variously modified fiuorochemicals are encompassed within the broad definition of fluorochemical as used in the instant application and suitable for use in the present invention. As such, each of the foregoing compounds may be used, alone or in combination with other compounds to form the stabilized dispersions of the present invention.
  • fluorocarbons or classes of fluorinated compounds, that may be useful as suspension media include, but are not limited to, fiuoroheptane, fiuorocycloheptane fluoromethylcycloheptane, fluorohexane, fluorocyclohexane, fluoropentane, fluorocyclopentane, fluoromethylcyclopentane, fiuororjmethylcyciopentanes, fluoromethylcyclobutane, fluorodimethylcyclobutane, fluorotrimethylcyclobutane, fluorobutane, fluorocyclobutane, fluoropropane, fluoroethers, fluoropolyethers and fluorotriethylamines.
  • the selected suspension medium will preferably have a vapor pressure less than about 5 atmospheres and more preferably less than about 2 atmospheres. Unless otherwise specified, all vapor pressures recited herein are measured at 25°C. In other embodiments, preferred suspension media compounds will have vapor pressures on the order of about 5 torr to about 760 torr, with more preferable compounds having vapor pressures on the order of from about 8 torr to about 600 torr, while still more preferable compounds will have vapor pressures on the order of from about 10 torr to about 350 torr.
  • suspension media may be used in conjunction with compressed air nebulizers, ultrasonic nebulizers or with mechanical atomizers to provide effective ventilation therapy.
  • more volatile compounds may be mixed with lower vapor pressure components to provide suspension media having specified physical characte ⁇ stics selected to further improve stability or enhance the bioavaiiability of the dispersed bioactive agent.
  • inventions directed to nebulizers will comp ⁇ se suspension media that boil at selected temperatures under ambient conditions (i.e. 1 atm).
  • prefened embodiments will comp ⁇ se suspension media compounds that boil above 0°C, above 5°C, above 10°C, above 15°, or above 20°C.
  • the suspension media compound may boil at or above 25°C or at or above 30°C.
  • the selected suspension media compound may boil at or above human body temperature (i.e. 37°C), above 45°C, 55°C, 65°C, 75°C, 85°C or above 100°C.
  • the stabilized dispersions of the present invention may be used in conjunction with liquid dose instillation or LDI techniques.
  • Liquid dose instillation involves the direct administration of a stabilized dispersion to the lung
  • direct pulmonary administration of bioactive compounds is particularly effective in the treatment of disorders especially where poor vascular circulation of diseased portions of a lung reduces the effectiveness of intravenous drug delivery
  • the stabilized dispersions are preferably used in conjunction with partial liquid ventilation or total liquid ventilation
  • the present invention may further comprise introducing a therapeutically beneficial amount of a physiologically acceptable gas (such as nit ⁇ c oxide or oxygen) into the pharmaceutical microdispersion prior to, du ⁇ ng or following administration
  • a physiologically acceptable gas such as nit ⁇ c oxide or oxygen
  • the dispersions of the present invention may be administered to the lung using a pulmonary delivery conduit.
  • pulmonary delivery conduit shall be construed in a broad sense to comprise any device or apparatus, or component thereof, that provides for the instillation or administration of a liquid in the lungs.
  • a pulmonary delivery conduit or delivery conduit shall be held to mean any bore, lumen, catheter, tube, conduit, syn ⁇ ge, actuator, mouthpiece, endotrach ⁇ al tube or bronchoscope that provides for the administration or instillation of the disclosed dispersions to at least a portion of the pulmonary air passages of a patient in need thereof.
  • the delivery conduit may or may not be associated with a liquid ventilator or gas ventilator.
  • the delivery conduit shall comprise an e ⁇ dotracheal tube or bronchoscope.
  • the dispersions of the present invention may be administered to ventilated (e.g. those connected to a mechanical ventilator) or nonventilated, patients (e.g. those undergoing spontaneous respiration). Accordingly, in preferred embodiments the methods and systems of the present invention may comprise the use or inclusion of a mechanical ventilator. Further, the stabilized dispersions of the present invention may also be used as a lavage agent to remove debris in the lung, or for diagnostic lavage procedures. In any case the introduction of liquids, particularly fiuorochemicals, into the lungs of a patient is well known and could be accomplished by a skilled artisan in possession of the instant specification without undue experimentation.
  • suspension media compatible with LDI techniques are similar to those set forth above for use in conjunction with nebulizers. Accordingly, for the purposes of the present application suspension media for dispersions compatible with LDI shall be equivalent to those enumerated above in conjunction with use in nebulizers In any event, it will be appreciated that in particularly preferred LDI embodiments the selected suspension medium shall comprise a fluorochemical that is liquid under ambient conditions
  • the disclosed dispersions are preferably administered directly to at least a portion of the pulmonary air passages of a mammal.
  • direct instillation or “direct administration” shall be held to mean the introduction of a stabilized dispersion into the lung cavity of a mammal.
  • the dispersion will preferably be administered through the trachea of a patient and into the lungs as a relatively free flowing liquid passing through a delivery conduit and into the pulmonary air passages
  • the flow of the dispersion may be gravity assisted or may be afforded by induced pressure such as through a pump or the compression of a syringe plunger
  • the amount of dispersion administered may be monitored by mechanical devices such as flow meters or by visual inspection.
  • the stabilized dispersions may be administered up to the functional residual capacity of the lungs of a patient, it will be appreciated that selected embodiments will comprise the pulmonary administration of much smaller volumes (e.g. on the order of a milliliter or less).
  • the volume administered may be on the order of 1, 3, 5, 10, 20, 50, 100, 200 or 500 milliliters.
  • the liquid volume is less than 0.25 or 0.5 percent FRC.
  • the liquid volume is 0.1 percent FRC or less.
  • LDI treatment as disclosed herein represents a new alternative for critically ill patients on mechanical ventilators, and opens the door for treatment of less ill patients with bro ⁇ choscopic administration.
  • osmotic agents can be added to fine tune the stabilized dispersions for maximum life and ease of administration.
  • Such components may be added directly to the suspension medium or associated with, or inco ⁇ orated in, the perforated microstructures. Considerations such as ste ⁇ lity, isotomcity, and biocompatibilit ⁇ may govern the use of conventional additives to the disclosed compositions. The use of such agents will be understood to those of ordinary skill in the art and, the specific quantities, ratios, and types of agents can be determined empmcally without undue expenmentation.
  • the stabilized dispersions of the present invention are particularly suitable for the pulmonary administration of bioactive agents, they may also be used for the localized or systemic administration of compounds to any location of the body Accordingly, it should be emphasized that, in preferred embodiments, the formulations may be administered using a number of different routes including, but not limited to, the gastrointestinal tract, the respiratory tract, topically, intramuscularly, intrape ⁇ toneally, nasally, vaginaily, rectally, aurally, orally or ocular More generally, the stabilized dispersions of the present invention may be used to deliver agents topically or by administration to a non pulmonary body cavity In preferred embodiments the body cavity is selected from the group consisting of the peritoneum, sinus cavity, rectum, urethra, gastrointestinal tract, nasal cavity, vagina, auditory meatus, oral cavity, buccal pouch and pleura Among other indications, stabilized dispersions comprising the appropriate bioactive agent, (e.g.
  • the dispersions of the present invention may be used to selectively deliver pharmaceutical compounds to the lining of the stomach for the treatment of H. py/on infections or other ulcer related disorders
  • the perforated microstructure powders and stabilized dispersions disclosed herein may be advantageously supplied to the physician or other health care professional, in a ste ⁇ le, prepackaged or kit form. More particularly, the formulations may be supplied as stable powders or preformed dispersions ready for administration to the patient. Conversely, they may be provided as separate, ready to mix components. When provided in a ready to use form, the powders or dispersions may be packaged in single use containers or reservoirs, as well as in multi-use containers or reservoirs. In either case, the container or reservoir may be associated with the selected inhalation or administration device and used as described herein.
  • the stabilized preparations When provided as individual components (e.g., as powdered microspheres and as neat suspension medium) the stabilized preparations may then be formed at any time p ⁇ or to use by simply combining the contents of the containers as directed. Additionally, such kits may contain a number of ready to mix, or prepackaged dosing units so that the user can then administer them as needed.
  • kits may contain a number of ready to mix, or prepackaged dosing units so that the user can then administer them as needed.
  • preferred embodiments of the present invention comprise powders and stabilized dispersions for use in pharmaceutical applications, it will be appreciated that the perforated microstructures and disclosed dispersions may be used for a number of non pharmaceutical applications. That is, the present invention provides perforated microstructures which have a broad range of applications where a powder is suspended and/or aerosolized.
  • the present invention is especially effective where an active or bioactive ingredient must be dissolved, suspended or solubilized as fast as possible.
  • an active or bioactive ingredient must be dissolved, suspended or solubilized as fast as possible.
  • suitable excipients as described herein, will result in an improvement in dispersibility, and/or suspension stability.
  • rapid dispersement applications include, but are not limited to: detergents, dishwasher detergents, food sweeteners, condiments, spices, mineral flotation detergents, thickening agents, foliar fertilizers, phytohormones, insect pheromones, insect repellents, pet repellents, pesticides, fungicides, disinfectants, perfumes, deodorants, etc.
  • non-aqueous suspension media i.e., solid , liquid or gaseous
  • the use of perforated microstructures to provide a "homodispersion" minimizes particle-particle interactions.
  • the perforated microspheres and stabilized suspensions of the present invention are particularly compatible with applications that require: inorganic pigments, dyes, inks, paints, explosives, pyrotechnic, adsorbents, absorbents, catalyst, nucleating agents, polymers, resins, insulators, fillers, etc.
  • the present invention offers benefits over prior art preparations for use in applications which require aerosolization or atomization.
  • the preparations can be in the form of a liquid suspension (such as with a propellant) or as a dry powder.
  • Preferred embodiments comprising perforated microstructures as described herein include, but are not limited to, ink jet printing formulations, powder coating, spray paint, spray pesticides etc.
  • Perforated microstructures comprising gentamicin sulfate were prepared by a spray drying technique using a B-191 Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N 2 flow: 2,800 L/hr. Variations in powder porosity were examined as a function of the blowing agent concentration.
  • Fluorocarbon-in-water emulsions of perfluorooctyl bromide containing a 1 :1 w/w ratio of phosphatidylcholine (PC), and gentamicin sulfate were prepared varying only the PFC/PC ratio.
  • 1.3 grams of hydrogenated egg phosphatidylcholine was dispersed in 25 mL deionized water using an Ultra-Turrax mixer
  • the fomiulation devoid of perfluorooctyl bromide produced microstructures that appeared to be highly agglomerated and readily adhered to the surface of the glass vial.
  • smooth, spherically shaped microparticles were obtained when relatively little (PFC/PC ratio - 1.1 or 2.2) blowing agent was used.
  • PFC/PC ratio was increased the porosity and surface roughness increased dramatically.
  • the hollow nature of the microstructures was also enhanced by the incorporation of additional blowing agent. More particularly, the series of six micrographs labeled 1A2 to 1 F2 show cross sections of fractured microstructures as revealed by transmission electron microscopy (TEM). Each of these images was produced using the same microstructure preparation as was used to produce the corresponding SEM micrograph in the left hand column. Both the hollow nature and wall thickness of the resulting perforated microstructures appeared to be largely dependent on the concentration of the selected blowing agent. That is, the hollow nature of the preparation appeared to increase and the thickness of the particle walls appeared to decrease as the PFC/PC ratio increased. As may be seen in Figs.
  • the blowing agent in these formulations consisted of an emulsified fluorochemical (FC) oil.
  • Emulsions were prepared with the following FCs: PFH, Freon 113, Perflubron and FDC.
  • FCs PFH, Freon 113, Perflubron and FDC.
  • FC-in- water emulsion was mixed for a total of not less than 4 minutes.
  • the resulting emulsions were then further processed using an Avestin (Ottawa, Canada) high pressure homogenizer at 15,000 psi and 5 passes.
  • Gentamicin sulfate was dissolved in approximately 4 to 5 mL deionized water and subsequently mixed with the FC emulsion.
  • the gentamicin powders were obtained by spray drying (B ⁇ chi, 191 Mini Spray Dryer). Each emulsion was fed at a rate of 2.5 mL/min.
  • the inlet and outlet temperatures of the spray dryer were 85°C and 55°C respectively.
  • the nebulization air and aspiration flows were 2800 L/hr and 100% respectively.
  • a free flowing pale yellow dry powder was obtained for all formulations.
  • the yield for the various formulations ranged from 35 to 60%.
  • the various gentamicin sulfate powders had a mean volume weighted particle diameters that ranged from 1.52 to 4.91 ⁇ m.
  • Gentamicin Sulfate Sprav-Dried Powders A strong dependence of the powder morphology, porosity, and production yield (amount of powder captured in the cyclone) was observed as a function of the blowing agent boiling point. In this respect the powders produced in Example III were observed using scanning electron microscopy. Spray drying a fluorochemical (FC) emulsion with a boiling point below the 55°C outlet temperature (e.g., perfluorohexane [PFH] or Freon 113), yielded amorphously shaped (shriveled or deflated) powders that contained little or no pores.
  • FC fluorochemical
  • emulsions formulated with higher boiling FCs produced spherical porous particles.
  • Powders produced with higher boiling blowing agents also had production yields approximately two times greater than powders produced using relatively low boiling point blowing agents.
  • the selected blowing agents and their boiling points are shown in Table II directly below.
  • Example IV illustrates that the physical characteristics of the blowing agent (i.e., boiling point) greatly influences the ability to provide perforated microparticles.
  • a particular advantage of the present invention is the ability to alter the microstructure morphology and porosity by modifying the conditions and nature of the blowing agent.
  • Albuterol sulfate powder was prepared by spray-drying technique by using a B-191 Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following conditions: Aspiration: 100% Inlet temperature: 85°C Outlet temperature: 61 °C Feed pump: 2.5 mL/min. N 2 flow: 47 L/min.
  • the feed solution was prepared by mixing solutions A and B prior to spray drying.
  • Solution A Twenty grams of water was used to dissolve 1.0 grams of Albuterol sulfate and 0.021 grams of poloxamer 188.
  • Solution B represented an emulsion of a fluorocarbon in water, stabilized by a phosphohpid, which was prepared in the following way.
  • the resulting emuision was then processed using an Avestin (Ottawa, Canada) high-pressure homogenizer at 18,000 psi and 5 passes.
  • Solutions A and B were combined and fed into the spray dryer under the conditions described above.
  • a free flowing, white powder was collected at the cyclone separator as is standard for this spray dryer.
  • the albuterol sulfate powders had mean volume weighted particle diameters ranging from 1.28 to 2.77 ⁇ m, as determined by an Aerosizer (Amherst Process Instruments, Amherst, MA). By SEM, the albuterol sulfate/phospholipid spray dried powders were spherical and highly porous.
  • Example V further demonstrates the wide variety of blowing agents that may be used to provide perforated microparticles.
  • a particular advantage of the present invention is the ability to alter the microstructure morphology and porosity by manipulating the formulation and spray drying conditions.
  • Example V demonstrates the particle diversity achieved by the present invention and the ability to effectively inco ⁇ orate a wide variety of pharmaceutical agents therein.
  • Aerosol OT/polyvinyi alcohol particles were prepared by spray-drying technique using a B-191 Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following conditions: Aspiration: 85% Inlet temperature: 60°C Outlet temperature: 43°C Feed pump: 7.5 mL/min. N 2 flow: 36 L/min.
  • Solution A Twenty grams of water was used to dissolve 500 milligrams of polyvinyl alcohol (PVA).
  • PVA polyvinyl alcohol
  • Solution B represented an emulsion of carbon tetrachloride in water, stabilized by aerosol OT, which was prepared in the following way.
  • the resulting emulsion was then processed using an Avestin (Ottawa, Canada) high-pressure homogenizer at 12,000 psi and 2 passes.
  • the emulsion was then fed into the spray dryer under the conditions described above.
  • a free flowing, white powder was collected at the cyclone separator as is standard for this spray dryer.
  • the Aerosol OT/PVA powder had a mean volume weighted particle diameter of 5.28 ⁇ 3.27 ⁇ m as determined by an Aerosizer (Amherst Process
  • Example VI further demonstrates the variety of emulsion systems (here, reverse water-in-oil), formulations and conditions that may be used to provide perforated microparticles.
  • a particular advantage of the present invention is the ability to alter formulations and/or conditions to produce compositions having a microstructure with selected porosity. This principle is further illustrated in the following example.
  • Span 60/poiycaprolactone particles were prepared by spray-drying technique by using a B-191 Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following conditions: Aspiration: 85%
  • Feed pump 7.5 mL/min.
  • a water-in-carbon tetrachloride emulsion was prepared in the following manner. Two grams of Span 60, was dispersed in 80 grams of carbon tetrachloride using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 15 to 20° C). Twenty grams of deionized water was added dropwise during mixing. After the addition was complete, the water-in-oil emulsion was mixed for a total of not less than 4 minutes (T - 15 to 20°C). The resulting emulsion was then further processed using an Avestin (Ottawa, Canada) high- pressure homogenizer at 12,000 psi and 2 passes.
  • Avestin Ottawa, Canada
  • Poloxamer 188 (BASF, Mount Olive, NJ)
  • solution 1 The ingredients of solution 1 were dissolved in warm water using a stir plate.
  • the surfactants in solution 2 were dispersed in water using a high shear mixer.
  • the solutions were combined following emulsification and saturated with nitrogen prior to spray drying.
  • the resulting dry, free flowing, hollow spherical product had a mean particle diameter of 2.6 ⁇ 1.5 ⁇ m.
  • the particles were spherical and porous as determined by SEM. This example illustrates the point that a wide of blowing agents (here nitrogen) may be used to provide microstructures exhibiting the desired morphology. Indeed, one of the primary advantages of the present invention is the ability to alter formation conditions so as to preserve biological activity (i.e. with proteins), or to produce microstructures having selected porosity.
  • the suspension stability was defined as, the resistance of powders to cream in a nonaqueous medium using a dynamic photosedimentation method. Each sample was suspended in Perflubron at a concentration of 0.8 mg/mL. The creaming rates were measured using a Horiba CAPA-700 photosedimentation particle size analyzer (Irvine, CA) under the following conditions:
  • Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following spray conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N 2 flow: 2,800 L/hr.
  • the feed solution was prepared by mixing two solutions A and B immediately prior to spray drying.
  • Solution A 20g of water was used to dissolve 1g of albuterol sulfate (Accurate Chemical, Westbury, NY) and 0.021 g of poloxamer 188 NF grade (BASF, Mount Olive, NJ).
  • Solution B A fluorocarbon-in-water emulsion stabilized by phosphohpid was prepared in the following manner.
  • the phosphohpid 1 g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 150g of hot deionized water (T - 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70° C). 25g of perfluorooctyl bromide (Atochem, Paris, France) was added dropwise during mixing. After the fluorocarbon was added, the emulsion was mixed for a period of not less than 4 minutes.
  • the resulting coarse emulsion was then passed through a high pressure homogenizer (Avesti ' n, Ottawa, Canada) at 18,000 psi for 5 passes.
  • Solutions A and B were combined and fed into the spray-dryer under the conditions described above.
  • a free flowing, white powder was collected at the cyclone separator.
  • the hollow porous albuterol sulfate particles had a volume-weighted mean aerodynamic diameter of 1.18 ⁇ 1.42 ⁇ m as determined by a time-of- flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). Scanning electron microscopy (SEM) analysis showed the powders to be spherical and highly porous.
  • the tap density of the powder was determined to be less than 0.1 g/cm 3 .
  • Perforated microstructures comprising cromolyn sodium were prepared by a spray-drying technique with a B-191 Mini Spray-Drier (B ⁇ chi, Flawil, Switzerland) under the following spray conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N 2 flow: 2,800 L/hr.
  • the feed solution was prepared by mixing two solutions A and B immediately prior to spray drying.
  • Solution A 20g of water was used to dissolve 1g of cromolyn sodium (Sigma Chemical Co, St. Louis, MO) and 0.021 g of poloxamer 188 NF grade (BASF, Mount Olive, NJ).
  • Solution B A fluorocarbon-in-water emulsion stabilized by phospholipid was prepared in the following manner.
  • the phospholipid 1g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 150g of hot deionized water (T - 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to
  • a free flowing, pale yellow powder was collected at the cyclone separator.
  • the hollow porous cromolyn sodium particles had a volume-weighted mean aerodynamic diameter of 1.23 ⁇ 1.31 ⁇ m as determined by a time-of-flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). As shown in Fig. 3, scanning electron microscopy (SEM) analysis showed the powders to be both hollow and porous. The tap density of the powder was determined to be less than 0.1 g/cm 3 .
  • Solution A 20g of water was used to dissolve 0.5gr of human pancreas DNase I (Calbiochem, San Diego CA) and 0.012g of poloxamer 188 NF grade (BASF, Mount Olive, NJ).
  • Solution B A fluorocarbon-in-water emulsion stabilized by phospholipid was prepared in the following way. The phospholipid, 0.52g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 87g of hot deionized water (T - 50 to 60° C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70°C).
  • Solutions A and B were combined and fed into the spray dryer under the conditions described above.
  • a free flowing, pale yellow powder was collected at the cyclone separator.
  • the hollow porous DNase I particles had a volume-weighted mean aerodynamic diameter of 1.29 ⁇ 1.40 ⁇ m as determined by a time-of- flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). Scanning electron microscopy (SEM) analysis showed the powders to be both hollow and porous.
  • the tap density of the powder was determined to be less than 0.1 g/cm 3 .
  • the foregoing example further illustrates the extraordinary compatibility of the present invention with a va ⁇ ety of bioactive agents. That is, in addition to relatively small, hardy compounds such as steroids, the preparations of the present invention may be formulated to effectively inco ⁇ orate larger, fragile molecules such as proteins and genetic matenal.
  • the reaction is allowed to proceed at 50°C for 8 hours
  • the reaction is then terminated by spray drying the emulsion using a high pressure liquid chromatography (HPLC) pump.
  • HPLC high pressure liquid chromatography
  • the emulsion is pumped through a 200 x 0.030 inch i d stainless steel tubing into a Niro atomizer portable spray dryer (Niro Atomize, Copenhagen, Denmark) equipped with a two fluid nozzle (0.01 " i.d.) employing the following settings
  • Atomizer nitrogen flow 45 L/m ⁇ n, 1,800 psi
  • microparticles have the advantage of incorporating the pigment directly into the polymeric matrix.
  • the process allows for the production of different particle sizes by modifying the components and the spray drying conditions with the pigment particle diameter largely dictated by the diameter of the copolymer resin particles XV Andersen Impactor Test for Assessing MDI and DPI Performance The MDIs and DPIs were tested using commonly accepted pharmaceutical procedures. The method utilized was compliant with the United State Pharmacopeia (USP) procedure (Pharmacopeia!
  • a pre weighed amount of the hollow porous particles prepared in Examples I, X, XI, and XII were placed into 10 ml aluminum cans, and dried in a vacuum oven under the flow of nitrogen for 3 4 hours at
  • the amount of powder filled into the can was determined by the amount of drug required for therapeutic effect. After this, the can was crimp sealed using a DF31/50act 50 I valve (Valois of America, Greenwich, CT) and filled with HFA-134a (DuPont, Wilmington, DE) propellant by overpressure through the stem. The amount of the propellant in the can was determined by weighing the can before and after the fill.
  • MDIs were prepared as in Example XVI with various preparations of perforated microstructures comprising gentamicin formulations as described in Example I.
  • MDIs containing 0.48 wt % spray dried powders in HFA 134a were studied.
  • the spray dried powders exhibit varying porosity.
  • the formulations were filled in clear glass vials to allow for visual examination.
  • the MDI formulated with perforated microstructures was found to have superior aerosol performance compared with Intal * .
  • the spray dried cromolyn formulations possessed a substantially higher fine particle fraction ( " 67%), and significantly decreased throat deposition (6-fold), along with a smaller MMAD value.
  • the effective delivery provided for by the present invention allowed for a fine particle dose that was approximately the same as the prior art commercial formulation even though the amount of perforated microstructures administered (300 ⁇ g) was roughly a third of the Intaf dose administered (800 ⁇ g).
  • Example X The in vitro aerodynamic properties of hollow porous albuterol sulfate microspheres as prepared in Example X was characterized using an Andersen Mark II Cascade Impactor (Andersen Sampler, Atlanta, GA) and an Amherst Aerosizer (Amherst Instruments, Amherst, MA).
  • Example XVI A MDI preparation of albuterol sulfate microspheres was prepared as in Example XVI A single actuation was discharged into the aerosizer sample chamber for particle size analysis. Twenty actuations were discharged from the device into the impactor A 30 second interval was used between each actuation. Again, the results were quantitated as described in Example XV.
  • the results comparing the particle size analysis of the neat albuterol sulfate powder and the albuterol sulfate powder discharged from either a DPI or MDI are shown in Table V below.
  • the albuterol sulfate powder delivered from the DPI was indistinguishable from the neat powder which indicates that little or no aggregation had occurred during actuation.
  • some aggregation was observed using an MDI as evidenced by the larger aerodynamic diameter of particles delivered from the device
  • the spray dried albuterol sulfate powder delivered from the DPI had enhanced deep lung deposition and minimized throat deposition when compared with the MDI
  • the MDI formulation had a fine particle fraction (FPF) of 79% and a fine particle dose (FPD) of 77 ⁇ g/actuation, while the DPI had a FPF of 87% and a FPD of 100 ⁇ g/ actuation.
  • Figure 5 and the Example above exemplifies the excellent flow and aerodynamic properties of the herein described spray d ⁇ ed powders delivered from a DPI.
  • one of the primary advantages of the present invention is the ability to produce small aerodynamically light particles which aerosolize with ease and which have excellent inhalation properties. These powders have the unique properties which enable them to be effectively and efficiently delivered from either a MDI or DPI This principle is further illustrated in the next Example.
  • BDP Beclomethasone Dipropionate Microspheres Delivered From DPIs and MDIs
  • the in vitro aerodynamic properties of hollow porous beclomethasone dipropionate (BDP) microspheres as prepared in Example XI was characterized using an Andersen Mark II Cascade Impactor (Andersen Sampler, Atlanta, GA) and an Amherst Aerosizer (Amherst Instruments, Amherst, MA).
  • Example XVI A MDI preparation of beclomethasone dipropionate (BDP) microspheres was prepared as in Example XVI. A single actuation was discharged into the aerosizer sample chamber for particle size analysis Twenty actuations were discharged from the device into the impactor A 30 second interval was used between each actuation
  • Example XX the BDP powder delivered from the DPI was indistinguishable from the neat powder which indicates that little or no aggregation had occurred during actuation. On the other hand, some aggregation was observed using an MDI as evidenced by the larger aerodynamic diameter of particles delivered from the device.
  • the spray dried BDP powder delivered from the DPI had enhanced deep lung deposition and minimized throat deposition when compared with the MDI.
  • the MDI formulation had a fine particle fraction (FPF) of 79% and a fine particle dose (FPD) of 77 ⁇ g/actuation, while the DPI had a FPF of 87% and a FPD of 100 ⁇ g/ actuation.
  • FPF fine particle fraction
  • FPD fine particle dose
  • This foregoing example serves to illustrate the inherent diversity of the present invention as a drug delivery platform capable of effectively incorporating any one of a number of pharmaceutical agents and effectively delivered from various types of delivery devices (here MDI and DPI) currently used in the pharmaceutical arena.
  • the excellent flow and aerodynamic properties of the dry powders shown in the proceeding examples is further exemplified in the next example
  • Example X Preparation of the albuterol sulfate microspheres is described in Example X with albuterol sulfate deposition in the cascade impactor analyzed as desc ⁇ bed in Example XV Approximately 300 ⁇ g of albuterol sulfate microspheres were manually loaded into empty Ventohn Rotocap gelatin capsules The procedure described in the package insert for loading and actuating drug capsules with a Rotohaler device was followed. Ten actuations were discharged from the device into the impactor A 30 second interval was used between each actuation
  • the hollow porous albuterol sulfate powder delivered from the Rotohaler device had a significantly higher fine particle fraction (3 fold) and a smaller MMAD value as compared with Ventohn Rotocaps *
  • the commercially available Ventohn Rotocap' formulation had a fine particle fraction (FPF) of 20% and a fine particle dose (FPD) of 15 ⁇ g/actuat ⁇ on
  • the hollow porous albuterol sulfate microspheres had a FPF of 63% and a FPD of 60 ⁇ g/ actuation.
  • Phospholipids and Cromolyn sodium in Perfluorooctyletha ⁇ e using a MicroMist Nebulizer Forty milligrams of the lipid based microspheres containing 50% cromolyn sodium by weight (as from Example XII) were dispersed in 10 ml perfluorooctylethane (PFOE) by shaking, forming a suspension. The suspension was nebulized until the fluorocarbon liquid was delivered or had evaporated using a MicroMist (DeVilbiss) disposable nebulizer using a PulmoAide* air compressor (DeVilbiss). As described above in Example XV, an Andersen Cascade Impactor was used to measure the resulting particle size distribution.
  • PFOE perfluorooctylethane
  • the fine particle fraction is the ratio of particles deposited in stages 2 through 7 to those deposited in all stages of the impactor.
  • the fine particle mass is the weight of material deposited in stages 2 through 7.
  • the deep lung fraction is the ratio of particles deposited in stages 5 through 7 of the impactor (which correlate to the alveoli) to those deposited in all stages.
  • the deep lung mass is the weight of material deposited in stages 5 through 7. Table VIII immediately below provides a summary of the results.
  • XXIV Nebulization of Porous Paniculate Structures Comprising Phospholipids and Cromolyn Sodium in Perfluorooctylethane using a Raindrop * Nebulizer
  • a quantity of lipid based microspheres containing 50% cromolyn sodium, as from Example XII, weighing 40 mg was dispersed in 10 ml perfluorooctylethane (PFOE) by shaking, thereby forming a suspension.
  • the suspension was nebulized until the fluorocarbon liquid was delivered or had evaporated using a Raindrop" disposable nebulizer (Nellcor Puritan Bennet) connected to a PulmoAide * air compressor (DeVilbiss).
  • An Andersen Cascade Impactor was used to measure the resulting particle size distribution in the manner described in Examples XV and XXIII. Table IX immediately below provides a summary of the results.
  • XXV Nebulization of Agueous Cromolyn Sodium Solution
  • the contents of plastic vial containing a unit dose inhalation solution of 20 mg of cromolyn sodium in 2 ml purified water (Dey Laboratories) was nebulized using a MicroMist disposable nebulizer (DeVilbiss) using a PulmoAide * air compressor (DeVilbiss).
  • the cromolyn sodium solution was nebulized for 30 minutes.
  • An Andersen Cascade Impactor was used to measure the resulting size distribution of the nebulized particles, by the method described above in Example XV. Table X immediately below provides a summary of the results.
  • the formulations nebulized from fluorocarbon suspension mediums in Examples XXIll and XXIV provided a greater percentage of deep lung deposition than the aqueous solution. Such high deposition rates deep in the lung is particularly desirable when delivering agents to the systemic circulation of a patient.

Abstract

Engineered particles are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.

Description

PERFORATED MICROPARTICLES AND METHODS OF USE
Field of the Invention
The present invention relates to formulations and methods for the production of perforated microstructures which comprise an active agent In particularly preferred embodiments, the active agent will comprise a bioactive agent. The perforated microstructures will preferably be used in conjunction with inhalation devices such as a metered dose inhaler, dry powder inhaler or nebulizer for both topical and systemic delivery via pulmonary or nasal routes.
Background of the Invention
Targeted drug delivery means are particularly desirable where toxicity or bioavailabi ty of the pharmaceutical compound is an issue. Specific drug delivery methods and compositions that effectively deposit the compound at the site of action potentially serve to minimize toxic side effects, lower dosing requirements and decrease therapeutic costs. In this regard, the development of such systems for pulmonary drug delivery has long been a goal of the pharmaceutical industry.
The three most common systems presently used to deliver drugs locally to the pulmonary air passages are dry powder inhalers (DPIs), metered dose inhalers (MDIs) and nebulizers. MDIs, the most popular method of inhalation administration, may be used to deliver medicaments in a solubilized form or as a dispersion. Typically MDIs compπse a Freon or other relatively high vapor pressure propellant that forces aerosolized medication into the respiratory tract upon activation of the device. Unlike MDIs, DPIs generally rely entirely on the patient's inspiratory efforts to introduce a medicament in a dry powder form to the lungs. Finally, nebulizers form a medicament aerosol to be inhaled by imparting energy to a liquid solution. More recently, direct pulmonary delivery of drugs duπng liquid ventilation or pulmonary lavage using a fluorochemical medium has also been explored. While each of these methods and associated systems may prove effective in selected situations, inherent drawbacks, including formulation limitations, can limit their use.
The MDI is dependent on the propulsive force of the propellant system used in its manufacture. Traditionally, the propellant system has consisted of a mixture of chiorofluorocarbons (CFCs) which are selected to provide the desired vapor pressure and suspension stability. Currently, CFCs such as Freon 11, Freon 12, and Freon 114 are the most widely used propellents in aerosol formulations for inhalation administration. While such systems may be used to deliver solubilized drug, the selected bioactive agent is typically incorporated in the form of a fine particulate to provide a dispersion. To minimize or prevent the problem of aggregation in such systems, surfactants are often used to coat the surfaces of the bioactive agent and assist in wetting the particles with the aerosol propellant. The use of surfactants in this way to maintain substantially uniform dispersions is said to "stabilize" the suspensions. Unfortunately, traditional chlorofluorocarbon propellants are now believed to deplete stratosphenc ozone and, as a consequence, are being phased out. This, in turn, has led to the development of aerosol formulations for pulmonary drug delivery employing so-called environmentally fnendly propellants. Classes of propellants which are believed to have minimal ozone depletion potential in companson with CFCs are perfluoπnated compounds (PFCs) and hydrofluoroalkanes (HFAs). While selected compounds in these classes may function effectively as biocompatible propellants, many of the surfactants that were effective in stabilizing drug suspensions in CFCs are no longer effective in these new propellant systems. As the solubility of the surfactant in the HFA decreases, diffusion of the surfactant to the interface between the drug particle and HFA becomes exceedingly slow, leading to poor wetting of the medicament particles and a loss of suspension stability. This decreased solubility for surfactants in HFA propellants is likely to result in decreased efficacy with regard to any incorporated bioactive agent.
More generally, drug suspensions in liquid fluorochemtcais, including HFAs, comprise heterogeneous systems which usually require redispersion prior to use. Yet, because of factors such as patient compliance obtaining a relatively homogeneous distribution of the pharmaceutical compound is not always easy or successful. In addition, prior art formulations comprising micronized particulates may be prone to aggregation of the particles which can result in inadequate delivery of the drug Crystal growth of the suspensions via Ostwald ripening may also lead to particle size heterogeneity and can significantly reduce the shelf life of the formulation Another problem with conventional dispersions comprising micronized dispersants is particle coarsening. Coarsening may occur via several mechanisms such as flocculatioπ, fusion, molecular diffusion, and coalescence Over a relatively short period of time these processes can coarsen the formulation to the point where it is no longer usable. As such, while conventional systems compnsiπg fluorochemical suspensions for MDIs or liquid ventilation are certainly a substantial improvement over pπor art non fluorochemical delivery vehicles, the drug suspensions may be improved upon to enable formulations with improved stability that also offer more efficient and accurate dosing at the desired site Similarly, conventional powdered preparations for use in DPIs often fail to provide accurate, reproducible dosing over extended periods In this respect, those skilled in the art will appreciate that conventional powders (i.e. micronized) tend to aggregate due to hydrophobic or electrostatic interactions between the fine particles These changes in particle size and increases in cohesive forces over time tend to provide powders that give undesirable pulmonary distribution profiles upon activation of the device. More particularly, fine particle aggregation disrupts the aerodynamic properties of the powder, thereby preventing large amounts of the aerosolized medicament from reaching the deeper airways of the lung where it is most effective
In order to overcome the unwanted increases in cohesive forces, prior art formulations have typically used large carrier particles compnsing lactose to prevent the fine drug particles from aggregating. Such carrier systems allow for at least some of the drug particles to loosely bind to the lactose surface and disengage upon inhalation. However, substantial amounts of the drug fail to disengage from the large lactose particles and are deposited in the throat. As such, these carrier systems are relatively inefficient with respect to the fine particle fraction provided per actuation of the DPI. Another solution to particle aggregation is proposed in WO 98/31346 wherein particles having relatively large geometric diameters (i e preferably greater than 10 μm) are used to reduce the amount of particle interactions thereby preserving the flowability of the powder. As with the prior art earner systems, the use of large particles apparently reduces the overall surface area of the powder preparation reportedly resulting in improvements in flowability and fine particle fraction Unfortunately, the use of relatively large particles may result in dosing limitations when used in standard DPIs and provide for less than optimal dosing due to the potentially prolonged dissolution times As such, there still remains a need for standard sized particles that resist aggregation and preserve the flowability and dispersibility of the resulting powder.
Accordingly, it is an object of the present invention to provide methods and preparations that advantageously allow for the nasal or pulmonary administration of powders having relatively high fine particle fractions. It is a further object of the present invention to provide stabilized preparations suitable for aerosolization and subsequent administration to the pulmonary air passages of a patient in need thereof.
It is yet another object of the present invention to provide powders that may be used to provide stabilized dispersions.
It is still a further object of the present invention to provide powders exhibiting relatively low cohesive forces that are compatible for use in dry powder inhalers.
Summary of the Invention
These and other objects are provided for by the invention disclosed and claimed herein To that end, the methods and associated compositions of the present invention provide, in a broad aspect, for the improved delivery of agents to a desired site. More particularly, the present invention may provide for the delivery of bioactive agents to selected physiological target sites using perforated microstructure powders In preferred embodiments, the bioactive agents are in a form for administration to at least a portion of the pulmonary air passages of a patient in need thereof To that end, the present invention provides for the formation and use of perforated microstructures and delivery systems comprising such powders, as well as individual components thereof. The disclosed powders may further be dispersed in selected suspension media to provide stabilized dispersions Unlike prior art powders or dispersions for drug delivery, the present invention preferably employs novel techniques to reduce attractive forces between the particles As such, the disclosed powders exhibit improved flowability and dispersibilty while the disclosed dispersions exhibit reduced degradation by flocculation, sedimentation or creaming. Moreover, the stabilized preparations of the present invention preferably compπse a suspension medium (e g a fluorochemical) that further serves to reduce the rate of degradation with respect to the incorporated bioactive agent. Accordingly, the dispersions or powders of the present invention may be used in conjunction with metered dose inhalers, dry powder inhalers atomizers, nebulizers or liquid dose instillation (LDI) techniques to provide for effective drug delivery
With regard to particularly preferred embodiments, the hollow and/or porous perforated microstructures substantially reduce attractive molecular forces, such as van der Waals forces, which dominate pπor art powdered preparations and dispersions. In this respect, the powdered compositions typically have relatively low bulk densities which contπbute to the flowability of the preparations while providing the desired characteristics for inhalation therapies. More particularly, the use of relatively low density perforated (or porous) microstructures or microparticulates significantly reduces attractive forces between the particles thereby loweπng the shear forces and increasing the flowability of the resulting powders. The relatively low density of the perforated microstructures also provides for supenor aerodynamic performance when used in inhalation therapy. When used in dispersions, the physical characteπstics of the powders provide for the formation of stable preparations. Moreover, by selecting dispersion components in accordance with the teachings herein, interparticle attractive forces may further be reduced to provide formulations having enhanced stability.
Accordingly, select embodiments of the invention provide for powders having increased dispersibility compnsing a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder compnses an active agent.
With regard to the perforated microstructures, those skilled in the art will appreciate that they may be formed of any biocompatible matenal providing the desired physical characteπstics or morphology. In this respect, the perforated microstructures will preferably compπse pores, voids, defects or other interstitial spaces that act to reduce attractive forces by minimizing surface interactions and decreasing shear forces Yet, given these constraints, it will be appreciated that any material or configuration may be used to form the microstructure matrix. As to the selected mateπals, it is desirable that the microstructure incorporates at least one surfactant. Preferably, this surfactant will compπse a phospho pid or other surfactant approved for pulmonary use. Similarly, it is preferred that the microstructures incorporate at least one active agent which may be a bioactive agent As to the configuration, particularly preferred embodiments of the invention incorporate spray dried, hollow microspheres having a relatively thin porous wall defining a large internal void, although, other void containing or perforated structures are contemplated as well. In preferred embodiments the perforated microstructures will further comprise a bioactive agent
Accordingly, the present invention provides for the use of a bioactive agent in the manufacture of a medicament for pulmonary delivery whereby the medicament compπses a plurality of perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament compnsing said bioactive agent wherein said aerosolized medicament is administered to at least a portion of the nasal or pulmonary air passages of a patient in need thereof.
It will further be appreciated that, in selected embodiments, the present invention compnses methods for forming perforated microstructures that exhibit improved dispersibility. In this regard, it will he appreciated that the disclosed perforated microstructures reduce attractive molecular forces, such as van der Waals forces, which dominate pπor art powdered preparations. That is, unlike pnor art preparations comprising relatively dense, solid particles or nonporous particles (e.g. micronized), the powdered compositions of the present invention exhibit increased flowability and dispersibility due to the lower shear forces. In part, this reduction in cohesive forces is a result of the novel production methods used to provide the desired powders.
As such, preferred embodiments of the invention provide methods for forming a perforated microstructure compnsing the steps of: providing a liquid feed stock compnsing an active agent; atomizing said liquid feed stock to produce dispersed liquid droplets; drying said liquid droplets under predetermined conditions to form perforated microstructures compnsing said active agent; and collecting said perforated microstructures.
With regard to the formation of the perforated microstructures it will be appreciated that, in preferred embodiments, the particles will be spray dπed using commercially available equipment. In this regard the feed stock will preferably compnse a blowing agent that may be selected from fiuoπnated compounds and nonfluoπnated oils.
Preferably, the fluoπnated compounds will have a boiling point of greater than about 60°C. Within the context of the instant invention the fluoπnated blowing agent may be retained in the perforated microstructures to further increase the dispersibility of the resulting powder or improve the stability of dispersions incorporating the same. Further, nonfluoπnated oils may be used to increase the solubility of selected bioactive agents (e.g. steroids) in the feed stock, resulting in increased concentrations of bioactive agents in the perforated microstructures.
As discussed above, the dispersibility of the perforated microstructure powders may be increased by reducing, or minimizing, the van der Waals attractive forces between the constituent perforated microstructures In this regard, the present invention further provides methods for increasing the dispersibility of a powder compnsing the steps of: providing a liquid feed stock compnsing an active agent; and spray drying said liquid feed stock to produce a perforated microstructure powder having a bulk density of less than about 0.5 g/cm3 wherein said powder exhibits reduced van der Waals attractive forces when compared to a relatively non porous powder of the same composition In particularly preferred embodiments the perforated microstructures will compnse hollow, porous microspheres. The blowing agent may be dispersed in the earner using techniques known in the art for the production of homogenous dispersions such a sonication, mechanical mixing or high pressure homogenization. Other methods contemplated for the dispersion of blowing agents in the feed solution include co mixing of two fluids pπor to atomization as described for double nebulization techniques. Of course, it will be appreciated that the atomizer can be customized to optimize the desired particle characteπstics such as particle size. In special cases a double liquid nozzle may be employed. In another embodiment, the blowing agent may be dispersed by introducing the agent into the solution under elevated pressures such as in the case of nitrogen or carbon dioxide gas.
As to the delivery of perforated microstructure powders or stabilized dispersions, another aspect of the present invention is directed to inhalation systems for the administration of one or more bioactive agents to a patient. As such, the present invention provides systems for the pulmonary administration of a bioactive agent to a patient comprising: an inhalation device compnsing a reservoir; and a powder in said reservoir wherein said powder compnses a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder compnses a bioactive agent whereby said inhalation device provides for the aerosolized administration of said powder to at least a portion of the pulmonary air passages of a patient in need thereof. As alluded to above, it will be appreciated that an inhalation device may compπse an atomizer, a sprayer, a dry powder inhaler, a metered dose inhaler or a nebulizer. Moreover, the reservior may be a unit dose container or bulk reservior.
In other ernodiments, the perforated microstructure powders may be dispersed in an appropnate suspension medium to provide stabilized dispersions for delivery of a selected agent. Such dispersions are particularly useful in metered dose inhalers and nebulizers In this regard, particularly preferred suspension mediums compπse fiuorochemicals (e.g. perfluorocarboπs or fluorocarbons) that are liquid at room temperature As discussed above, It is well established that many fiuorochemicals have a proven history of safety and biocornpatibi ty in the lung Further, in contrast to aqueous solutions, fiuorochemicals do not negatively impact gas exchange. Moreover, because of their unique wettabi ty characteristics, fiuorochemicals may be able to provide for the dispersion of particles deeper into the lung, thereby improving systemic delivery Finally, many fiuorochemicals are also bacteπostatic thereby decreasing the potential for microbial growth in compatible preparations
Whether administered in the form of a dry powder or stabilized dispersion, the present invention provides for the effective delivery of bioactive agents As used herein, the terms "bioactive agent" refers to a substance which is used in connection with an application that is therapeutic or diagnostic in nature, such as methods for diagnosing the presence or absence of a disease in a patient and/or methods for treating disease in a patient As to compatible bioactive agents, those skilled in the art will appreciate that any therapeutic or diagnostic agent may be incorporated in the stabilized dispersions of the present invention For example, the bioactive agent may be selected from the group consisting of antiallergics, bronchodilators, broπchocoπstπctors, pulmonary lung surfactants, analgesics, antibiotics, leukotπene inhibitors or antagonists, anticholinergics, mast cell inhibitors, antihistamines, antiiπflammatoπes, antineoplastics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof In preferred embodiments the bioactive agents comprise compounds which are to be administered systemically (i.e. to the systemic circulation of a patient) such as peptides, proteins or polynucleotides As will be disclosed in more detail below, the bioactive agent may be incorporated, blended in, coated on or otherwise associated with the perforated microstructure.
Accordingly, the present invention provides methods for the pulmonary delivery of one or more bioactive agents compnsing the steps of: providing a powder compnsing a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder compπses a bioactive agent; aerosolizing said perforated microstructure powder to provide an aerosolized medicament; and admirasteπng a therapeutically effective amount of said aerosolized medicament to at least a portion of the nasal or pulmonary passages of a patient in need thereof. As used herein the term "aerosolized" shall be held to mean a gaseous suspension of fine solid or liquid particles unless otherwise dictated by contextual restraints. That is, an aerosol or aerosolized medicament may be generated, for example, by a dry powder inhaler, a metered dose inhaler, an atomizer or a nebulizer.
With respect to the disclosed powders, the selected agent or bioactive agent, or agents, may be used as the sole structural component of the perforated microstructures. Conversely, the perforated microstructures may compnse one or more components (i e. structural mateπals, surfactants, excipients, etc ) in addition to the incorporated agent. In particularly preferred embodiments, the suspended perforated microstructures will comprise relatively high concentrations of surfactant (greater than about 10% w/w) along with an incorporated bioactive agent(s). Finally, it should be appreciated that the particulate or perforated microstructure may be coated, linked or otherwise associated with an agent or bioactive agent in a non integral manner Whatever configuration is selected, it will be appreciated that any associated bioactive agent may be used in its natural form, or as one or more salts known in the art
While the powders or stabilized dispersions of the present invention are particularly suitable for the pulmonary administration of bioactive agents, they may also be used for the localized or systemic administration of compounds to any location of the body. Accordingly, it should be emphasized that, in preferred embodiments, the formulations may be administered using a number of different routes including, but not limited to, the gastrointestinal tract, the respiratory tract, topically, intramuscularly, intrapeπtoneally, nasally, vagmally, rectaily, aurally, orally or ocularly.
Other objects, features and advantages of the present invention will be apparent to those skilled in the art from a consideration of the following detailed descπption of preferred exemplary embodiments thereof
Brief Descπption of the Drawings
Figs. 1 A1 to 1 F2 illustrate changes in particle morphology as a function of vaπation in the ratio of fluorocarbon blowing agent to phosphohpid (PFC/PC) present in the spray dry feed. The micrographs, produced using scanning electron microscopy and transmission electron microscopy techniques, show that in the absence of FCs, or at low PFC/PC ratios, the resulting spray dried microstructures comprising gentamicin sulfate are neither particularly hollow nor porous. Conversely, at high PFC/PC ratios, the particles contain numerous pores and are substantially hollow with thin wails.
Fig. 2 depicts the suspension stability of gentamicin particles in Perflubron as a function of formulation PFC/PC ratio or particle porosity. The particle porosity increased with increasing PFC'PC ratio.
Maximum stability was observed with PFC/PC ratios between 3 to 15, illustrating a preferred morphology for the perflubron suspension media.
Fig. 3 is a scanning electron microscopy image of perforated microstructures comprising cromolyn sodium illustrating a preferred hollow/porous morphology. Figs. 4A to 4D are photographs illustrating the enhanced stability provided by the dispersions of the present invention over time as compared to a commercial cromolyn sodium formulation (Intaf, Rhone-Poulenc- Rorer). In the photographs, the commercial formulation on the left rapidly separates while the dispersion on the right, formed in accordance with the teachings herein, remains stable over an extended period.
Fig. 5 presents results of in-vitro Andersen cascade impactor studies comparing the same hollow porous albuterol sulfate formulation delivered via a MDI in HFA-134a, or from an exemplary DPI. Efficient delivery of particles was observed from both devices. MDI delivery of the particles was maximized on plate 4 corresponding to upper airway delivery. DPI delivery of the particles results in substantial deposition on the later stages in the impactor corresponding to improved systemic delivery in-vivo.
Detailed Description Preferred Embodiments
While the present invention may be embodied in many different forms, disclosed herein are specific illustrative embodiments thereof that exemplify the principles of the invention. It should be emphasized that the present invention is not limited to the specific embodiments illustrated.
As discussed above, the present invention provides methods, systems and compositions that comprise perforated microstructures which, in preferred embodiments, may advantageously be used for the delivery of bioactive agents. In particularly preferred embodiments, the disclosed perforated microstructure powders may be used in a dry state (e.g. as in a DPI) or in the form of a stabilized dispersion (e.g. as in a MDI, LDI or nebulizer formulation) to deliver bioactive agents to the nasal or pulmonary air passages of a patient. It will be appreciated that the perforated microstructures disclosed herein comprise a structural matrix that exhibits, defines or comprises voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes. The absolute shape (as opposed to the morphology) of the perforated microstructure is generally not critical and any overall configuration that provides the desired characteristics is contemplated as being within the scope of the invention. Accordingly, preferred embodiments can comprise approximately microspherical shapes. However, collapsed, deformed or fractured particulates are also compatible. With this caveat, it will further be appreciated that, particularly preferred embodiments of the invention comprise spray dried hollow, porous microspheres. In any case the disclosed powders of perforated microstructures provide several advantages including, but not limited to, increases in suspension stability, improved dispersibility, superior sampling characteristics, elimination of carrier particles and enhanced aerodynamics.
Those skilled in the art will appreciate that many of these aspects are of particular use for dry powder inhaler applications. Unlike prior art formulations, the present invention provides unique methods and compositions to reduce cohesive forces between dry particles, thereby minimizing paniculate aggregation which can result in an improved delivery efficiency. As such, the disclosed preparations provide a highly flowable, dry powders that can be efficiently aerosolized, uniformly delivered and penetrate deeply in the lung or nasal passages. Furthermore, the perforated microstructures of the present invention result in surprisingly low throat deposition upon administration.
In preferred embodiments, the perforated microstructure powders have relatively low bulk density, allowing the powders to provide superior sampling properties over compositions known in the art. Currently, as explained above, many commercial dry powder formulations comprise large lactose particles which have micronized drug aggregated on their surface. For these prior art formulations, the lactose particles serve as a carrier for the active agents and as a bulking agent, thereby providing means to partially control the fine particle dose delivered from the device. In addition, the lactose particles provide the means for the commercial filling capability of dry particles into unit dose containers by adding mass and volume to the dosage form.
By way of contrast, the present invention uses methods and compositions that yield powder formulations having extraordinarily low bulk density, thereby reducing the minimal filling weight that is commercially feasible for use in dry powder inhalation devices. That is, most unit dose containers designed for DPIs are filled using fixed volume or gravimetric techniques. Contrary to prior art formulations, the present invention provides powders wherein the active or bioactive agent and the incipients or bulking agents make-up the entire inhaled particle. Compositions according to the present invention typically yield powders with bulk densities less than 0.5 g/cm3 or 0.3 g/cm3, preferably less 0.1 g/cm3 and most preferably less than
0.05 g/cm3. By providing particles with very low bulk density, the minimum powder mass that can be filled into a unit dose container is reduced, which eliminates the need for carrier particles. That is, the relatively low density of the powders of the present invention provides for the reproducible administration of relatively low dose pharmaceutical compounds. Moreover, the elimination of carrier particles will potentially minimize throat deposition and any "gag" effect, since the large lactose particles will impact the throat and upper airways due to their size.
In accordance with the teachings herein the perforated microstructures will preferably be provided in a "dry" state. That is the microparticles will possess a moisture content that allows the powder to remain chemically and physically stable during storage at ambient temperature and easily dispersibie. As such, the moisture content of the microparticles is typically less than 6% by weight, and preferably less 3% by weight. In some instances the moisture content will be as low as 1 % by weight. Of course it will be appreciated that the moisture content is, at least in part, dictated by the formulation and is controlled by the process conditions employed, e.g., inlet temperature, feed concentration, pump rate, and blowing agent type, concentration and post drying With respect to the composition of the structural matrix defining the perforated microstructures, they may be formed of any mateπal which possesses physical and chemical characteπstics that are compatible with any incorporated active agents. While a wide vaπety of matenals may be used to form the particles, in particularly preferred pharmaceutical embodiments the structural matrix is associated with, or compπses, a surfactant such as phosphohpid or fluonnated surfactant. Although not required, the incorporation of a compatible surfactant can improve powder flowability, increase aerosol efficiency, improve dispersion stability, and facilitate preparation of a suspension. It will be appreciated that, as used herein, the terms "structural matπx" or "microstructure matπx" are equivalent and shall be held to mean any solid atenal forming the perforated microstructures which define a plurality of voids, apertures, hollows, defects, pores, holes, fissures, etc. that provide the desired characteπstics. In preferred embodiments, the perforated microstructure defined by the structural matπx compπses a spray dned hollow porous microsphere incorporating at least one surfactant. It will further be appreciated that, by altering the matrix components, the density of the structural matrix may be adjusted. Finally, as will be discussed in further detail below, the perforated microstructures preferably compπse at least one active or bioactive agent.
As indicated, the perforated microstructures of the present invention may optionally be associated with, or compπse, one or more surfactants. Moreover, miscible surfactants may optionally be combined in the case where the microparticles are formulated in a suspension medium liquid phase It will be appreciated by those skilled in the art that the use of surfactants, while not necessary to practice the instant invention, may further increase dispersion stability, powder flowability, simplify fomiulation procedures or increase efficiency of delivery Of course combinations of surfactants, including the use of one or more in the liquid phase and one or more associated with the perforated microstructures are contemplated as being within the scope of the invention By "associated with or compπse" it is meant that the structural matπx or perforated microstructure may incorporate, adsorb, absorb, be coated with or be formed by the surfactant.
In a broad sense, surfactants suitable for use in the present invention include any compound or composition that aids in the formation of perforated microparticles or provides enhanced suspension stability, improved powder dispersibility or decreased particle aggregation. The surfactant may compπse a single compound or any combination of compounds, such as in the case of co surfactants. Particularly preferred surfactants are nonfluonnated and selected from the group consisting of saturated and unsaturated lipids, noπionic detergents, nomonic block copolymers, ionic surfactants and combinations thereof. In those embodiments comprising stabilized dispersions, such nonfluonnated surfactants will preferably be relatively insoluble in the suspension medium. It should be emphasized that, in addition to the aforementioned surfactants, suitable fluonnated surfactants are compatible with the teachings herein and may be used to provide the desired preparations. Lipids, including phospholipids, from both natural and synthetic sources are particularly compatible with the present invention and may be used in varying concentrations to form the structural matπx. Generally compatible lipids comprise those that have a gel to liquid crystal phase transition greater than about 40°C. Preferably the incorporated lipids are relatively long chain d e C,B C22) saturated pids and more preferably comprise phospholipids. Exemplary phospholipids useful in the disclosed stabilized preparations compnse, dipalmitoylphosphatidylchohne, disteroylphosphatidylchohne, diarachidoylphosphatidylcholine dibehenoylphosphatidylchohne, short chain phosphatidylcholmes, long-chain saturated phosphatidylethanolamines, long chain saturated phosphatidylserines, long chain saturated phosphatidylglycerols, long chain saturated phosphatidyhnositols, glyco pids, ganghoside GM1, sphingomyelin, phosphatidic acid, cardiolipin; lipids bearing polymer chains such as polyethylene glycol, chitin, hyaluromc acid, or polyvinylpyrrohdoπe, lipids bearing sulfonated mono , di , and poiysacchaπdes, fatty acids such as palmitic acid, steanc acid, and oleic acid; cholesterol, cholesterol esters, and cholesterol hemisuccinate Due to their excellent biocompatibihty characteristics, phospholipids and combinations of phospholipids and poloxa ers are particularly suitable for use in the pharmaceutical embodiments disclosed herein Compatible nomonic detergents comprise- sorbitaπ esters including sorbitan tπoleate (Span" 85), sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, glycerol esters, and sucrose esters. Other suitable nomonic detergents can be easily identified using McCutcheon's Emulsifiers and Detergents (McPublishing Co., Glen Rock, New Jersey) which is incorporated herein in its entirety. Preferred block copolymers include diblock and tnblock copolymers of polyoxyethylene and polyoxypropylene, including poloxamer 188 (Pluronic * F 68), poloxamer 407 (Pluronic " F 127), and poloxamer 338. Ionic surfactants such as sodium sulfosuccinate, and fatty acid soaps may also be utilized. In preferred embodiments the microstructures may comprise oleic acid or its alkali salt. In addition to the aforementioned surfactants, cationic surfactants or lipids are preferred especially in the case of delivery or RNA or DMA Examples of suitable cationic lipids include: DOTMA, N [1 (2,3 dioleyloxylpropyl] N,N,N tπmethylammoπium chloride, DOTAP, 1,2 dioleyloxy 3 (trιmethylammonιo)propane, and DOTB, 1,2 dioleyl 3 (4' tπmethylammoniolbutanoyl sn glycerol Polycationic ammo acids such as polylysme, and polyargimne are also contemplated. Besides those surfactants enumerated above, it will further be appreciated that a wide range of surfactants may optionally be used in conjunction with the present invention. Moreover, the optimum surfactant or combination thereof for a given application can readily be determined by empirical studies that do not require undue experimentation. Finally, as discussed in more detail below, surfactants compnsing the structural matrix may also be useful in the formation of precursor oil in water emulsions (i ε. spray drying feed stock) used duπng processing to form the perforated microstructures. Unlike pπor art formulations, it has surprisingly been found that the incorporation of relatively high levels of surfactants (e.g., phospholipids) may be used to improve powder dispersibility, increase suspension stability and decrease powder aggregation of the disclosed applications. That is, on a weight to weight basis, the structural matπx of the perforated microstructures may compπse relatively high levels of surfactant. In this regard, the perforated microstructures will preferably compnse greater than about 1 %, 5%, 10%, 15%, 18%, or even 20% w/w surfactant. More preferably, the perforated microstructures will compnse greater than about 25%, 30%, 35%, 40%, 45%, or 50% w/w surfactant. Still other exemplary embodiments will compπse perforated microstructures wherein the surfactant or surfactants are present at greater than about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or even 95% w/w. In selected embodiments the perforated microstructures will compπse essentially 100% w/w of a surfactant such as a phosphohpid. Those skilled in the art will appreciate that, in such cases, the balance of the structural matnx (where applicable) will likely comprise a bioactive agent or non surface active excipients or additives
While such surfactant levels are preferably employed in perforated microstructures, they may be used to provide stabilized systems compnsing relatively nonporous, or substantially solid, particulatεs. That is, while preferred embodiments will compπse perforated microstructures associated with high levels of surfactant, acceptable microspheres may be formed using relatively low porosity particulates of the same surfactant concentration (i.e greater than about 20% w/w). In this respect such high surfactant embodiments are specifically contemplated as being within the scope of the present invention.
In other preferred embodiments, of the invention the structural matπx defining the perforated microstructure optionally compπses synthetic or natural polymers or combinations thereof. In this respect useful polymers compπse polylactides, polylactide-glycolides, cyclodextπns, polyacrylates, methylcellulose, carboxymethylcellulose, polyvinyl alcohols, polyanhydndes, polylactams, polyvinyl pyrrolidones, polysacchandes (dextrans, starches, chitin, chitosan, etc.), hyaluronic acid, proteins, (albumin, collagen, gelatin, etc.). Examples of polymeric resins that would be useful for the preparation of perforated ink microparticles include: styrene butadiene, styreπe-isoprene, styrene acryloπitnle, ethylene-vmyl acetate, ethylene-acrylate, ethylene-acry c acid, ethylene methylacrylatate, ethylene ethyl acrylate, vinyl methyl methacrylate, acrylic acid methyl methacrylate, and vinyl chloride-vinyl acetate. Those skilled in the art will appreciate that, by selecting the appropriate polymers, the delivery efficiency of the perforated microparticles and/or the stability of the dispersions may be tailored to optimize the effectiveness of the active or bioactive agent. Besides the aforementioned polymer materials and surfactants, it may be desirable to add other excipients to a microsphere formulation to improve particle rigidity, production yield, delivery efficiency and deposition, shelf life and patient acceptance. Such optional excipients include, but are not limited to- coloring agents, taste masking agents, buffers, hygroscopic agents, aπtioxidaπts, and chemical stabilizers. Further, various excipients may be incorporated in, or added to, the paniculate matrix to provide structure and form to the perforated microstructures (i.e. microspheres such as latex particles). In this regard it will be appreciated that the πgidifying components can be removed using a post-production technique such as selective solvent extraction.
Other ngidifying excipients may include, but are not limited to, carbohydrates including monosacchaπdes, disacchaπdes and polysacchandes. For example, monosacchandes such as dextrose (anhydrous and monohydrate), galactose, mannitol, D-mannose, sorbitol, sorbose and the like; disacchandes such as lactose, maltose, sucrose, trehalosε, and the like; trisacchandes such as raffmose and the like; and other carbohydrates such as starches (hydroxyethylstarch), cyclodextππs and maltodextπns. Ammo acids are also suitable excipients with glycine preferred. Mixtures of carbohydrates and ammo acids are further held to be within the scope of the present invention. The inclusion of both inorganic (e.g. sodium chloride, calcium chloride, etc.), organic salts (e.g. sodium citrate, sodium ascorbate, magnesium gluconate, sodium glucoπate, tromethamine hydrochloride, etc.) and buffers is also contemplated. The inclusion of salts and organic solids such as ammonium carbonate, ammonium acetate, ammonium chloride or camphor are also contemplated
Yet other preferred embodiments include perforated microstructures that may compπse, or may be coated with, charged species that prolong residence time at the point of contact or εnhancε penetration through mucosae. For example, anionic charges are known to favor mucoadhesion while cationic charges may be used to associate the formed microparticulate with negatively charged bioactive agents such as genetic matenal. The charges may be imparted through the association or incorporation of polyaniomc or polycationic mateπals such as polyacry c acids, polylysine, polylactic acid and chitosan.
In addition to, or instead of, the components discussed above, the perforated microstructures will preferably compπse at least one active or bioactive agent As used herein, the term "active agent" simply refers to a substance that enables the perforated microstructures to perform the desired function. Further, the term "active agent" shall be held inclusive of the term "bioactive agent" unless otherwise dictated by contextual restraints As to the term "bioactive agent" it shall be held to compπse any substance that is used in connection with the diagnosis or treatment of a disease, condition or physiological abnormality in a patient Particularly preferred bioactive agents for use in accordance with the invention include anti allergies, peptides and proteins, pulmonary lung surfactants, bronchodilators and anti inflammatory steroids for use in the treatment of respiratory disorders such as asthma by inhalation therapy. Preferred active agents for use in accordance with the present invention include pigments, dyes, inks, paints, detergents, food sweeteners, spices, adsorbants, absorbents, catalysts, nucleating agents, thickening agents, polymers, resins, insulators, fillers, fertilizers, phytohormones, insect pheromones, insect repellents, pet repellents, antifou ng agents, pesticides, fungicides, disinfectants, perfumes, deodorants, and combinations of thereof.
It will be appreciated that the perforated microstructures of the present invention may exclusively compπse one or more active or bioactive agents (i.e. 100% w/w). However, in selected embodiments the perforated microstructures may incorporate much less bioactive agent depending on the activity thereof. Accordingly, for highly active matenals the perforated microstructures may incorporate as little as 0.001 % by weight although a concentration of greater than about 0.1 % w/w is preferred. Other embodiments of the invention may compπse greater than about 5%, 10%, 15%, 20%, 25%, 30% or even 40% w/w active or bioactive agent. Still more preferably the perforated microstructures may comprise greater than about 50%, 60%, 70%, 75%, 80% or even 90% w/w active or bioactive agent. The precise amount of active or bioactive agent incorporated in the perforated microstructures of the present invention is dependent upon the agent of choice, the required dose, and the form of the agent actually used for incorporation. Those skilled in the art will appreciate that such determinations may be made by using well-known pharmacological techniques in combination with the teachings of the present invention.
With regard to pharmaceutical preparations, any bioactive agent that may be formulated in the disclosed perforated microstructures is expressly held to be within the scope of the present invention. In particularly preferred embodiments, the selected bioactive agent may be administered in the form of an aerosolized medicaments. Accordingly, particularly compatible bioactive agents comprise any drug that may be formulated as a flowable dry powder or which is relatively insoluble in selected dispersion media In addition, it is preferred that the formulated agents are subject to pulmonary or nasal uptake in physiologically effective amounts. Compatible bioactive agents compπse hydrophi c and Iipophi c respiratory agents, pulmonary surfactants, bronchodilators, antibiotics, antivirals, anti-infiammatones, steroids, antihistaminics, leukotπene inhibitors or antagonists, anticholinergics, antineoplastics, anesthetics, enzymes, cardiovascular agents, genetic matenal including DNA and RNA, viral vectors, immuπoactive agents, imaging agents, vaccines, immunosuppressive agents, peptides, proteins and combinations thereof. Particularly preferred bioactive agents for inhalation therapy comprise mast cell inhibitors (anti allergies), bronchodilators, and anti inflammatory steroids such as, for example, cromoglycate (e.g. the sodium salt), and albuterol (e.g. the sulfate salt).
More specifically, exemplary medicaments or bioactive agents may be selected from, for example, analgesics, e g. codeine, dihydromorphine, ergotamine, fεntanyl, or morphine; anginal preparations, e.g. diltiazem; mast cεll inhibitors, e.g. cromolyn sodium; antimfectives, e.g. cephalospoπns, macrohdes, quinolines, penicillins, streptomycin, sulphona ides, tetracyclines and pentamidme; antihistamiπes, e g methapyπlene; anti-inflammatoπes, e.g. fluticasoπe propionate, beclomethasone dipropionate, flunisolide, budesomde, tπpedane, cortisone, predmsone, predmsilone, dexamethasone, beta ethasone, or tπamcinolone acetomde; aπtitussives, e.g. πoscapine; bronchodilators, e.g. ephednne, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, salbuta ol, albuterol, salmeterol, terbutaline; diuretics, e.g amiloπde; anticholinergics, e.g. ipatropium, atropine, or oxitropium; lung surfactants e.g. Surfaxiπ, Exosurf, Survanta; xanthiπes, e.g. aminophylline, theophylhne, caffeine; therapeutic proteins and peptides, e g. DNAse, insulin, glucagon, LHRH, πafarehn, gosere n, leuprolide, interferoπ, rhu IL 1 receptor, macrophage activation factors such as lymphokines and muramyl dipeptides, opioid peptides and neuropeptidεs such as enkaphaiins, endophins, renin inhibitors, cholecystokiπins, DNAse, growth hormones, leukotπene inhibitors and the like. In addition, bioactive agents that compπse an RNA or DNA sequence, particularly those useful for gene therapy, genetic vaccination, genetic tolenzation or antisense applications, may be incorporated in the disclosed dispersions as descπbed herein. Representative ONA plasmids include, but are not limited to pCMVβ (available from Genzyme Corp, Framington, MA) and pCMV-β-gal (a CMV promotor linked to the E. coli Lac-Z gene, which codes for the enzyme β galactosidasel.
In any event, the selected active or bioactive agent(s) may be associated with, or incorporated in, the perforated microstructures in any form that provides the desired efficacy and is compatible with the chosen production techniques. As used herein, the terms "associate" or "associating" mean that the structural matrix or perforated microstructure may compπse, incorporate, adsorb, absorb, be coated with or be formed by the active or bioactive agent. Where appropriate, the actives may be used in the form of salts (e g. alkali metal or amine salts or as acid addition salts) or as esters or as solvates (hydrates). In this regard the form of the active or bioactive agents may be selected to optimize the activity and/or stability of the actives and/or to minimize the solubility of the agent in the suspension medium and/or to minimize particle aggregation.
It will further be appreciated that the perforated microstructures according to the invention may, if desired, contain a combination of two or more active ingredients. The agents may be provided in combination in a single species of perforated microstructure or individually in separate species of perforated microstructures. For example, two or more active or bioactive agents may be incorporated in a single feed stock preparation and spray dried to provide a single microstructure species comprising a plurality of active agents. Conversely, the individual actives could be added to separate stocks and spray dried separately to provide a plurality of microstructure species with different compositions These individual species could be added to the suspension medium or dry powder dispensing compartment in any desired proportion and placed in the aerosol delivery system as described below. Further, as alluded to above, the perforated microstructures (with or without an associated agent) may be combined with one or more conventional (e.g. a micronized drug) active or bioactive agents to provide the desired dispersion stability or powder dispersibility
Based on the foregoing, it will be appreciated by those skilled in the art that a wide vaπety of active or bioactive agents may be incorporated in the disclosed perforated microstructures Accordingly, the list of preferred active agents above is exemplary only and not intended to be limitinα. It will also be appreciated by those skilled in the art that the proper amount of bioactive agent and the timing of the dosages may be determined for the formulations in accordance with already existing information and without undue expeπmentation.
As seen from the passages above, various components may be associated with, or incorporated in the perforated microstructures of the present invention. Similarly, several techniques may be used to provide particulates having the desired morphology (e.g. a perforated or hollow/porous configuration), dispersibility and density. Among other methods, perforated microstructures compatible with the instant invention may be formed by techniques including spray drying, vacuum drying, solvent extraction, emulsification or lyophilization, and combinations thereof. It will further be appreciated that the basic concepts of many of these techniques are well known in the pπor art and would not, in view of the teachings herein, require undue expenmentation to adapt them so as to provide the desired perforated microstructures. While several procedures are generally compatible with the present invention, particularly preferred embodiments typically comprise perforated microstructures formed by spray drying. As is well known, spray drying is a one-step process that converts a liquid feed to a dπed paniculate form. With respect to pharmaceutical applications, it will be appreciated that spray drying has been used to provide powdered material for various administrative routes including inhalation. See, for example, M. Sacchetti and M.M. Van Oort in' Inhalation
Aerosols: Physical and Biological Basis for Therapy, A.J. Hickey, ed Marcel Dekkar, New York, 1996, which is incorporated herein by reference.
In general, spray drying consists of bringing together a highly dispersed liquid, and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets. The preparation to be spray dried or feed (or feed stock) can be any solution, course suspension, slurry, colloidal dispersion, or paste that may be atomized using the selected spray drying apparatus. In preferred embodiments the feed stock will comprise a colloidal system such as an emulsion, reverse emulsion, microemulsion, multiple emulsion, paniculate dispersion, or slurry. Typically the feed is sprayed into a current of warm filtered air that evaporates the solvent and conveys the dried product to a collector. The spent air is then exhausted with the solvent. Those skilled in the art will appreciate that several different types of apparatus may be used to provide the desired product. For example, commercial spray dryers manufactured by Buchi Ltd. or Niro Corp. will effectively produce particles of desired size.
It will further be appreciated that these spray dryers, and specifically their atomizers, may be modified or customized for specialized applications, i.e. the simultaneous spraying of two solutions using a double nozzle technique. More specifically, a water in oil emulsion can be atomized from one nozzle and a solution containing an anti-adherent such as mannitol can be co atomized from a second nozzle. In other cases it may be desirable to push the feed solution though a custom designed nozzle using a high pressure liquid chromatography (HPLC) pump. Provided that microstructures comprising the correct morphology and/or composition are produced the choice of apparatus is not cπtical and would be apparent to the skilled artisan in view of the teachings herein.
While the resulting spray dried powdered particles typically are approximately spherical in shape, nearly uniform in size and frequently are hollow, there may be some degree of irregularity in shape depending upon the incorporated medicament and the spray drying conditions. In many instances dispersion stability and dispersibility of the perforated microstructures appears to be improved if an inflating agent (or blowing agent) is used in their production. Particularly preferred embodiments may compnse an emulsion with the inflating agent as the disperse or continuous phase. The inflating agent is preferably dispersed with a surfactant solution, using, for instance, a commercially available microfluidizer at a pressure of about 5000 to 15,000 psi. This process forms an emulsion, preferably stabilized by an incorporated surfactant, typically compnsing submicron droplets of water immiscible blowing agent dispersed in an aqueous continuous phase. The formation of such emulsions using this and other techniques are common and well known to those in the art. The blowing agent is preferably a fluonnated compound (e.g. perfluorohexane, perfiuorooctyl bromide, perfluorodecalin, perfluorobutyl ethane) which vaporizes during the spray drying process, leaving behind generally hollow, porous aerodynamically light microspheres. As will be discussed in more detail below, other suitable liquid blowing agents include nonfluonnated oils, chloroform, Freons, ethyl acetate, alcohols and hydrocarbons Nitrogen and carbon dioxide gases are also contemplated as a suitable blowing agent.
Besides the aforementioned compounds, inorganic and organic substances which can be removed under reduced pressure by sublimation in a post production step are also compatible with the instant invention. These sublimating compounds can be dissolved or dispersed as micronized crystals in the spray drying feed solution and include ammonium carbonate and camphor. Other compounds compatible with the present invention comprise πgidifying solid structures which can be dispersed in the feed solution or prepared in-situ. These structures are then extracted after the initial particle generation using a post production solvent extraction step. For example, latex particles can be dispersed and subsequently dried with other wall forming compounds, followed by extraction with a suitable solvent
Although the perforated microstructures are preferably formed using a blowing agent as described above, it will be appreciated that, in some instances, no additional blowing agent is required and an aqueous dispersion of the medicament and/or excipients and surfactant(s) are spray dried directly In such cases, the formulation may be amenable to process conditions (e.g., elevated temperatures) that may lead to the formation of hollow, relatively porous microparticles Moreover, the medicament may possess special physicochemical properties (e.g., high crystallmity, elevated melting temperature, surface activity, etc.) that makes it particularly suitable for use in such techniques.
When a blowing agent is employed, the degree of porosity and dispersibility of the perforated microstructure appears to depend, at least in part, on the nature of the blowing agent, its concentration in the feed stock (e.g. as an emulsion), and the spray drying conditions. With respect to controlling porosity and, in suspensions, dispersibility it has surprisingly been found that the use of compounds, heretofore unappreciated as blowing agents, may provide perforated microstructures having particularly desirable characteristics. More particularly, in this novel and unexpected aspect of the present invention it has been found that the use of fluonnated compounds having relatively high boiling points (i.e. greater than about 40°C) may be used to produce particulates that are particularly porous. Such perforated microstructures are especially suitable for inhalation therapies. In this regard it is possible to use fluonnated or partially fluonnated blowing agents having boiling points of greater than about 40°C, 50°C, 60°C, 70°C, 80°C, 90°C or even 95°C. Particularly preferred blowing agents have boiling points greater than the boiling point of water, i.e. greater than 100°C (e.g. perflubron, perfluorodecalin). In addition blowing agents with relatively low water solubility ( < 106 M) are preferred since they enable the production of stable emulsion dispersions with mean weighted particle diameters less than 0.3 μm. As previously described, these blowing agents will preferably be incorporated in an emulsified feed stock pπor to spray drying. For the purposes of the present invention this feed stock will also preferably comprise one or more active or bioactive agents, one or more surfactants or one or more excipients. Of course, combinations of the aforementioned components are also within the scope of the invention While high boiling ( > 100°C) fluonnated blowing agents comprise one preferred aspect of the present invention, it will be appreciated that nonfluonnated blowing agents with similar boiling points ( > 100°C) may be used to provide perforated microstructures. Exemplary nonfluoπnated blowing agents suitable for use in the present invention comprise the formula-
R' X R2 or R' X wherein- R1 or R2 is hydrogen, alkyl, alkenyl, alkynl, aromatic, cyclic or combinations thereof, X is any group containing carbon, sulfur, nitrogen, halogens, phosphorus, oxygen and combinations thereof.
While not limiting the invention in any way it is hypothesized that, as the aqueous feed component evaporates during spray drying it leaves a thin crust at the surface of the particle. The resulting particle wall or crust formed during the initial moments of spray drying appears to trap any high boiling blowing agents as hundreds of emulsion droplets (ca. 200 300 nm). As the drying process continues, the pressure inside the paniculate increases thereby vaporizing at least part of the incorporated blowing agent and forcing it through the relatively thin crust. This venting or outgassiπg apparently leads to the formation of pores or other defects in the microstructure At the same time remaining paniculate components (possibly including some blowing agent) migrate from the interior to the surface as the particle solidifies. This migration apparently slows duπng the drying process as a result of increased resistance to mass transfer caused by an increased internal viscosity. Once the migration ceases the particle solidifies, leaving voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes The number of pores or defects, their size, and the resulting wall thickness is largely dependent on the formulation and/or the nature of the selected blowing agent (e g boiling point), its concentration in the emulsion, total solids concentration, and the spray drying conditions. It can be greatly appreciated that this type of particle morphology in part contributes to the improved powder dispersibility, suspension stability and aerodynamics
It has been surprisingly found that substantial amounts of these relatively high boiling blowing agents may be retained in the resulting spray dried product That is, spray dried perforated microstructures as described herein may comprise as much as 1 %, 3%, 5%, 10%, 20%, 30% or even 40% w/w of the blowing agent. In such cases, higher production yields were obtained as a result an increased particle density caused by residual blowing agent. It will be appreciated by those skilled in the art that retained fluonnated blowing agent may alter the surface characteristics of the perforated microstructures, thereby minimizing particle aggregation duππg processing and further increasing dispersion stability. Residual fluonnated blowing agent in the particle may also reduce the cohesive forces between particles by providing a barrier or by attenuating the attractive forces produced during manufacturing (e.g., electrostatics). This reduction in cohesive forces may be particularly advantageous when using the disclosed microstructures in conjunction with dry powder inhalers.
Furthermore, the amount of residual blowing agent can be attenuated through the process conditions (such as outlet temperature), blowing agent concentration, or boiling point If the outlet temperature is at or above the boiling point, the blowing agent escapes the particle and the production yield decreases. Preferred outlet temperature will generally be operated at 20, 30, 40, 50, 60, 70, 80, 90 or even 100°C less than the blowing agent boiling point. More preferably the temperature differential between the outlet temperature and the boiling point will range from 50 to 150°C It will be appreciated by those skilled in the art that particle porosity, production yield, electrostatics and dispersibility can be optimized by first identifying the range of process conditions (e g., outlet temperature) that are suitable for the selected active agents and/or excipients The preferred blowing agent can be then chosen using the maximum outlet temperature such that the temperature differential with be at least 20 and up to 150°C In some cases, the temperature differential can be outside this range such as, for example, when producing the particulates under supercritical conditions or using lyophilization techniques. Those skilled in the art will further appreciate that the preferred concentration of blowing agent can be determined experimentally without undue experimentation using techniques similar to those described in the Examples herein.
While residual blowing agent may be advantageous in selected embodiments it may be desirable to substantially remove any blowing agent from the spray dried product. In this respect, the residual blowing agent can easily be removed with a post production evaporation step in a vacuum oven. Moreover, such post production techniques may be used to provide perforations in the particulates For example, pores may be formed by spray drying a bioactive agent and an excipient that can be removed from the formed particulates under a vacuum.
In any event, typical concentrations of blowing agent in the feed stock are between 2% and 50% v/v, and more preferably between about 10% to 45% v/v In other embodiments blowing agent concentrations will preferably be greater than about 5%, 10%, 15%, 20%, 25% or even 30% v/v. Yet other feed stock emulsions may comprise 35%, 40%, 45% or even 50% v/v of the selected high boiling point compound.
In preferred embodiments, another method of identifying the concentration of blowing agent used in the feed is to provide it as a ratio of the concentration of the blowing agent to that of the stabilizing surfactant (e g. phosphatidylcholine or PC) in the precursor or feed emulsion For fluorocarbon blowing agents
(e.g. perfluorooctyl bromide), and for the purposes of explanation, this ratio has been termed the PFC/PC ratio More generally, it will be appreciated that compatible blowing agents and/or surfactants may be substituted for the exemplary compounds without falling outside of the scope of the present invention. In any event, the typical PFC/PC ratio will range from about 1 to about 60 and more preferably from about 10 to about 50. For preferred embodiments the ratio will generally be greater than about 5, 10, 20, 25, 30, 40 or even 50. In this respect, Fig. 1 shows a series of pictures taken of perforated microstructures formed of phosphatidylcholine (PC) using various amounts of perfluorooctyl bromide (PFC), a relatively high boiling point fluorocarbon as the blowing agent. The PFC/PC ratios are provided under each subset of pictures, i.e. from 1A to 1 F. Formation and imaging conditions are discussed in greater detail in Examples I and II below. With regard to the micrographs, the column on the left shows the intact microstructures while the column on the right illustrates cross sections of fractured microstructures from the same preparations
As may easily be seen in the Fig. 1, the use of higher PFC/PC ratios provides structures of a more hollow and porous nature. More particularly, those methods employing a PFC/PC ratio of greater than about 4.8 tended to provide structures that are particularly compatible with the dry power formulations and dispersions disclosed herein. Similarly, Fig. 3, a micrograph which will be discussed in more detail in Example
XII below, illustrates a preferably porous morphology obtained by using higher boiling point blowing agents (in this case perfluorodecalin).
While relatively high boiling point blowing agents comprise one preferred aspect of the instant invention, it will be appreciated that more conventional and unconventional blowing or inflating agents may also be used to provide compatible perforated microstructures. The blowing agent comprises any volatile substance, which can be incorporated into the feed solution for the purpose of producing a perforated foam like structure in the resulting dry microspheres. The blowing agent may be removed during the initial drying process or during a post production step such as vacuum drying or solvent extraction. Suitable agents include:
1. Dissolved low-boiling (below 100 C) agents irascible with aqueous solutions, such as methylene chloπde, acetone, ethyl acetate, and alcohols used to saturate the solution.
2. A gas, such as C02 or N2,or liquid such as Freons, CFCs, HFAs, PFCs, HFCs, HFBs, fiuoroalkanes, and hydrocarbons used at elevated pressure.
3. Emulsions of immiscible low-boiling (below 100 C) liquids suitable for use with the present invention are generally of the formula: R'-X R2 or R' X wherein: R' or R2 ιs hydrogen, alkyl, alkenyl, alkynl, aromatic, cyclic or combinations thereof, X is any groups containing carbon, sulfur, nitrogen, halogens, phosphorus, oxygen and combinations thereof. . Such liquids include: Freons, CFCs, HFAs, PFCs, HFCs, HFBs, fiuoroalkanes, and hydrocarbons.
4. Dissolved or dispersed salts or organic substances which can be removed under reduced pressure by sublimation in a post-production step, such as ammonium salts, camphor, etc.
5. Dispersed solids which can be extracted after the initial particle generation using a post-production solvent extraction step, such particles include latex, etc With respect to these lower boiling point inflating agents, they are typically added to the feed stock in quantities of about 1 % to 40% v/v of the surfactant solution. Approximately 15% v/v inflating agent has been found to produce a spray dned powder that may be used to form the stabilized dispersions of the present invention.
Regardless of which blowing agent is ultimately selected, it has been found that compatible perforated microstructures may be produced particularly efficiently using a Buchi mini spray drier (model B
191, Switzerland) As will be appreciated by those skilled in the art, the inlet temperature and the outlet temperature of the spray drier are not critical but will be of such a level to provide the desired particle size and to result in a product that has the desired activity of the medicament. In this regard, the inlet and outlet temperatures are adjusted depending on the melting characteristics of the formulation components and the composition of the feed stock. The inlet temperature may thus be between 60°C and 170°C, with the outlet temperatures of about 40°C to 120°C depending on the composition of the feed and the desired paniculate characteristics. Preferably these temperatures will be from 90°C to 120°C for the inlet and from 60°C to 90°C for the outlet The flow rate which is used in the spray drying equipment wili generally be about 3 ml per minute to about 15 ml per minute The atomizer air flow rate will vary between values of 25 liters per minute to about 50 liters per minute. Commercially available spray dryers are well known to those in the art, and suitable settings for any particular dispersion can be readily determined through standard empiπcal testing, with due reference to the examples that follow. Of course, the conditions may be adjusted so as to preserve biological activity in larger molecules such as proteins or peptides
Though the perforated microstructures are preferably formed using fluonnated blowing agents in the form of an emulsion, it will be appreciated that nonfluonnated oils may be used to increase the loading capacity of active or bioactive agents without compromising the microstructure. In this case, selection of the nonfluoπnated oil is based upon the solubility of the active or bioactive agent, water solubility, boiling point, and flash point. The active or bioactive agent will be dissolved in the oil and subsequently emulsified in the feed solution. Preferably the oil will have substantial solubihzation capacity with respect to the selected agent, low water solubility ( < 103M), boiling point greater than water and a flash point greater than the drying outlet temperature. The addition of surfactants, and co solvents to the nonfluonnated oil to increase the solubihzation capacity is also within the scope of the present invention.
In particularly preferred embodiments nonfluoπnated oils may be used to solubilize agents or bioactive agents that have limited solubility in aqueous compositions. The use of nonfluonnated oils is of particular use for increasing the loading capacity of steroids such as beclomethasone dipropionate and tnamcinolone acetonide. Preferably the oil or oil mixture for solubilizmg these clathrate forming steroids will have a refractive index between 1.36 and 1.41 (e.g. ethyl butyrate, butyl carbonate, dibutyl ether). In addition, process conditions, such as temperature and pressure, may be adjusted in order to boost solubility of the selected agent. It will be appreciated that selection of an appropnate oil or oil mixtures and processing conditions to maximize the loading capacity of an agent are well within the purview of a skilled artisan in view of the teachings herein and may be accomplished without undue experimentation.
Particularly preferred embodiments of the present invention compπse spray drying preparations compnsing a surfactant such as a phosphohpid and at least one active or bioactive agent. In other embodiments the spray drying preparation may further compnse an excipient comprising a hydrophi c moiety such as, for example, a carbohydrate (ι.e. glucose, lactose, or starch) in addition to any selected surfactant. In this regard various starches and deπvatized starches suitable for use in the present invention. Other optional components may include conventional viscosity modifiers, buffers such as phosphate buffers or other conventional biocompatible buffers or pH adjusting agents such as acids or bases, and osmotic agents (to provide isotonicity, hyperosmolaπty, or hyposmolaπty). Examples of suitable salts include sodium phosphate (both monobasic and dibasic), sodium chloride, calcium phosphate, calcium chloride and other physiologically acceptable salts.
Whatever components are selected, the first step in paniculate production typically comprises feed stock preparation. Preferably the selected drug is dissolved in water to produce a concentrated solution. The drug may also be dispersed directly in the emulsion, particularly in the case of water insoluble agents. Alternatively, the drug may be incorporated in the form of a solid paniculate dispersion. The concentration of the active or bioactive agent used is dependent on the amount of agent required in the final powder and the performance of the delivery device employed (e.g., the fine particle dose for a MDI or DPI). As needed, cosurfactants such as poloxamer 188 or span 80 may be dispersed into this annex solution. Additionally, excipients such as sugars and starches can also be added. In selected embodiments an oil in water emulsion is then formed in a separate vessel. The oil employed is preferably a fluorocarbon (e.g., perfluorooctyl bromide, perfluorodecalin) which is emulsified using a surfactant such as a long chain saturated phosphohpid. For example, one gram of phosphohpid may be homogenized in 150 g hot distilled water (e.g., 60°C) using a suitable high shear mechanical mixer (e.g.. Ultra Turrax model T 25 mixer) at 8000 rpm for 2 to 5 minutes. Typically 5 to 25 g of fluorocarbon is added dropwise to the dispersed surfactant solution while mixing. The resulting perfluorocarboπ in water emulsion is then processed using a high pressure homogenizer to reduce the particle size. Typically the emulsion is processed at 12,000 to 18,000 psi, 5 discrete passes and kept at 50 to 80°C.
The active or bioactive agent solution and perfluorocarbon emulsion are then combined and fed into the spray dryer. Typically the two preparations will be miscible as the emulsion will preferably comprise an aqueous continuous phase. While the bioactive agent is solubilized separately for the purposes of the instant discussion it will be appreciated that, in other embodiments, the active or bioactive agent may be solubilized (or dispersed) directly in the emulsion. In such cases, the active or bioactive emulsion is simply spray dried without combining a separate drug preparation.
In any event, operating conditions such as inlet and outlet temperature, feed rate, atomization pressure, flow rate of the drying air, and nozzle configuration can be adjusted in accordance with the manufacturer's guidelines in order to produce the required particle size, and production yield of the resulting dry microstructures. Exemplary settings are as follows, an air inlet temperature between 60°C and 170°C, an air outlet between 40°C to 120°C; a feed rate between 3 ml to about 15 ml per minute; and an aspiration air flow of 300 L/min. and an atomization air flow rate between 25 to 50 L/min The selection of appropnate apparatus and processing conditions are well within the purview of a skilled artisan in view of the teachings herein and may be accomplished without undue experimentation. In any event, the use of these and substantially equivalent methods provide for the formation of hollow porous aerodynamically light microspheres with particle diameters appropriate for aerosol deposition into the lung microstructures that are both hollow and porous, almost honeycombed or foam like in appearance. In especially preferred embodiments the perforated microstructures comprise hollow, porous spray dried microspheres
Along with spray drying, perforated microstructures useful in the present invention may be formed by lyophilization. Those skilled in the art will appreciate that lyophilization is a freeze drying process in which water is sublimed from the composition after it is frozen. The particular advantage associated with the lyophilization process is that bioiogicals and pharmaceuticals that are relatively unstable in an aqueous solution can be dried without elevated temperatures (thereby eliminating the adverse thermal effects), and then stored in a dry state where there are few stability problems. With respect to the instant invention such techniques are particularly compatible with the incorporation of peptides, proteins, genetic matenal and other natural and synthetic macromolecules in particulates or perforated microstructures without compromising physiological activity. Methods for providing lyophilized particulates are known to those of skill in the art and it would clearly not require undue expeπmentation to provide dispersion compatible microstructures in accordance with the teachings herein. The lyophilized cake containing a fine foam like structure can be micronized using techniques known in the art to provide 3 to 10μm sized particles. Accordingly, to the extent that lyophilization processes may be used to provide microstructures having the desired porosity and size they are conformance with the teachings herein and are expressly contemplated as being within the scope of the instant invention.
Besides the aforementioned techniques, the perforated microstructures or particles of the present invention may also be formed using a method where a feed solution (either emulsion or aqueous) containing wall forming agents is rapidly added to a reservoir of heated oil (e.g. perflubron or other high boiling FCs) under reduced pressure. The water and volatile solvents of the feed solution rapidly boils and are evaporated This process provides a perforated structure from the wall forming agents similar to puffed πce or popcorn.
Preferably the wall forming agents are insoluble in the heated oil. The resulting particles can then separated from the heated oil using a filtering technique and subsequently dried under vacuum.
Additionally, the perforated microstructures of the present invention may also be formed using a double emulsion method. In the double emulsion method the medicament is first dispersed in a polymer dissolved in an organic solvent (e.g. methyiene chloride) by somcation or homogemzation. This primary emulsion is then stabilized by forming a multiple emulsion in a continuous aqueous phase containing an emulsifier such as polyvinylalcohol. Evaporation or extraction using conventional techniques and apparatus then removes the organic solvent. The resulting microspheres are washed, filtered and dried prior to combining them with an appropriate suspension medium in accordance with the present invention Whatever production method is ultimately selected for production of the perforated microstructures, the resulting powders have a number of advantageous properties that make them particularly compatible for use in devices for inhalation therapies. In particular, the physical characteristics of the perforated microstructures make them extremely effective for use in dry powder inhalers and in the formation of stabilized dispersions that may be used in conjunction with metered dose inhalers, nebulizers and liquid dose instillation. As such, the perforated microstructures provide for the effective pulmonary administration of bioactive agents.
In order to maximize dispersibility, dispersion stability and optimize distπbution upon administration, the mean geometric particle size of the perforated microstructures is preferably about 0.5 50 m, more preferably 1 30 m. It will be appreciated that large particles (i.e. greater than 50 m) may not be preferred in applications where a valve or small oπfice is employed, since large particles tend to aggregate or separate from a suspension which could potentially clog the device. In especially preferred embodiments the mean geometnc particle size (or diameter) of the perforated microstructures is less than 20 m or less than 10 m. More preferably the mean geometnc diameter is less than about 7 m or 5 , and even more preferably less than about 2.5 m. Other preferred embodiments will compπse preparations wherein the mean geometnc diameter of the perforated microstructures is between about 1 m and 5 m. In especially preferred embodiments the perforated microstructures will comprise a powder of dry, hollow, porous microspheπcal shells of approximately 1 to 10 m or 1 to 5 m m diameter, with shell thicknesses of approximately 0.1 to approximately 0.5 m It is a particular advantage of the present invention that the particulate concentration of the dispersions and structural matrix components can be adjusted to optimize the delivery charactenstics of the selected particle size As alluded to throughout the instant specification the porosity of the microstructures may play a significant part is establishing dispersibility (e.g. in DPIs) or dispersion stability (e.g. for MDIs or nebulizers). In this respect, the mean porosity of the perforated microstructures may be determined through electron microscopy coupled with modern imaging techniques. More specifically, electron micrographs of representative samples of the perforated microstructures may be obtained and digitally analyzed to quantify the porosity of the preparation. Such methodology is well known in the art and may be undertaken without undue expeπmentation
For the purposes of the present invention, the mean porosity (i.e. the percentage of the particle surface area that is open to the interior and/or a central void) of the perforated microstructures may range from approximately 0.5% to approximately 80%. In more preferred embodiments, the mean porosity will range from approximately 2% to approximately 40%. Based on selected production parameters, the mean porosity may be greater than approximately, 2%, 5%, 10%, 15%, 20%, 25% or 30% of the microstructure surface area, in other embodiments, the mean porosity of the microstructures may be greater than about 40%, 50%, 60%, 70% or even 80%. As to the pores themselves, they typically range in size from about 5 nm to about 400 nm with mean pore sizes preferably in the range of from about 20 nm to about 200 nm. In particularly preferred embodiments the mean pore size will be in the range of from about 50 nm to about 100 nm. As may be seen in Figs. 1A1 to 1 F2 and discussed in more detail below, it is a significant advantage of the present invention that the pore size and porosity may be closely controlled by careful selection of the incorporated components and production parameters.
In this regard, the particle morphology and/or hollow design of the perforated microstructures also plays an important role on the dispersibility or cohesiveness of the dry powder formulations disclosed herein That is, it has been surpπsingly discovered that the inherent cohesive character of fine powders can be overcome by lowering the van der Waals, electrostatic attractive and liquid bridging forces that typically exist between dry particles. More specifically, in concordance with the teachings herein, improved powder dispersibility may be provided by engineenng the particle morphology and density, as well as control of humidity and charge To that end, the perforated microstructures of the present invention compπse pores, voids, hollows, defects or other interstitial spaces which reduce the surface contact area between particles thereby minimizing interparticle forces. In addition, the use of surfactants such as phospholipids and fluonnated blowing agents in accordance with the teachings herein may contribute to improvements in the flow properties of the powders by tempering the charge and strength of the electrostatic forces as well as moisture content.
Most fine powders (e.g. < 5 m) exhibit poor dispersibility which can be problematic when attempting to deliver, aerosolize and/or package the powders. In this respect the major forces which control particle interactions can typically be divided into long and short range forces. Long range forces include gravitational attractive forces and electrostatics, where the interaction varies as a square of the separation distance or particle diameter. Important short range forces for dry powders include van der Waals interactions, hydrogen bonding and liquid bndges. The latter two short range forces differ from the others in that they occur where there is already contact between particles. It is a major advantage of the present invention that these attractive forces may be substantially attenuated or reduced through the use of perforated microstructures as descπbed herein.
In an effort to overcome these attractive forces, typical pπor art dry powder formulations for DPIs compπse micronized drug particles that are deposited on large earner particles (e.g., 30 to 90 μm) such as lactose or agglomerated units of pure drug particles or agglomeration of fine lactose particles with pure drug, since they are more readily fluidized than neat drug particles. In addition, the mass of drug required per actuation is typically less than 100 μg and is thus prohibitively too small to meter. Hence, the larger lactose particles in pnor art formulations function as both a earner particle for aerosolization and a bulking agent for meteπng. The use of large particles in these formulations are employed since powder dispersibility and aerosolization efficiency improves with increasing increasing particle size as a result of diminished interparticle forces (French, D.L, Edwards, D.A., sand Niven, R.W., J. Aerosol Sci. 27, 769 783, 1996 which is incorporated herein by reference). That is, prior art formulations often use large particles or earners to overcome the pπnciple forces controlling dispersibility such as van der Waals forces, liquid bπdging, and electrostatic attractive forces that exists between particles.
Those skilled in the art will appreciate that the van der Waals (VDW) attractive force occurs at short range and depends, at least in part, on the surface contact between the interacting particles. When two dry particles approach each other the VDW forces increase with an increase in contact area. For two dry particles, the magnitude of the VDW interaction force, F0^, can be calculated using the following equation-
Figure imgf000028_0001
where h is Planck's constant, σ is the angular frequency, αV, is the distance at which the adhesional force is at a maximum, and r, and r2 are the radii of the two interacting particles. Accordingly, it will be appreciated that one way to minimize the magnitude and strength of the VDW force for dry powders is to decrease the interparticle area of contact. It is important to note that the magnitude d0 ιs a reflection of this area of contact The minimal area of contact between two opposing bodies will occur if the particles are perfect spheres. In addition, the area of contact will be further minimized if the particles are highly porous. Accordingly, the perforated microstructures of the present invention act to reduce interparticle contact and corresponding VDW attractive forces. It is important to note that this reduction in VDW forces is largely a result of the unique particle morphology of the powders of the present invention rather than an increase in geometnc particle diameter. In this regard, it will be appreciated that particularly preferred embodiments of the present invention provide powders having average or smaii particulates (e.g. mean geometnc diameter < 10 μm) exhibiting relatively low VDW attractive forces. Conversely, solid, noπ-spheπcal particles such as conventional micronized drugs of the same size will exert greater interparticle forces between them and, hence, will exhibit poor powder dispersibility.
Further, as indicated above, the electrostatic force affecting powders occurs when either or both of the particles are electrically charged. This phenomenon will result with either an attraction or repulsion between particles depending on the similarity or dissimilarity of charge In the simplest case, the electric charges can be descπbed using Coulomb's Law. One way to modulate or decrease the electrostatic forces between particles is if either or both particles have non conducting surfaces. Thus, if the perforated microstructure powders compπse excipients, surfactants or active agents that are relatively non-conducting, then any charge generated in the particle will be unevenly distπbuted over the surface. As a result, the charge half life of powders compnsing non conducting components will be relatively short since the retention of elevated charges is dictated by the resistivity of the matenal. Resistive or non conducting components are materials which will neither function as an efficient electron donor or acceptor. Derjaguin et al. (Muller, V.M., Yushchenko, V.S., and Derjaguin, B.V., J. Colloid Interface Sci. 1980, 77, 115 119), which is incorporated herein by reference, provide a list ranking molecular groups for their ability to accept or donate an electron. In this regard exemplary groups may be ranked as follows.
Donor: -NH > OH > OR > COOR > CH3 > C6H5 > halogen > COOH > CO > CN Acceptor:
The present invention provides for the reduction of electrostatic effects in the disclosed powders though the use of relatively non conductive mateπals. Using the above rankings, preferred non conductive mateπals would include halogenated and/or hydrogenated components. Mateπals such as phospholipids and fluonnated blowing agents (which may be retained to some extent in the spray dried powders) are preferred since they can provide resistance to particle charging It will be appreciated that the retention of residual blowing agent (e g fiuorochemicals) in the particles, even at relatively low levels, may help minimize charging of the perforated microstructures as is typically imparted during spray drying and cyclone separation. Based on general electrostatic principles and the teachings herein, one skilled in the art would be able to identify additional mateπals that serve to reduce the electrostatic forces of the disclosed powders without undue experimentation Further, if needed, the electrostatic forces can also be manipulated and minimized using electrification and charging techniques.
In addition to the surpπsing advantages described above, the present invention further provides for the attenuation or reduction of hydrogen and liquid bonding. As known to those skilled in the art, both hydrogen bonding and liquid bπdging can result from moisture that is absorbed by the powder. In general, higher humidities produce higher interparticle forces for hydrophilic surfaces. This is a substantial problem in pnor art pharmaceutical formulations for inhalation therapies which tend to employ relatively hydrophilic compounds such as lactose However, in accordance with the teachings herein, adhesion forces due to adsorbed water can be modulated or reduced by increasing the hydrophobicity of the contacting surfaces One skilled in the art can appreciate that an increase in particle hydrophobicity can be achieved through excφieπt selection and/or use a post production spray drying coating technique such as employed using a fluidized bed Thus, preferred excipients include hydrophobic surfactants such as phospholipids, fatty acid soaps and cholesterol. In view of the teachings herein, it is submitted that a skilled artisan would be able to identify mateπals exhibiting similar desirable properties without undue experimentation. In accordance with the present invention, methods such as angle of repose or shear index can be used to assess the flow properties of dry powders. The angle of repose is defined as the angle formed when a cone of powder is poured onto a flat surface Powders having an angle of repose ranging from 45° to 20° are preferred and indicate suitable powder flow. More particularly, powders which possess an angle of repose between 33° and 20° exhibit relatively low shear forces and are especially useful in pharmaceutical preparations for use in inhalation therapies (e.g. DPIs). The shear index, though more time consuming to measure than angle of repose, is considered more reliable and easy to determine. Those skilled in the art will appreciate that the expenmental procedure outlined by Amidon and Houghton (G E. Amidon, and M E. Houghton, Pharm Manuf., 2, 20, 1985, incorporated herein by reference) can be used estimate the shear index for the purposes of the present invention. As descnbed in S. Kocova and N Pilpel, J Pharm Pharmacol. 8, 33 55, 1973, also incorporated herein by reference, the shear index is estimated from powder parameters such as, yield stress, effective angle of internal fnction, tensile strength, and specific cohesion. In the present invention powders having a shear index less than about 0.98 are desirable. More preferably, powders used in the disclosed compositions, methods and systems will have shear indices less than about 1 1 In particularly preferred embodiments the shear index will be less than about 1 3 or even less than about 1.5 Of course powders having different shear indices may be used provided the result in the effective deposition of the active or bioactive agent at the site of interest
It will also be appreciated that the flow properties of powders have been shown correlate well with bulk density measurements In this regard, conventional pπor art thinking (C F Harwood, J Pharm. Sci , 60, 161 163, 1971) held that an increase in bulk density correlates with improved flow properties as predicted by the shear index of the material Conversely, it has surpπsingly been found that, for the perforated microstructures of the present invention, superior flow properties were exhibited by powders having relatively low bulk densities. That is, the hollow porous powders of the present invention exhibited supeπor flow properties over powders substantially devoid of pores. To that end, it has been found that it is possible to provide powders having bulk densities of less than 0.5 g/cm3 that exhibit particularly favorable flow properties More surprisingly, it has been found that it is possible to provide perforated microstructure powders having bulk densities of less than 0.3 g/cm3 or even less than about 0 1 g/cm3 that exhibit excellent flow properties The ability to produce low bulk density powders having supeπor flowability further accentuates the novel and unexpected nature of the present invention.
In addition, it will be appreciated that the reduced attractive forces (e g. van der Waals, electrostatic, hydrogen and liquid bonding, etc.) and excellent flowability provided by the perforated microstructure powders make them particularly useful in preparations for inhalation therapies (e g in inhalation devices such as DPIs, MDIs, nebulizers). Along with the superior flowability, the perforated or porous and/or hollow design of the microstructures also plays an important role in the resulting aerosol properties of the powder when discharged. This phenomenon holds true for perforated microstructures aerosolized as a suspension, as in the case of an MDI or a nebulizer, or delivery of perforated microstructures in dry form as in the case of a DPI In this respect the perforated structure and relatively high surface area of the dispersed microparticles enables them to be earned along in the flow of gases during inhalation with greater ease for longer distances than non perforated particles of comparable size.
More articulady, because of their high porosity, the density of the particles is significantly less than 1.0 g/cm3, typically less than 0.5 g/cm3, more often on the order of 0.1 g/cm3, and as low as 0.01 g/cm3 Unlike the geometric particle size, the aerodynamic particle size, daer , of the perforated microstructures depends substantially on the particle density, p : daer = dgeop, where dgeo is the geometnc diameter. For a particle density of 0.1 g/cm3, daer will be roughly three times smaller than dgeo, leading to increased particle deposition into the peripheral regions of the lung and correspondingly less deposition in the throat. In this regard, the mean aerodynamic diameter of the perforated microstructures is preferably less than about 5 μm, more preferably less than about 3 μm, and, in particularly preferred embodiments, less than about 2 μm Such particle distributions will act to increase the deep lung deposition of the bioactive agent whether administered using a DPI, MDI or nebulizer Further, having a larger geometric diameter than aerodynamic diameter brings the particles closer to the wall of the alveolus thus increasing the deposition of small aerodynamic diameter particles.
As will be shown subsequently in the Examples, the particle size distribution of the aerosol formulations of the present invention are measurable by conventional techniques such as, for example, cascade impactioπ or by time of flight analytical methods. In addition, determination of the emitted dose from inhalation devices were done according to the proposed U S Pharmacopeia method {Pharmacopeia/ Previews 22(1996) 3065) which is incorporated herein by reference. These and related techniques enable the "fine particle fraction" of the aerosol, which corresponds to those particulates that are likely to effectively deposited in the lung, to be calculated. As used herein the phrase "fine particle fraction" refers to the percentage of the total amount of active medicament delivered per actuation from the mouthpiece of a DPI, MDI or nebulizer onto plates 2 7 of an 8 stage Andersen cascade impactor. Based on such measurements the formulations of the present invention will preferably have a fine particle fraction of approximately 20% or more by weight of the perforated microstructures (w/w), more preferably they will exhibit a fine particle fraction of from about 25% to 80% w/w, and even more preferably from about 30 to 70% w/w In selected embodiments the present invention will preferably comprise a fine particle fraction of greater than about 30%, 40%, 50%, 60%, 70% or 80% by weight
Further, it has also been found that the formulations of the present invention exhibit relatively low deposition rates, when compared with prior art preparations, on the induction port and onto plates 0 and 1 of the impactor Deposition on these components is linked with deposition in the throat in humans. More specifically, most commercially available MDIs and DPIs have simulated throat depositions of approximately 40 70% (w/w) of the total dose, while the formulations of the present invention typically deposit less than about 20% w/w Accordingly, preferred embodiments of the present invention have simulated throat depositions of less than about 40%, 35%, 30%, 25%, 20%, 15% or even 10% w/w. Those skilled in the art will appreciate that significant decrease in throat deposition provided by the present invention will result in a corresponding decrease in associated local side effects such as throat irritation and candidiasis.
With respect to the advantageous deposition profile provided by the instant invention it is well known that MDI propellants typically force suspended particles out of the device at a high velocity towards the back of the throat. Since prior art formulations typically contain a significant percentage of large particles and/or aggregates, as much as two-thirds or more of the emitted dose may impact the throat Moreover, the undesirable delivery profile of conventional powder preparations is also exhibited under conditions of low particle velocity, as occurs with DPI devices. In general, this problem is inherent when aerosolizing solid, dense, particulates which are subject to aggregation. Yet, as discussed above, the novel and unexpected properties of the stabilized dispersions of the present invention result in surprisingly low throat deposition upon administration from inhalation device such as a DPI, MDI atomizer or nebulizer.
While not wishing to be bound by any particular theory, it appears that the reduced throat deposition provided by the instant invention results from decreases in particle aggregation and from the hollow and/or porous morphology of the incorporated microstructures. That is, the hollow and porous nature of the dispersed microstructures slows the velocity of particles in the propellant stream (or gas stream in the case of DPIs), just as a hollow/porous whiffle ball decelerates faster than a baseball. Thus, rather than impacting and sticking to the back of the throat, the relatively slow traveling particles are subject to inhalation by the patient. Moreover, the highly porous nature of the particles allows th propellant within the perforated microstructure to rapidly leave and the particle density to drop before impacting the throat. Accordingly, a substantially higher percentage of the administered bioactive agent is deposited in the pulmonary air passages where it may be efficiently absorbed.
With respect to inhalation therapies, those skilled in the art will appreciate that the perforated microstructure powders of the present invention are particularly useful in DPIs. Conventional DPIs, or dry powder inhalers, compπse powdered formulations and devices where a predetermined dose of medicament, either alone or in a blend with lactose carrier particles, is delivered as a fine mist or aerosol of dry powder for inhalation. The medicament is fomiulated in a way such that it readily disperses into discrete particles with a size rage between 0.5 to 20 μm. The powder is actuated either by inspiration or by some external delivery force, such as pressurized air. DPI formulations are typically packaged in single dose units or they employ reservoir systems capable of metering multiple doses with manual transfer of the dose to the device.
DPIs are generally classified based on the dose delivery system employed, in this respect, the two major types of DPIs compπse unit dose delivery devices and bulk reservoir delivery systems. As used herein, the term
"reservoir" shall be used in a general sense and held to encompass both configurations unless otherwise dictated by contextual restraints. In any event, unit dose delivery systems require the dose of powder formulation presented to the device as a single unit. With this system, the fomiulation is prefilled into dosing wells which may be foil-packaged or presented in blister strips to prevent moisture ingress. Other unit dose packages include hard gelatin capsules. Most unit dose containers designed for DPIs are filled using a fixed volume technique. As a result, there are physical limitations (here density) to the minimal dose that can be metered into a unit package, which is dictated by the powder flowability and bulk density. Currently, the range of dry powder that can be filled into a unit dose container is in the range of 5 to 15 mg which corresponds to drug loading in the range of 25 to 500μg per dose. Conversely, bulk reservoir delivery systems provide a precise quantity of powder to be metered upon individual delivery for up to approximately 200 doses. Again like the unit dose systems, the powder is metered using a fixed volume cell or chamber that the powder is filled into. Thus, the density of the powder is a major factor limiting the minimal dose that can be delivered with this device. Currently bulk reservoir type DPIs can meter between 200μg to 20 mg powder per actuation.
DPIs are designed to be manipulated such that they break open the capsule/blister or to load bulk powder during actuation, followed by dispersion from a mouthpiece or actuator due to the patient's inspiration. When the prior art formulations are actuated from a DPI device the lactose/drug aggregates are aerosolized and the patient inhales the mist of dry powder. During the inhalation process, the carrier particles encounter shear forces whereby some of the micronized drug particles are separated from the lactose paniculate surface. It will be appreciated that the drug particles are subsequently carried into the lung. The large lactose particles impact the throat and upper airways due to size and inertial force constraints. The efficiency of delivery of the drug particles is dictated by their degree of adhesion with the carrier particles and their aerodynamic property.
Deaggregation can be increased through formulation, process and device design improvements. For example fine particle lactose (FPL) is often mixed with coarse lactose carriers, wherein the FPL will occupy high-energy binding sites on the carrier particles. This process provides more passive sites for adhesion of the micronized drug particles. This tertiary blend with the drug has been shown to provide statistically significant increases in fine particle fraction. Other strategies include specialized process conditions where drug particles are mixed with FPL to produce agglomerated units. In order to further increase paniculate deposition, many DPIs are designed to provide deaggregation by passing the dosage form over baffles, or through tortuous channels that disrupts the flow properties.
The addition of FPL, agglomeration with FPL and specialized device design provides an improvement in the deaggregation of formulations, however, the clinically important parameter is the fine particle dose received by the patient. Though improvements in deaggregation can be provided, a major problem still exists with current DPI devices in that there is an increase in respirable dose with an increased inspiratory effort. This is a result of an increased fine particle fraction corresponding to the increased disaggregation of particle agglomerates as the airflow increases through the inhaler with increasing inspiratory effort. Consequently dosing accuracy is compromised, leading to complications when the devices are used to administer highly efficacious drugs to sensitive populations such as children, adolescents and the elderly. Moreover, the dosing inaccuracy associated with conventional preparations could complicate regulatory approval. In stark contrast, the perforated microstructure powders of the present invention obviate many of the difficulties associated with prior art carrier preparations. That is, an improvement in DPI performance may be provided by engineering the particle, size, aerodynamics, morphology and density, as well as control of humidity and charge. In this respect the present invention provides formulations wherein the medicament and the incipients or bulking agents are preferably associated with or comprise the perforated microstructures. As set forth above, preferred compositions according to the present invention typically yield powders with bulk densities less than 0.1 g/cm3 and often less than 0.05 g/cm3. It will be appreciated that providing powders having bulk densities an order of a magnitude less than conventional DPI formulations allows for much lower doses of the selected bioactive agent to be filled into a unit dose container or metered via reservoir-based DPIs. The ability to effectively meter small quantities is of particular importance for low dose steroid, long acting bronchodilators and new protein or peptide medicaments proposed for DPI delivery. Moreover, the ability to effectively deliver particulates without associated carrier particles simplifies product formulation, filling and reduces undesirable side effects.
As discussed above, the hollow porous powders of the present invention exhibit superior flow properties, as measured by the angle of repose or shear index methods described herein, with respect to equivalent powders substantially devoid of pores. That is, superior powder flow, which appears to be a function of bulk density and particle morphology, is observed where the powders have a bulk density less than 0.5 g/cm3. Preferably the powders have bulk densities of less than about 0.3 g/cm3, 0.1 g/cm3 or even less than about 0.05 g/cm3. In this regard, it is theorized that the perforated microstructures comprising pores, voids, hollows, defects or other interstitial spaces contribute to powder flow properties by reducing the surface contact area between particles and minimizing inteφarticle forces. In addition, the use of phospholipids in preferred embodiments and retention of fluonnated blowing agents may also contribute to improvements in the flow properties of the powders by tempering the charge and strength of the electrostatic forces as well as moisture content.
In addition to the aforementioned advantages, the disclosed powders exhibit favorable aerodynamic properties that make them particularly effective for use in DPIs. More specifically, the perforated structure and relatively high surface area of the microparticles enables them to be carried along in the flow of gases during inhalation with greater ease and for longer distances than relatively non-perforated particles of comparable size. Because of their high porosity and low density, administration of the perforated microstructures with a DPI provides for increased particle deposition into the peripheral regions of the lung and correspondingly less deposition in the throat. Such particle distribution acts to increase the deep lung deposition of the administered agent which is preferable for systemic administration. Moreover, in a substantial improvement over prior art DPI preparations the low-density, highly porous powders of the present invention preferably eliminate the need for carrier particles. Since the large lactose carrier particles will impact the throat and upper airways due to their size, the elimination of such particles minimizes throat deposition and any associated "gag" effect associated with conventional DPIs. Along with their use in a dry powder configuration, it will be appreciated that the perforated microstructures of the present invention may be incorporated in a suspension medium to provide stabilized dispersions. Among other uses, the stabilized dispersions provide for the effective delivery of bioactive agents to the pulmonary air passages of a patient using MDIs, nebulizers or liquid dose instillation (LDI techniques). As with the DPI embodiments, Administration of a bioactive agent using an MDI, nebulizer or LDI technique may be indicated for the treatment of mild, moderate or severe, acute or chronic symptoms or for prophylactic treatment. Moreover, the bioactive agent may be administered to treat local or systemic conditions or disorders. It will be appreciated that, the precise dose administered will depend on the age and condition of the patient, the particular medicament used and the frequency of administration, and will ultimately be at the discretion of the attendant physician. When combinations of bioactive agents are employed, the dose of each component of the combination will generally be that employed for each component when used alone.
Those skilled in the art will appreciate the enhanced stability of the disclosed dispersions or suspensions is largely achieved by lowering the van der Waals attractive forces between the suspended particles, and by reducing the differences in density between the suspension medium and the particles In accordance with the teachings herein, the increases in suspension stability may be imparted by engineering perforated microstructures which are then dispersed in a compatible suspension medium As discussed above, the perforated microstructures comprise pores, voids, hollows, defects or other interstitial spaces that allow the fluid suspension medium to freely permeate or perfuse the paniculate boundary Particularly preferred embodiments comprise perforated microstructures that are both hollow and porous, almost honeycombed or foam like in appearance. In especially preferred embodiments the perforated microstructures compπse hollow, porous spray dried microspheres.
When the perforated microstructures are placed in the suspension medium (i e. propellant), the suspension medium is able to permeate the particles, thereby creating a "ho odispersion", wherein both the continuous and dispersed phases are indistinguishable Since the defined or "virtual" particles (i e compnsing the volume circumscribed by the microparticuiate matrix) are made up almost entirely of the medium in which they are suspended, the forces driving particle aggregation (flocculation) are minimized Additionally, the differences in density between the defined particles and the continuous phase are minimized by having the microstructures filled with the medium thereby effectively slowing particle creaming or sedimentation. As such, the perforated microspheres and stabilized suspensions of the present invention are particularly compatible with many aerosolization techniques, such as MDI and nebulization Moreover, the stabilized dispersions may be used in liquid dose instillation applications
Typical prior art suspensions (e g for MDIs) comprise mostly solid particles and small amounts ( < 1 % w/w) of surfactant (e g. lecithin, Span 85, oleic acid) to increase electrostatic repulsion between particles or polymers to steπcally decrease particle interaction In sharp contrast, the suspensions of the present invention are designed not to increase repulsion between particles, but rather to decrease the attractive forces between particles. The principal forces driving flocculation in nonaqueous media are van der Waals attractive forces. As discussed above, VDW forces are quantum mechanical in origin, and can be visualized as attractions between fluctuating dipoles (i e induced dipole induced dipole interactions) Dispersion forces are extremely short range and scale as the sixth power of the distance between atoms When two macroscopic bodies approach one another the dispersion attractions between the atoms sums up. The resulting force is of considerably longer range, and depends on the geometry of the interacting bodies
More specifically, for two spherical particles, the magnitude of the VDW potential, VA , can be approximated by: v = ~ A <n /? i -ft 2 where Aeff is the effective Hamaker constant which
6 0 ( R , + Λ 2 ) accounts for the nature of the particles and the medium, H0 is the distance between particles, and R and R2 are the radii of spherical particles 1 and 2. The effective Ηamaker constant is proportional to the difference in the polaπzabihties of the dispersed particles and the suspension medium.
Ae/f = (yJASM - * ΑPλRT ) ' , where A and APART are the Ηamaker constants for the suspension medium and the particles, respectively. As the suspended particles and the dispersion medium become similar in nature, AΑ{ and AP4RT become closer in magnitude, and Aeff and VA become smaller That is, by reducing the differences between the Ηamaker constant associated with suspension medium and the Ηamaker constant associated with the dispersed particles, the effective Ηamaker constant (and corresponding van der Waals attractive forces) may be reduced.
One way to minimize the differences in the Ηamaker constants is to create a "homodispersion", that is make both the continuous and dispersed phases essentially indistinguishable as discussed above. Besides exploiting the morphology of the particles to reduce the effective Ηamaker constant, the components of the structural matrix (defining the perforated microstructures) will preferably be chosen so as to exhibit a Ηamaker constant relatively close to that of the selected suspension medium In this respect, one may use the actual values of the Ηamaker constants of the suspension medium and the paniculate components to determine the compatibility of the dispersion ingredients and provide a good indication as to the stability of the preparation. Alternatively, one could select relatively compatible perforated microstructure components and suspension mediums using characteristic physical values that coincide with measurable Ηamaker constants but are more readily discernible.
In this respect, it has been found that the refractive index values of many compounds tend to scale with the corresponding Ηamaker constant. Accordingly, easily measurable refractive index values may be used to provide a fairly good indication as to which combination of suspension medium and particle excipients will provide a dispersion having a relatively low effective Ηamaker constant and associated stability. It will be appreciated that, since refractive indices of compounds are widely available or easily derived, the use of such values allows for the formation of stabilized dispersions in accordance with the present invention without undue experimentation. For the purpose of illustration only, the refractive indices of several compounds compatible with the disclosed dispersions are provided in Table I immediately below:
Table I Compound Refractive Index
HFA- 134a 1.172
HFA-227 1.223
CFC-12 1.287
CFC-114 1.288
PFOB 1.305
Mannitol 1.333
Ethanol 1.361 n-octane 1.397
DMPC 1.43
Pluronic F-68 1.43
Sucrose 1.538
Hydroxyethylstarch 1.54
Sodium chloride 1.544
Consistent with the compatible dispersion components set forth above, those skilled in the art will appreciate that, the formation of dispersions wherein the components have a refractive index differential of less than about 0.5 is preferred. That is, the refractive index of the suspension medium will preferably be within about 0.5 of the refractive index associated with the perforated particles or microstructures. It will further be appreciated that, the refractive index of the suspension medium and the particles may be measured directly or approximated using the refractive indices of the major component in each respective phase. For the perforated microstructures, the major component may be determined on a weight percent basis. For the suspension medium, the major component will typically be derived on a volume percentage basis. In selected embodiments of the present invention the refractive index differential value will preferably be less than about
0.45, about 0.4, about 0.35 or even less than about 0.3. Given that lower refractive index differentials imply greater dispersion stability, particularly preferred embodiments comprise index differentials of less than about 0.28, about 0.25, about 0.2, about 0.15 or even less than about 0.1. It is submitted that a skilled artisan will be able to determine which excipients are particularly compatible without undue experimentation given the instant disclosure. The ultimate choice of preferred excipients will also be influenced by other factors, including biocompatibility, regulatory status, ease of manufacture, cost.
As discussed above, the minimization of density differences between the particles and the continuous phase is largely dependent on the perforated and/or hollow nature of the microstructures, such that the suspension medium constitutes most of the particle volume. As used herein, the term "particle volume" corresponds to the volume of suspension medium that would be displaced by the incorporated hollow/porous particles if they were solid, i.e. the volume defined by the particle boundary. For the purposes of explanation, and as discussed above, these fluid filled particulate volumes may be referred to as "virtual particles." Preferably, the average volume of the bioactive agent/excipient shell or matrix (i.e. the volume of medium actually displaced by the perforated microstructure) comprises less than 70% of the average particle volume (or less than 70% of the virtual particle). More preferably, the volume of the microparticulate matrix comprises less than about 50%, 40%, 30% or even 20% of the average particle volume. Even more preferably, the average volume of the shell/matrix comprises less than about 10%, 5%, 3% or 1 % of the average particle volume. Those skilled in the art will appreciate that, such a matrix or shell volumes typically contributes little to the virtual particle density which is overwhelmingly dictated by the suspension medium found therein. Of course, in selected embodiments the excipients used to form the perforated microstructure may be chosen so the density of the resulting matrix or shell approximates the density of the surrounding suspension medium.
It will further be appreciated that, the use of such microstructures will allow the apparent density of the virtual particles to approach that of the suspension medium substantially eliminating the attractive van der Waals forces. Moreover, as previously discussed, the components of the microparticuiate matrix are preferably selected, as much as possible given other considerations, to approximate the density of suspension medium. Accordingly, in preferred embodiments of the present invention, the virtual particles and the suspension medium will have a density differential of less than about 0.6 g/cm3. That is, the mean density of the virtual particles (as defined by the matrix boundary) will be within approximately 0.6 g/cm3 of the suspension medium. More preferably, the mean density of the virtual particles will be within 0.5, 0.4, 0.3 or
0.2 g/cm3 of the selected suspension medium. In even more preferable embodiments the density differential will be less than about 0.1, 0.05, 0.01, or even less than 0.005 g/cm3.
In addition to the aforementioned advantages, the use of hollow, porous particles allows for the formation of free-flowing dispersions comprising much higher volume fractions of particles in suspension. It should be appreciated that, the formulation of prior art dispersions at volume fractions approaching close- packing generally results in dramatic increases in dispersion viscoelastic behavior. Rheological behavior of this type is not appropriate for MDI applications. Those skilled in the art will appreciate that, the volume fraction of the particles may be defined as the ratio of the apparent volume of the particles (i.e. the particle volume) to the total volume of the system. Each system has a maximum volume fraction or packing fraction. For example, particles in a simple cubic arrangement reach a maximum packing fraction of 0.52 while those in a face centered cubic/hexagonal close packed configuration reach a maximum packing fraction of approximately 0.74. For non-spherical particles or polydisperse systems, the derived values are different. Accordingly, the maximum packing fraction is often considered to be an empirical parameter for a given system. Here, it was surprisingly found that the porous structures of the present invention do not exhibit undesirable viscoelastic behavior even at high volume fractions, approaching close packing. To the contrary, they remain as free flowing, low viscosity suspensions having little or no yield stress when compared with analogous suspensions comprising solid particulates. The low viscosity of the disclosed suspensions is thought to be due, at least in large part, to the relatively low van der Waals attraction between the fluid-filled hollow, porous particles. As such, in selected embodiments the volume fraction of the disclosed dispersions is greater than approximately 0.3. Other embodiments may have packing values on the order of 0.3 to about 0.5 or on the order of 0.5 to about 0.8, with the higher values approaching a close packing condition. Moreover, as particle sedimentation tends to naturally decrease when the volume fraction approaches close packing, the formation of relatively concentrated dispersions may further increase formulation stability. Although the methods and compositions of the present invention may be used to form relatively concentrated suspensions, the stabilizing factors work equally well at much lower packing volumes and such dispersions are contemplated as being within the scope of the instant disclosure. In this regard, it will be appreciated that, dispersions comprising low volume fractions are extremely difficult to stabilize using prior art techniques. Conversely, dispersions incorporating perforated microstructures comprising a bioactive agent as described herein are particularly stable even at low volume fractions. Accordingly, the present invention allows for stabilized dispersions, and particulariy respiratory dispersions, to be formed and used at volume fractions less than 0.3. In some preferred embodiments, the volume fraction is approximately 0.0001 - 0.3, more preferably 0.001 - 0.01. Yet other preferred embodiments comprise stabilized suspensions having volume fractions from approximately 0.01 to approximately 0.1. The perforated microstructures of the present invention may also be used to stabilize dilute suspensions of micronized bioactive agents. In such embodiments the perforated microstructures may be added to increase the volume fraction of particles in the suspension, thereby increasing suspension stability to creaming or sedimentation. Further, in these embodiments the incorporated microstructures may also act in preventing close approach (aggregation) of the micronized drug particles. It should be appreciated that, the perforated microstructures incorporated in such embodiments do not necessarily comprise a bioactive agent.
Rather, they may be formed exclusively of various excipients, including surfactants.
Those skilled in the art will further appreciate that the stabilized suspensions or dispersions of the present invention may be prepared by dispersal of the microstructures in the selected suspension medium which may then be placed in a container or reservoir. In this regard, the stabilized preparations of the present invention can be made by simply combining the components in sufficient quantity to produce the final desired dispersion concentration. Although the microstructures readily disperse without mechanical energy, the application of mechanical energy to aid in dispersion (e.g. with the aid of sonication) is contemplated, particularly for the formation of stable emulsions or reverse emulsions. Alternatively, the components may be mixed by simple shaking or other type of agitation. The process is preferably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability. Once formed, the dispersion has a reduced susceptibility to flocculation and sedimentation.
As indicated throughout the instant specification, the dispersions of the present invention are preferably stabilized. In a broad sense, the term "stabilized dispersion" will be held to mean any dispersion that resists aggregation, flocculation or creaming to the extent required to provide for the effective delivery of a bioactive agent. While those skilled in the art will appreciate that there are several methods that may be used to assess the stability of a given dispersion, a preferred method for the puψoses of the present invention comprises determination of creaming or sedimentation time using a dynamic photosedimentation method. As seen in Example IX and Figure 2, a preferred method comprises subjecting suspended particles to a centrifugal force and measuring absorbance of the suspension as a function of time. A rapid decrease in the absorbance identifies a suspension with poor stability. It is submitted that those skilled in the art will be able to adapt the procedure to specific suspensions without undue experimentation.
For the purposes of the present invention the creaming time shall be defined as the time for the suspended drug particulates to cream to 1/2 the volume of the suspension medium. Similarly, the sedimentation time may be defined as the time it takes for the particulates to sediment in 1/2 the volume of the liquid medium. Besides the photosedimentation technique described above, a relatively simple way to determine the creaming time of a preparation is to provide the particulate suspension in a sealed glass vial. The vials are agitated or shaken to provide relatively homogeneous dispersions which are then set aside and observed using appropriate instrumentation or by visual inspection. The time necessary for the suspended particulates to cream to 1/2 the volume of the suspension medium (i.e., to rise to the top half of the suspension medium), or to sediment within 1/2 the volume (i.e., to settle in the bottom 1 /2 of the medium), is then noted. Suspension formulations having a creaming time greater than 1 minute are preferred and indicate suitable stability. More preferably, the stabilized dispersions comprise creaming times of greater than 1, 2, 5, 10, 15, 20 or 30 minutes. In particulariy preferred embodiments, the stabilized dispersions exhibit creaming times of greater than about 1, 1.5, 2, 2.5, or 3 hours. Substantially equivalent periods for sedimentation times are indicative of compatible dispersions. As discussed herein, the stabilized dispersions disclosed herein may preferably be administered to the nasal or pulmonary air passages of a patient via aerosolization, such as with a metered dose inhaler. The use of such stabilized preparations provides for superior dose reproducibility and improved lung deposition as described above. MDIs are well known in the art and could easily be employed for administration of the claimed dispersions without undue experimentation. Breath activated MDIs, as well as those comprising other types of improvements which have been, or will be, developed are also compatible with the stabilized dispersions and present invention and, as such, are contemplated as being with in the scope thereof. However, it should be emphasized that, in preferred embodiments, the stabilized dispersions may be administered with an MDI using a number of different routes including, but not limited to, topical, nasal, pulmonary or oral. Those skilled in the art will appreciate that, such routes are well known and that the dosing and administration procedures may be easily derived for the stabilized dispersions of the present invention.
MDI canisters generally comprise a container or reservoir capable of withstanding the vapor pressure of the propellant used such as, a plastic or plastic-coated glass bottle, or preferably, a metal can or, for example, an aluminum can which may optionally be anoized, lacquer-coated and/or plastic-coated, wherein the container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation. The valves incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as, for example, low density polyethylene, chlorobutyt, black and white butadiene-acryionitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DFIO, DF30, DF 31/50 ACT, DF60), Bespak pic, LTK (e.g. BK300, BK356) and 3M-Neotechnic Ltd., LIK (e.g. Spraymiser). Each filled canister is conveniently fitted into a suitable channeling device or actuator prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channeling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve, to the nose or mouth of a patient e.g., a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation such as, for example, in the range of 10 to 5000 micrograms of bioactive agent per actuation. Typically, a single charged canister will provide for tens or even hundreds of shots or doses.
With respect to MDIs, it is an advantage of the present invention that any biocompatible suspension medium having adequate vapor pressure to act as a propellant may be used. Particulariy preferred suspension media are compatible with use in a metered dose inhaler. That is, they will be able to form aerosols upon the activation of the metering valve and associated release of pressure. In general, the selected suspension medium should be biocompatible (i.e. relatively non-toxic) and non-reactive with respect to the suspended perforated microstructures comprising the bioactive agent. Preferably, the suspension medium will not act as a substantial solvent for any components incorporated in the perforated microspheres. Selected embodiments of the invention comprise suspension media selected from the group consisting of fluorocarbons (including those substituted with other halogens), hydrofluoroalkanes, perfluorocarbons, hydrocarbons, alcohols, ethers or combinations thereof. It will be appreciated that, the suspension medium may comprise a mixture of various compounds selected to impart specific characteristics.
Particularly suitable propellants for use in the MDI suspension mediums of the present invention are those propellant gases that can be liquefied under pressure at room temperature and, upon inhalation or topical use, are safe, toxicologically innocuous and free of side effects. In this regard, compatible propellants may comprise any hydrocarbon, fluorocarbon, hydrogen-containing fluorocarbon or mixtures thereof having a sufficient vapor pressure to efficiently form aerosols upon activation of a metered dose inhaler. Those propellants typically termed hydrofluoroalkanes or HFAs are especially compatible. Suitable propellants include, for example, short chain hydrocarbons, CM hydrogen-containing chlorofluorocarbons such as CH2CIF, CCI2F2CHCIF, CF3CHCIF, CHF2CCIF2, CHCIFCHF2, CF3CH2CI, and CCIF2CH3; CM hydrogen-containing fluorocarbons (e.g. HFAs) such as
CHF2CHF2, CF3CH2F, CHF2CH3, and CF3CHFCF3; and perfluorocarbons such as CF3CF3 and CF3CF2CF3. Preferably, a single perfluorocarbon or hydrogen-containing fluorocarbon is employed as the propellant. Particularly preferred as propellants are 1,1,1,2-tetrafluoroethane (CF3CH2F) (HFA-134a) and 1,1,1,2,3,3,3- heptafluoro-n-propane (CF3CHFCF3) (HFA-227), perfluoroethane, monocnlorodifluoromethane, 1,1-difluoroethane, and combinations thereof. It is desirable that the formulations contain no components that deplete stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarboπs such as CCI3F, CCI2F2, and CF3CCI3.
Specific fluorocarbons, or classes of fluonnated compounds, that are useful in the suspension media include, but are not limited to, fluoroheptane, fiuorocycloheptane, fluoromethylcycloheptane, fluorohexane, fluorocyclohexaπe, fluoropentane, fluorocyclopentane, fluoromethγlcyclopentane, fluoroαimethylcyclopentanes, fluoromethylcyclobutane, fluorodimethylcyclobutane, fluorotrimethylcyclobutane, fluorobutane, fluorocyclobutane, fluoropropane, fluoroethers, fluoropolyethers and fluorotriethylamines. It will be appreciated that, these compounds may be used alone or in combination with more volatile propellants. It is a distinct advantage that such compounds are generally environmentally sound and biologically non-reactive. In addition to the aforementioned fluorocarbons and hydrofluoroalkanes, various chlorofluorocarbons and substituted fluorinated compounds may also be used as suspension mediums in accordance with the teachings herein. In this respect, FC-11 (CCL3F), FC-11 B1 (CBrCI2F), FC-11B2 (CBr2CIF), FC12B2 (CF2Br2), FC21 (CHCI2F), FC21 B1 (CHBrCIF), FC-21 B2 (CHBr2F), FC-31 B1 (CH2BrF), FC113A (CCI3CF3), FC-122 (CCIF2CHCI2), FC-123 (CF3CHCI2), FC-132 (CHCIFCHCIF), FC-133 (CHCIFCHF2), FC-141 (CH2CICHCIF), FC-141 B (CCI2FCH3), FC-142 (CHF2CH2CI), FC-151 (CH2FCH2CI), FC-152
(CH2FCH2F), FC-1112 (CCIF- CCIF), FC-1121 (CHCI-CFCI) and FC-1131 (CHCI- CHF) are all compatible with the teachings herein despite possible attendant environmental concerns. As such, each of these compounds may be used, alone or in combination with other compounds (i.e. less volatile fluorocarbons) to form the stabilized respiratory dispersions of the present invention. Along with the aforementioned embodiments, the stabilized dispersions of the present invention may also be used in conjunction with nebulizers to provide an aerosolized medicament that may be administered to the pulmonary air passages of a patient in need thereof. Nebulizers are well known in the art and could easily be employed for administration of the claimed dispersions without undue experimentation. Breath activated nebulizers, as well as those comprising other types of improvements which have been, or will be, developed are also compatible with the stabilized dispersions and present invention and are contemplated as being with in the scope thereof.
Nebulizers work by forming aerosols, that is converting a bulk liquid into small droplets suspended in a breathable gas. Here, the aerosolized medicament to be administered (preferably to the pulmonary air passages) will comprise small droplets of suspension medium associated with perforated microstructures comprising a bioactive agent. In such embodiments, the stabilized dispersions of the present invention will typically be placed in a fluid reservoir operably associated with a nebulizer. The specific volumes of preparation provided, means of filling the reservoir, etc., will largely be dependent on the selection of the individual nebulizer and is well within the purview of the skilled artisan. Of course, the present invention is entirely compatible with single-dose nebulizers and multiple dose nebulizers.
Traditional prior art nebulizer preparations typically comprise aqueous solutions of the selected pharmaceutical compound. With such prior art nebulizer preparations, it has long been established that corruption of the incoφorated therapeutic compound can severely reduce efficacy. For example, with conventional aqueous multi- dose nebulizer preparations, bacterial contamination is a constant problem. In addition, the solubilized medicament may precipitate out, or degrade over time, adversely affecting the delivery profile. This is particularly true of larger, more labile biopolymers such as enzymes or other types of proteins. Precipitation of the incorporated bioactive agent may lead to particle growth that results in a substantial reduction in lung penetration and a corresponding decrease in bioavailability. Such dosing incongruities markedly decrease the effectiveness of any treatment.
The present invention overcomes these and other difficulties by providing stabilized dispersions with a suspension medium that preferably comprises a fluonnated compound (i.e. a fluorochemical, fluorocarbon or perfluorocarbon). Particulariy preferred embodiments of the present invention comprise fiuorochemicals that are liquid at room temperature. As indicated above, the use of such compounds, whether as a continuous phase or, as a suspension medium, provides several advantages over prior art liquid inhalation preparations. In this regard, it is well established that many fiuorochemicals have a proven history of safety and biocompatibility in the lung. Further, in contrast to aqueous solutions, fiuorochemicals do not negatively impact gas exchange following pulmonary administration. To the contrary, they may actually be able to improve gas exchange and, due to their unique wettability characteristics, are able to carry an aerosolized stream of particles deeper into the lung, thereby improving systemic delivery of the desired pharmaceutical compound. In addition, the relatively non-reactive nature of fiuorochemicals acts to retard any degradation of an incorporated bioactive agent. Finally, many fiuorochemicals are also bacteriostatic thereby decreasing the potential for microbial growth in compatible nebulizer devices.
In any event, nebulizer mediated aerosolization typically requires an input of energy in order to produce the increased surface area of the droplets and, in some cases, to provide transportation of the atomized or aerosolized medicament. One common mode of aerosolization is forcing a stream of fluid to be ejected from a nozzle, whereby droplets are formed. With respect to nebulized administration, additional energy is usually imparted to provide droplets that will be sufficiently small to be transported deep into the lungs. Thus, additional energy is needed, such as that provided by a high velocity gas stream or a piezoelectric crystal. Two popular types of nebulizers, jet nebulizers and ultrasonic nebulizers, rely on the aforementioned methods of applying additional energy to the fluid during atomization.
In terms of pulmonary delivery of bioactive agents to the systemic circulation via nebulization, recent research has focused on the use of portable hand-held ultrasonic nebulizers, also referred to as metered solutions. These devices, generally known as singie-bolus nebulizers, aerosolize a single bolus of medication in an aqueous solution with a particle size efficient for deep lung delivery in one or two breaths. These devices fail into three broad categories. The first category comprises pure piezoelectric single-bolus nebulizers such as those described by Mϋtteriein, et. al., (J. Aerosol Med. 1988; 1:231). In another category, the desired aerosol cloud may be generated by microchannel extrusion single-bolus nebulizers such as those described in U.S. Pat. No. 3,812,854. Finally, a third category comprises devices exemplified by Robertson, et. al., (WO 92/11050) which describes cyclic pressurization single-bolus nebulizers. Each of the aforementioned references is incoφorated herein in their entirety. Most devices are manually actuated, but some devices exist which are breath actuated. Breath actuated devices work by releasing aerosol when the device senses the patient inhaling through a circuit. Breath actuated nebulizers may also be placed in-line on a ventilator circuit to release aerosol into the air flow which comprises the inspiration gases for a patient. Regardless of which type of nebulizer is employed, it is an advantage of the present invention that biocompatible nonaqueous compounds may be used as suspension mediums. Preferably, they will be able to form aerosols upon the application of energy thereto. In general, the selected suspension medium should be biocompatible (i.e. relatively non-toxic) and non-reactive with respect to the suspended perforated microstructures comprising the bioactive agent. Preferred embodiments comprise suspension media selected from the group consisting of fiuorochemicals, fluorocarbons (including those substituted with other halogens), perfluorocarbons, fluorocarbon/hydrocarbon diblocks, hydrocarbons, alcohols, ethers, or combinations thereof. It will be appreciated that the suspension medium may comprise a mixture of various compounds selected to impart specific characteristics. It will also be appreciated that the perforated microstructures are preferably insoluble in the suspension medium, thereby providing for stabilized medicament particles, and effectively protecting a selected bioactive agent from degradation, as might occur during prolonged storage in an aqueous solution. In preferred embodiments, the selected suspension medium is bacteriostatic. The suspension formulation also protects the bioactive agent from degradation during the nebulization process.
As indicated above, the suspension media may comprise any one of a number of different compounds including hydrocarbons, fluorocarbons or hydrocarbon/fluorocarbon diblocks. In general, the contemplated hydrocarbons or highly fluonnated or perfluorinated compounds may be linear, branched or cyclic, saturated or unsaturated compounds. Conventional structural derivatives of these fiuorochemicals and hydrocarbons are also contemplated as being within the scope of the present invention as well. Selected embodiments comprising these totally or partially fluorinated compounds may contain one or more hetero-atoms and/or atoms of bromine or chlorine. Preferably, these fiuorochemicals comprise from 2 to 16 carbon atoms and include, but are not limited to, linear, cyclic or polycyclic perfluoroalkanes, bis(perfiuoroalkyl)alkenes, perfluoroethers, perfluoroamines, perfluoroalkyl bromides and perfluoroalkyl chlorides such as dichlorooctane. Particulariy preferred fluorinated compounds for use in the suspension medium may comprise perfluorooctyl bromide C8F,7Br (PFOB or perflubron), dichlorofluorooctane C8F16CI^ and the hydrofluoraalkane perfluorooctyl ethane CeFl7C2H5 (PFOE). With respect to other embodiments, the use of perfluorohexane or perfluoropentane as the suspension medium is especially preferred. More generally, exemplary fiuorochemicals which are contemplated for use in the present invention generally include halogenated fiuorochemicals (i.e. C„F2|H)X, XC„F2nX, where n - 2-10, X - Br, Cl or I) and, in particular, 1-bromo-F-butane n-C4F9Br, 1-bromo-F-hexane (n-C6F13Br), 1-bromo-F-heptane (n-C7Fl5Br), 1,4-dibromo-F- butane and 1,6-dibromo-F-hexane. Other useful bro inated fiuorochemicals are disclosed in US Patent No. 3,975,512 to Long and are incorporated herein by reference. Specific fiuorochemicals having chloride substituents, such as perfluorooctyl chloride (n-CβF17CI), 1,8-dicWoro-F-octane (n-CIC8F)6CI), 1,6-dichloro-F-hexane (n-CIC6Fl2CI), and 1, 4-dichloro-F-butane (n-CIC4FBCI) are also preferred.
Fluorocarbons, fiuorocarbon-hydrocarbon compounds and halogenated fiuorochemicals containing other linkage groups, such as esters, thioethers and amines are also suitable for use as suspension media in the present invention. For instance, compounds having the general formula, CnF2*ιOCrnF2m*ι, or C ^CH-CHC-J-a-.,, (as for example C4F9CH-CHC4Fg (F-44E), i-C3F9CH-CHC6F,3 (F-i36E), and C6F,3CH-CHC6F,3 (F-66E)) where n and m are the same or different and n and m are integers from about 2 to about 12 are compatible with teachings herein. Useful fluorochemical-hydrocarbon diblock and triblock compounds include those with the general formulas CnF2^,-CmH,.ι and C.F2B+1CB1Har-If where n - 2-12; m = 2-16 or CpH2p.,-CnF2„-CmH2m-n where p - 1-12, m - 1-12 and n = 2-12. Preferred compounds of this type include C8F,7C2H5 C6Ft3C,0H21 C8F,7CβH,7 C6F,3CH-CHC6H13 and
CβF,7CH-CHC10H21. Substituted ethers or polyethers (i.e. XC„F2nOCmF2mX, XCFOC„F2nOCF2X, where n and m = 1-4, X » Br, Cl or I) and fluorochemical-hydrocarbon ether diblocks or triblocks (i.e. CnF^-O-C-.H^,, where n - 2-10; = 2-16 or CpH2( l-0-CnF2n-0-C1.H2l-.1, where p - 2-12, m - 1-12 and n - 2-12) may also used as well as CnF2n,,0- C-,F2m0CpH2p.|, wherein n, m and p are from 1-12. Furthermore, depending on the application, perfluoroalkyl ated ethers or polyethers may be compatible with the claimed dispersions.
Polycyclic and cyclic fiuorochemicals, such as C10F18 (F-decalin or perfluorodecalin), perfluoroperhydrophenanthrene, perfluorotetramethylcyclohexane (AP-144) and perfluoro n-butyidecalin are also within the scope of the invention. Additional useful fiuorochemicals include perfluorinated amines, such as F- tripropylamine ("FTPA") and F-tributylamine ("FTBA"). F-4-methyloctahydroquinoiizine ("FMOQ"), F-N-methyl- decahydroisoquinoline ("FMIQ"), F-N-methyldecahydroquinoline ("FHQ"), F-N-cyclohexylpyrrolidine ("FCHP") and F-2- butyltetrahydrofuran ("FC-75"or "FC-77"). Still other useful fluorinated compounds include perfluorophenanthrene, perfluoromethyldecalin, perfluorodimethylethylcyclohexane, perfluorodimethyldecalin, perfluorodiethyldecalin, perfluoromethyladamantane, perfiuorodimethyladamantane. Other contemplated fiuorochemicals having nonfluorine substituents, such as, perfluorooctyl hydride, and similar compounds having different numbers of carbon atoms are also useful. Those skilled in the art will further appreciate that other variously modified fiuorochemicals are encompassed within the broad definition of fluorochemical as used in the instant application and suitable for use in the present invention. As such, each of the foregoing compounds may be used, alone or in combination with other compounds to form the stabilized dispersions of the present invention.
Specific fluorocarbons, or classes of fluorinated compounds, that may be useful as suspension media include, but are not limited to, fiuoroheptane, fiuorocycloheptane fluoromethylcycloheptane, fluorohexane, fluorocyclohexane, fluoropentane, fluorocyclopentane, fluoromethylcyclopentane, fiuororjmethylcyciopentanes, fluoromethylcyclobutane, fluorodimethylcyclobutane, fluorotrimethylcyclobutane, fluorobutane, fluorocyclobutane, fluoropropane, fluoroethers, fluoropolyethers and fluorotriethylamines. Such compounds are generally environmentally sound and are biologically non-reactive. While any fluid compound capable of producing an aerosol upon the application of energy may be used in conjunction with the present invention, the selected suspension medium will preferably have a vapor pressure less than about 5 atmospheres and more preferably less than about 2 atmospheres. Unless otherwise specified, all vapor pressures recited herein are measured at 25°C. In other embodiments, preferred suspension media compounds will have vapor pressures on the order of about 5 torr to about 760 torr, with more preferable compounds having vapor pressures on the order of from about 8 torr to about 600 torr, while still more preferable compounds will have vapor pressures on the order of from about 10 torr to about 350 torr. Such suspension media may be used in conjunction with compressed air nebulizers, ultrasonic nebulizers or with mechanical atomizers to provide effective ventilation therapy. Moreover, more volatile compounds may be mixed with lower vapor pressure components to provide suspension media having specified physical characteπstics selected to further improve stability or enhance the bioavaiiability of the dispersed bioactive agent.
Other embodiments of the present invention directed to nebulizers will compπse suspension media that boil at selected temperatures under ambient conditions (i.e. 1 atm). For example, prefened embodiments will compπse suspension media compounds that boil above 0°C, above 5°C, above 10°C, above 15°, or above 20°C. In other embodiments, the suspension media compound may boil at or above 25°C or at or above 30°C. In yet other embodiments, the selected suspension media compound may boil at or above human body temperature (i.e. 37°C), above 45°C, 55°C, 65°C, 75°C, 85°C or above 100°C.
Along with MDIs and nebulizers, it will be appreciated that the stabilized dispersions of the present invention may be used in conjunction with liquid dose instillation or LDI techniques. Liquid dose instillation involves the direct administration of a stabilized dispersion to the lung In this regard, direct pulmonary administration of bioactive compounds is particularly effective in the treatment of disorders especially where poor vascular circulation of diseased portions of a lung reduces the effectiveness of intravenous drug delivery With respect to LDI the stabilized dispersions are preferably used in conjunction with partial liquid ventilation or total liquid ventilation Moreover, the present invention may further comprise introducing a therapeutically beneficial amount of a physiologically acceptable gas (such as nitπc oxide or oxygen) into the pharmaceutical microdispersion prior to, duπng or following administration
For LDI, the dispersions of the present invention may be administered to the lung using a pulmonary delivery conduit. Those skilled in the art will appreciate the term "pulmonary delivery conduit", as used herein, shall be construed in a broad sense to comprise any device or apparatus, or component thereof, that provides for the instillation or administration of a liquid in the lungs. In this respect a pulmonary delivery conduit or delivery conduit shall be held to mean any bore, lumen, catheter, tube, conduit, synπge, actuator, mouthpiece, endotrachεal tube or bronchoscope that provides for the administration or instillation of the disclosed dispersions to at least a portion of the pulmonary air passages of a patient in need thereof. It will be appreciated that the delivery conduit may or may not be associated with a liquid ventilator or gas ventilator. In particularly preferred embodiments the delivery conduit shall comprise an eπdotracheal tube or bronchoscope.
Here it must be emphasized that the dispersions of the present invention may be administered to ventilated (e.g. those connected to a mechanical ventilator) or nonventilated, patients (e.g. those undergoing spontaneous respiration). Accordingly, in preferred embodiments the methods and systems of the present invention may comprise the use or inclusion of a mechanical ventilator. Further, the stabilized dispersions of the present invention may also be used as a lavage agent to remove debris in the lung, or for diagnostic lavage procedures. In any case the introduction of liquids, particularly fiuorochemicals, into the lungs of a patient is well known and could be accomplished by a skilled artisan in possession of the instant specification without undue experimentation.
Those skilled in the art will appreciate that suspension media compatible with LDI techniques are similar to those set forth above for use in conjunction with nebulizers. Accordingly, for the purposes of the present application suspension media for dispersions compatible with LDI shall be equivalent to those enumerated above in conjunction with use in nebulizers In any event, it will be appreciated that in particularly preferred LDI embodiments the selected suspension medium shall comprise a fluorochemical that is liquid under ambient conditions
It will be understood that, in connection with the present invention, the disclosed dispersions are preferably administered directly to at least a portion of the pulmonary air passages of a mammal. As used herein, the terms "direct instillation" or "direct administration" shall be held to mean the introduction of a stabilized dispersion into the lung cavity of a mammal. That is, the dispersion will preferably be administered through the trachea of a patient and into the lungs as a relatively free flowing liquid passing through a delivery conduit and into the pulmonary air passages In this regard, the flow of the dispersion may be gravity assisted or may be afforded by induced pressure such as through a pump or the compression of a syringe plunger In any case, the amount of dispersion administered may be monitored by mechanical devices such as flow meters or by visual inspection.
While the stabilized dispersions may be administered up to the functional residual capacity of the lungs of a patient, it will be appreciated that selected embodiments will comprise the pulmonary administration of much smaller volumes (e.g. on the order of a milliliter or less). For example, depending on the disorder to be treated, the volume administered may be on the order of 1, 3, 5, 10, 20, 50, 100, 200 or 500 milliliters. In preferred embodiments the liquid volume is less than 0.25 or 0.5 percent FRC. For particularly preferred embodiments, the liquid volume is 0.1 percent FRC or less. With respect to the administration of relatively low volumes of stabilized dispersions it will be appreciated that the wettabi ty and spreading characteristics of the suspension media (particularly fiuorochemicals) will facilitate the even distribution of the bioactive agent in the lung. However, in other embodiments it may be preferable to administer the suspensions a volumes of greater than 0.5, 0.75 or 0.9 percent FRC. In any event, LDI treatment as disclosed herein represents a new alternative for critically ill patients on mechanical ventilators, and opens the door for treatment of less ill patients with broπchoscopic administration.
It will also be understood that other components can be included in the stabilized dispersions of the present invention. For example, osmotic agents, stabilizers, chelators, buffers, viscosity modulators, salts, and sugars can be added to fine tune the stabilized dispersions for maximum life and ease of administration. Such components may be added directly to the suspension medium or associated with, or incoφorated in, the perforated microstructures. Considerations such as steπlity, isotomcity, and biocompatibilitγ may govern the use of conventional additives to the disclosed compositions. The use of such agents will be understood to those of ordinary skill in the art and, the specific quantities, ratios, and types of agents can be determined empmcally without undue expenmentation. Moreover, while the stabilized dispersions of the present invention are particularly suitable for the pulmonary administration of bioactive agents, they may also be used for the localized or systemic administration of compounds to any location of the body Accordingly, it should be emphasized that, in preferred embodiments, the formulations may be administered using a number of different routes including, but not limited to, the gastrointestinal tract, the respiratory tract, topically, intramuscularly, intrapeπtoneally, nasally, vaginaily, rectally, aurally, orally or ocular More generally, the stabilized dispersions of the present invention may be used to deliver agents topically or by administration to a non pulmonary body cavity In preferred embodiments the body cavity is selected from the group consisting of the peritoneum, sinus cavity, rectum, urethra, gastrointestinal tract, nasal cavity, vagina, auditory meatus, oral cavity, buccal pouch and pleura Among other indications, stabilized dispersions comprising the appropriate bioactive agent, (e.g. an antibiotic or an anti inflammatory), may be used to treat infections of the eye, sinusitis, infections of the auditory tract and even infections or disorders of the gastrointestinal tract With respect to the latter, the dispersions of the present invention may be used to selectively deliver pharmaceutical compounds to the lining of the stomach for the treatment of H. py/on infections or other ulcer related disorders
With regard to the perforated microstructure powders and stabilized dispersions disclosed herein those skilled in the art will appreciate that they may be advantageously supplied to the physician or other health care professional, in a steπle, prepackaged or kit form. More particularly, the formulations may be supplied as stable powders or preformed dispersions ready for administration to the patient. Conversely, they may be provided as separate, ready to mix components. When provided in a ready to use form, the powders or dispersions may be packaged in single use containers or reservoirs, as well as in multi-use containers or reservoirs. In either case, the container or reservoir may be associated with the selected inhalation or administration device and used as described herein. When provided as individual components (e.g., as powdered microspheres and as neat suspension medium) the stabilized preparations may then be formed at any time pπor to use by simply combining the contents of the containers as directed. Additionally, such kits may contain a number of ready to mix, or prepackaged dosing units so that the user can then administer them as needed. Although preferred embodiments of the present invention comprise powders and stabilized dispersions for use in pharmaceutical applications, it will be appreciated that the perforated microstructures and disclosed dispersions may be used for a number of non pharmaceutical applications. That is, the present invention provides perforated microstructures which have a broad range of applications where a powder is suspended and/or aerosolized. In particular, the present invention is especially effective where an active or bioactive ingredient must be dissolved, suspended or solubilized as fast as possible. By increasing the surface area of the porous microparticles or by incorporation with suitable excipients as described herein, will result in an improvement in dispersibility, and/or suspension stability. In this regard, rapid dispersement applications include, but are not limited to: detergents, dishwasher detergents, food sweeteners, condiments, spices, mineral flotation detergents, thickening agents, foliar fertilizers, phytohormones, insect pheromones, insect repellents, pet repellents, pesticides, fungicides, disinfectants, perfumes, deodorants, etc.
Applications that require finely divided particles in a non-aqueous suspension media (i.e., solid , liquid or gaseous) are also contemplated as being within the scope of the present invention. As explained herein, the use of perforated microstructures to provide a "homodispersion" minimizes particle-particle interactions. As such, the perforated microspheres and stabilized suspensions of the present invention are particularly compatible with applications that require: inorganic pigments, dyes, inks, paints, explosives, pyrotechnic, adsorbents, absorbents, catalyst, nucleating agents, polymers, resins, insulators, fillers, etc. The present invention offers benefits over prior art preparations for use in applications which require aerosolization or atomization. In such non pharmaceutical uses the preparations can be in the form of a liquid suspension (such as with a propellant) or as a dry powder. Preferred embodiments comprising perforated microstructures as described herein include, but are not limited to, ink jet printing formulations, powder coating, spray paint, spray pesticides etc.
The foregoing description will be more fully understood with reference to the following Examples. Such Examples, are, however, merely representative of preferred methods of practicing the present invention and should not be read as limiting the scope of the invention.
I
Preparation of Hollow Porous Particles of Gentamicin Sulfate by Sprav-Drvinq
40 to 60ml of the following solutions were prepared for spray drying: 50% w/w hydrogenated phosphatidylcholine, E-100-3
(Lipoid KG, Ludwigshafen, Germany) 50% w/w gentamicin sulfate (Amresco, Solon, OH) Perfluorooctylbromide, Perflubron (NMK, Japan) Deionized water
Perforated microstructures comprising gentamicin sulfate were prepared by a spray drying technique using a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N2 flow: 2,800 L/hr. Variations in powder porosity were examined as a function of the blowing agent concentration.
Fluorocarbon-in-water emulsions of perfluorooctyl bromide containing a 1 :1 w/w ratio of phosphatidylcholine (PC), and gentamicin sulfate were prepared varying only the PFC/PC ratio. 1.3 grams of hydrogenated egg phosphatidylcholine was dispersed in 25 mL deionized water using an Ultra-Turrax mixer
(model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70°C). A range from 0 to 40 grams of perflubron was added dropwise during mixing (T - 60-70° C). After addition was complete, the fluorocarbon-in-water emulsion was mixed for an additional period of not less than 4 minutes. The resulting coarse emulsions were then homogenized under high pressure with an Avestin (Ottawa, Canada) homogenizer at 15,000 psi for 5 passes. Gentamicin sulfate was dissolved in approximately 4 to 5 mL deionized water and subsequently mixed with the perflubron emulsion immediately prior to the spray dry process. The gentamicin powders were then obtained by spray drying using the conditions described above. A free flowing pale yellow powder was obtained for all perflubron containing formulations. The yield for each of the various formulations ranged from 35% to 60%.
II
Morphology of Gentamicin Sulfate Spray-Dried Powders A strong dependence of the powder morphology, degree of porosity, and production yield was observed as a function of the PFC/PC ratio by scanning electron microscopy (SEM). A series of six SEM micrographs illustrating these observations, labeled 1A1 to 1 F1, are shown in the left hand column of Fig. 1. As seen in these micrographs, the porosity and surface roughness was found to be highly dependent on the concentration of the blowing agent, where the surface roughness, number and size of the pores increased with increasing PFC/PC ratios. For example, the fomiulation devoid of perfluorooctyl bromide produced microstructures that appeared to be highly agglomerated and readily adhered to the surface of the glass vial. Similarly, smooth, spherically shaped microparticles were obtained when relatively little (PFC/PC ratio - 1.1 or 2.2) blowing agent was used. As the PFC/PC ratio was increased the porosity and surface roughness increased dramatically.
As shown in the right hand column of Fig. 1, the hollow nature of the microstructures was also enhanced by the incorporation of additional blowing agent. More particularly, the series of six micrographs labeled 1A2 to 1 F2 show cross sections of fractured microstructures as revealed by transmission electron microscopy (TEM). Each of these images was produced using the same microstructure preparation as was used to produce the corresponding SEM micrograph in the left hand column. Both the hollow nature and wall thickness of the resulting perforated microstructures appeared to be largely dependent on the concentration of the selected blowing agent. That is, the hollow nature of the preparation appeared to increase and the thickness of the particle walls appeared to decrease as the PFC/PC ratio increased. As may be seen in Figs. 1A2 to 1C2 substantially solid structures were obtained from formulations containing little or no fluorocarbon blowing agent. Conversely, the perforated microstructures produced using a relatively high PFC /PC ratio of approximately 45 (shown in Fig. 1 F2 proved to be extremely hollow with a relatively thin wall ranging from about 43.5 to 261 nm. Both types of particles are compatible for use in the present invention.
Preparation of Spray Dried Gentamicin
Sulfate Particles using Various Blowing Agents
40 milliliters of the following solutions were prepared for spray drying:
50% w/w Hydrogenated Phosphatidylcholine, E 100-3 (Lipoid KG, Ludwigshafen, Germany)
50% w/w Gentamicin Sulfate (Amresco, Solon Ohio) Deionized water.
Blowing Agents: Perfluorodecalin, FDC (Air products, Allenton PA)
Perfluorooctylbromide, Perflubron (Atochem, Pans, France)
Perfluorhexane, PFH (3M, St. Paul, MN)
1,1,2 trichlorotrifluoroethane, Freon 113 (Baxter, McGaw Park, IL)
Hollow porous microspheres with a model hydrophilic drug, e.g., gentamicin sulfate, were prepared by spray drying. The blowing agent in these formulations consisted of an emulsified fluorochemical (FC) oil. Emulsions were prepared with the following FCs: PFH, Freon 113, Perflubron and FDC. 1.3 grams of hydrogenated egg phosphatidylcholine was dispersed in 25 mL deionized water using a Ultra-Turrax mixer (model T 25) at 8000 rpm for 2 to 5 minutes (T = 60-70). 25 grams of FC was added dropwise during mixing (T = 60-70°C). After the addition was complete, the FC-in- water emulsion was mixed for a total of not less than 4 minutes. The resulting emulsions were then further processed using an Avestin (Ottawa, Canada) high pressure homogenizer at 15,000 psi and 5 passes. Gentamicin sulfate was dissolved in approximately 4 to 5 mL deionized water and subsequently mixed with the FC emulsion. The gentamicin powders were obtained by spray drying (Bϋchi, 191 Mini Spray Dryer). Each emulsion was fed at a rate of 2.5 mL/min. The inlet and outlet temperatures of the spray dryer were 85°C and 55°C respectively. The nebulization air and aspiration flows were 2800 L/hr and 100% respectively.
A free flowing pale yellow dry powder was obtained for all formulations. The yield for the various formulations ranged from 35 to 60%. The various gentamicin sulfate powders had a mean volume weighted particle diameters that ranged from 1.52 to 4.91 μm.
IV Effect of Blowing Agent on the Morphology of
Gentamicin Sulfate Sprav-Dried Powders A strong dependence of the powder morphology, porosity, and production yield (amount of powder captured in the cyclone) was observed as a function of the blowing agent boiling point. In this respect the powders produced in Example III were observed using scanning electron microscopy. Spray drying a fluorochemical (FC) emulsion with a boiling point below the 55°C outlet temperature (e.g., perfluorohexane [PFH] or Freon 113), yielded amorphously shaped (shriveled or deflated) powders that contained little or no pores. Whereas, emulsions formulated with higher boiling FCs (e.g., perflubron, perfluorodecalin, FDC) produced spherical porous particles. Powders produced with higher boiling blowing agents also had production yields approximately two times greater than powders produced using relatively low boiling point blowing agents. The selected blowing agents and their boiling points are shown in Table II directly below.
Table II
Figure imgf000052_0001
Example IV illustrates that the physical characteristics of the blowing agent (i.e., boiling point) greatly influences the ability to provide perforated microparticles. A particular advantage of the present invention is the ability to alter the microstructure morphology and porosity by modifying the conditions and nature of the blowing agent.
V Preparation of Spray Dried Albuterol Sulfate Particles using Various Blowing Agents
Approximately 185 ml of the following solutions were prepared for spray drying:
49% w/w Hydrogenated Phosphatidylcholine, E 100-3
(Lipoid KG, Ludwigshafen, Germany) 50% w/w Albuterol Sulfate
(Accurate Chemical, Westbury, NY) 1 % w/w Poloxamer 188, NF grade (Mount Olive, NJ) Deionized water.
Blowing Agents:
Perfluorodecalin, FDC (Air products, Allenton PA) Perfluorooctylbromide, Perflubron (Atochem, Paris) Perfluorobutylethane F4H2 (F-Tech, Japan) Perfluorotributylamine FTBA (3M, St. Paul, MN)
Albuterol sulfate powder was prepared by spray-drying technique by using a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following conditions: Aspiration: 100% Inlet temperature: 85°C Outlet temperature: 61 °C Feed pump: 2.5 mL/min. N2 flow: 47 L/min.
The feed solution was prepared by mixing solutions A and B prior to spray drying. Solution A: Twenty grams of water was used to dissolve 1.0 grams of Albuterol sulfate and 0.021 grams of poloxamer 188.
Solution B represented an emulsion of a fluorocarbon in water, stabilized by a phosphohpid, which was prepared in the following way. Hydrogenated phosphatidylcholine (1.0 grams) was homogenized in 150 grams of hot deionized water (T = 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm, for 2 to 5 minutes (T - 60-70°C). Twenty-five grams of Perflubron (Atochem, Paris, France) was added dropwise during mixing. After the addition was complete, the Huorochemical-in-water emulsion was mixed for at least 4 minutes. The resulting emuision was then processed using an Avestin (Ottawa, Canada) high-pressure homogenizer at 18,000 psi and 5 passes. Solutions A and B were combined and fed into the spray dryer under the conditions described above. A free flowing, white powder was collected at the cyclone separator as is standard for this spray dryer. The albuterol sulfate powders had mean volume weighted particle diameters ranging from 1.28 to 2.77 μm, as determined by an Aerosizer (Amherst Process Instruments, Amherst, MA). By SEM, the albuterol sulfate/phospholipid spray dried powders were spherical and highly porous. Example V further demonstrates the wide variety of blowing agents that may be used to provide perforated microparticles. A particular advantage of the present invention is the ability to alter the microstructure morphology and porosity by manipulating the formulation and spray drying conditions. Furthermore, Example V demonstrates the particle diversity achieved by the present invention and the ability to effectively incoφorate a wide variety of pharmaceutical agents therein.
VI Preparation of Hollow Porous PVA Particles by Spray Drying a Water-in-oil Emulsion
100 ml of the following solutions were prepared for spray drying: 80% w/w Bis-(2-ethylhexyl) Sulf osuccinic Sodium Salt,
(Aerosol OT, Kodak, Rochester, NY) 20% w/w Polyvinyl Alcohol, average molecular weight =30,000-70,000
(Sigma Chemicals, St. Louis, MO) Carbon Tetrachloride (Aldrich Chemicals, Milwaukee, Wl) Deionized water.
Aerosol OT/polyvinyi alcohol particles were prepared by spray-drying technique using a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following conditions: Aspiration: 85% Inlet temperature: 60°C Outlet temperature: 43°C Feed pump: 7.5 mL/min. N2 flow: 36 L/min.
Solution A: Twenty grams of water was used to dissolve 500 milligrams of polyvinyl alcohol (PVA).
Solution B represented an emulsion of carbon tetrachloride in water, stabilized by aerosol OT, which was prepared in the following way. Two grams of aerosol OT, was dispersed in 80 grams of carbon tetrachloride using a Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T = 15° to 20°C). Twenty grams of 2.5% w/v PVA was added dropwise during mixing. After the addition was complete, the water- in-oil emulsion was mixed for a total of not less than 4 minutes (T = 15° to 20 °C). The resulting emulsion was then processed using an Avestin (Ottawa, Canada) high-pressure homogenizer at 12,000 psi and 2 passes. The emulsion was then fed into the spray dryer under the conditions described above. A free flowing, white powder was collected at the cyclone separator as is standard for this spray dryer. The Aerosol OT/PVA powder had a mean volume weighted particle diameter of 5.28 ± 3.27 μm as determined by an Aerosizer (Amherst Process
Instruments, Amherst, MA).
Example VI further demonstrates the variety of emulsion systems (here, reverse water-in-oil), formulations and conditions that may be used to provide perforated microparticles. A particular advantage of the present invention is the ability to alter formulations and/or conditions to produce compositions having a microstructure with selected porosity. This principle is further illustrated in the following example.
VII Preparation of Hollow Porous Polvcaorolactone Particles by Spray Drying a Water-in-Oil Emulsion 100 is of the following solutions were prepared for spray drying:
80% w/w Sorbitan Monostearate, Span 60 (Aldrich Chemicals, Milwaukee, Wl) 20% w/w Polycaprolactone, average molecular weight - 65,000 (Aldrich Chemicals, Milwaukee, Wl) Carbon Tetrachloride (Aldrich Chemicals, Milwaukee, Wl)
Deionized water.
Span 60/poiycaprolactone particles were prepared by spray-drying technique by using a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following conditions: Aspiration: 85%
Inlet temperature: 50°C
Outlet temperature: 38°C
Feed pump: 7.5 mL/min.
N2 flow: 36 L/min. A water-in-carbon tetrachloride emulsion was prepared in the following manner. Two grams of Span 60, was dispersed in 80 grams of carbon tetrachloride using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 15 to 20° C). Twenty grams of deionized water was added dropwise during mixing. After the addition was complete, the water-in-oil emulsion was mixed for a total of not less than 4 minutes (T - 15 to 20°C). The resulting emulsion was then further processed using an Avestin (Ottawa, Canada) high- pressure homogenizer at 12,000 psi and 2 passes. Five hundred milligrams of polycaprolactone was added directly to the emulsion and, mixed until thoroughly dissolved. The emulsion was then fed into the spray dryer under the conditions described above. A free flowing, white powder was collected at the cyclone separator as is standard for this dryer. The resulting Span 60/polycaprolactone powder had a mean volume weighted particle diameter of 3.15 ± 2.17 μm. Again, the present Example demonstrates the versatility the instant invention with regard to the feed stock used to provide the desired perforated microstructure.
Preparation of hollow porous powder by spray drying a gas-in-water emulsion The following solutions were prepared with water for injection: Solution 1 :
3.9% w/v m-HES hydroxyethylstarch (Ajinomoto, Tokyo, Japan) 3.25% w/v Sodium chloride (Mallinckrodt, St. Louis, MO)
2.83% w/v Sodium phosphate, dibasic (Mallinckrodt, St. Louis, MO)
0.42% w/v Sodium phosphate, monobasic (Mallinckrodt, St. Louis, MO)
Solution 2:
0.45% w/v Poloxamer 188 (BASF, Mount Olive, NJ)
1.35% w/v Hydrogenated egg phosphatidylcholine, EPC-3
(Lipoid KG, Ludwigshafen, Germany)
The ingredients of solution 1 were dissolved in warm water using a stir plate. The surfactants in solution 2 were dispersed in water using a high shear mixer. The solutions were combined following emulsification and saturated with nitrogen prior to spray drying.
The resulting dry, free flowing, hollow spherical product had a mean particle diameter of 2.6 ± 1.5 μm. The particles were spherical and porous as determined by SEM. This example illustrates the point that a wide of blowing agents (here nitrogen) may be used to provide microstructures exhibiting the desired morphology. Indeed, one of the primary advantages of the present invention is the ability to alter formation conditions so as to preserve biological activity (i.e. with proteins), or to produce microstructures having selected porosity.
IX
Suspension Stability of Gentamicin Sulfate Spray-Dried Powders The suspension stability was defined as, the resistance of powders to cream in a nonaqueous medium using a dynamic photosedimentation method. Each sample was suspended in Perflubron at a concentration of 0.8 mg/mL. The creaming rates were measured using a Horiba CAPA-700 photosedimentation particle size analyzer (Irvine, CA) under the following conditions:
D (max): 3.00 μm
D (min.): 0.30 μm
D (Div): 0.1 O μm
Rotor Speed: 3000 rpm
X: 10 mm
The suspended particles were subjected to a centrifugal force and the absorbance of the suspension was measured as a function of time. A rapid decrease in the absorbance identifies a suspension with poor stability. Absorbance data was plotted versus time and the area under the curve was integrated between 0.1 and 1 min., which was taken as a relative measurement of stability. Figure 2 graphically depicts suspension stability as a function of PFC/PC ratio or porosity. In this case, the powder porosity was found to increase with increasing PFC/PC. Maximum suspension stability was observed with formulations having PFC/PC ratios between 3 to 15. For the most part, these formulations appeared stable for periods greater than 30 minutes using visual inspection techniques. At points beyond this ratio, the suspensions flocculated rapidly indicating decreased stability. Similar results were observed using the cream layer ratio method, where it was observed that suspensions with PFC/PC ratios between 3 to 15 had a reduced cream layer thickness, indicating favorable suspension stability.
X
Preparation of Hollow Porous Particles of Albuterol Sulfate by Sprav-Drvinq Hollow porous albuterol sulfate particles were prepared by a spray-drying technique with a B 191
Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following spray conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N2 flow: 2,800 L/hr. The feed solution was prepared by mixing two solutions A and B immediately prior to spray drying.
Solution A: 20g of water was used to dissolve 1g of albuterol sulfate (Accurate Chemical, Westbury, NY) and 0.021 g of poloxamer 188 NF grade (BASF, Mount Olive, NJ).
Solution B: A fluorocarbon-in-water emulsion stabilized by phosphohpid was prepared in the following manner. The phosphohpid, 1 g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 150g of hot deionized water (T - 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70° C). 25g of perfluorooctyl bromide (Atochem, Paris, France) was added dropwise during mixing. After the fluorocarbon was added, the emulsion was mixed for a period of not less than 4 minutes. The resulting coarse emulsion was then passed through a high pressure homogenizer (Avesti'n, Ottawa, Canada) at 18,000 psi for 5 passes. Solutions A and B were combined and fed into the spray-dryer under the conditions described above. A free flowing, white powder was collected at the cyclone separator. The hollow porous albuterol sulfate particles had a volume-weighted mean aerodynamic diameter of 1.18 ± 1.42 μm as determined by a time-of- flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). Scanning electron microscopy (SEM) analysis showed the powders to be spherical and highly porous. The tap density of the powder was determined to be less than 0.1 g/cm3.
This foregoing example serves to illustrate the inherent diversity of the present invention as a drug delivery platform capable of effectively incoφorating any one of a number of pharmaceutical agents. The principle is further illustrated in the next example.
XI Preparation of Hollow Porous Particles of BDP by Sprav-Drving Perforated microstructures comprising beclomethasone dipropionate (BDP) particles were prepared by a spray-drying technique with a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following spray conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N2 flow: 2,800 L/hr. The feed stock was prepared by mixing 0.11g of lactose with a fluorocarbon-in-water emulsion immediately prior to spray drying. The emulsion was prepared by the technique described below.
74 mg of BDP (Sigma, Chemical Co., St. Louis, MO), 0.5g of EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), 15mg sodium oleate (Sigma), and 7mg of poloxamer 188 (BASF, Mount Olive, NJ) were dissolved in 2 ml of hot methanol. The methanol was then evaporated to obtain a thin film of the phospholipid/steroid mixture. The phospholipid/steroid mixture was then dispersed in 64g of hot deionized water (T - 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70°C). 8 g of perflubron (Atochem, Paris, France) was added dropwise during mixing. After the addition was complete, the emulsion was mixed for an additional period of not less than 4 minutes. The resulting coarse emulsion was then passed through a high pressure homogenizer (Avestin, Ottawa, Canada) at 18,000 psi for 5 passes. This emulsion was then used to form the feed stock which was spray dried as described above. A free flowing, white powder was collected at the cyclone separator. The hollow porous BDP particles had a tap density of less than 0.1 g/cm3.
XII Preparation of Hollow Porous Particles of Cromolyn Sodium by Sprav-Drving
Perforated microstructures comprising cromolyn sodium were prepared by a spray-drying technique with a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following spray conditions: aspiration: 100%, inlet temperature: 85°C; outlet temperature: 61 °C; feed pump: 10%; N2 flow: 2,800 L/hr. The feed solution was prepared by mixing two solutions A and B immediately prior to spray drying. Solution A: 20g of water was used to dissolve 1g of cromolyn sodium (Sigma Chemical Co, St. Louis, MO) and 0.021 g of poloxamer 188 NF grade (BASF, Mount Olive, NJ).
Solution B: A fluorocarbon-in-water emulsion stabilized by phospholipid was prepared in the following manner. The phospholipid, 1g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 150g of hot deionized water (T - 50 to 60°C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to
5 minutes (T - 60-70°C). 27g of perfluorodecalin (Air Products, Allentown, PA) was added dropwise during mixing. After the fluorocarbon was added, the emulsion was mixed for at least 4 minutes. The resulting coarse emulsion was then passed through a high pressure homogenizer (Avestin, Ottawa, Canada) at 18,000 psi for 5 passes. Solutions A and B were combined and fed into the spray dryer under the conditions described above.
A free flowing, pale yellow powder was collected at the cyclone separator. The hollow porous cromolyn sodium particles had a volume-weighted mean aerodynamic diameter of 1.23 ± 1.31 μm as determined by a time-of-flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). As shown in Fig. 3, scanning electron microscopy (SEM) analysis showed the powders to be both hollow and porous. The tap density of the powder was determined to be less than 0.1 g/cm3.
XIII Preparation of Hollow Porous Particles of DNase I by Spray-Drying Hollow porous DNase I particles were prepared by a spray drying technique with a B-191 Mini Spray-Drier (Bϋchi, Flawil, Switzerland) under the following conditions: aspiration: 100%, inlet temperature:
80°C; outlet temperature: 61°C; feed pump: 10%; N2 flow: 2,800 L/hr. The feed was prepared by mixing two solutions A and B immediately prior to spray drying.
Solution A: 20g of water was used to dissolve 0.5gr of human pancreas DNase I (Calbiochem, San Diego CA) and 0.012g of poloxamer 188 NF grade (BASF, Mount Olive, NJ). Solution B: A fluorocarbon-in-water emulsion stabilized by phospholipid was prepared in the following way. The phospholipid, 0.52g EPC-100-3 (Lipoid KG, Ludwigshafen, Germany), was homogenized in 87g of hot deionized water (T - 50 to 60° C) using an Ultra-Turrax mixer (model T-25) at 8000 rpm for 2 to 5 minutes (T - 60-70°C). 13g of perflubron (Atochem, Paris, France) was added dropwise during mixing. After the fluorocarbon was added, the emulsion was mixed for at least 4 minutes. The resulting coarse emulsion was then passed through a high pressure homogenizer (Avestin, Ottawa, Canada) at 18,000 psi for 5 passes.
Solutions A and B were combined and fed into the spray dryer under the conditions described above. A free flowing, pale yellow powder was collected at the cyclone separator. The hollow porous DNase I particles had a volume-weighted mean aerodynamic diameter of 1.29 ± 1.40 μm as determined by a time-of- flight analytical method (Aerosizer, Amherst Process Instruments, Amherst, MA). Scanning electron microscopy (SEM) analysis showed the powders to be both hollow and porous. The tap density of the powder was determined to be less than 0.1 g/cm3.
The foregoing example further illustrates the extraordinary compatibility of the present invention with a vaπety of bioactive agents. That is, in addition to relatively small, hardy compounds such as steroids, the preparations of the present invention may be formulated to effectively incoφorate larger, fragile molecules such as proteins and genetic matenal.
XIV Preparation of Perforated Ink Polymeric Particles by Spray Drying In the following hypothetical example, finely divided porous spherical resin particles which may contain coloring material such as a pigment, a dye, etc. are formed using the following formulation in accordance with the teachings herein-
Formulation-
Butadiene 7.5 g co monomer
Styrene 2.5 g co monomer
Water 18.0 g carrier
Fatty Acid Soap 0.5 g emulsifier n-Dodecyi Mercaptan 0.050 g modifier potassium persulfatε 0 030 g initiator carbon Black 0.50 g pigment
The reaction is allowed to proceed at 50°C for 8 hours The reaction is then terminated by spray drying the emulsion using a high pressure liquid chromatography (HPLC) pump. The emulsion is pumped through a 200 x 0.030 inch i d stainless steel tubing into a Niro atomizer portable spray dryer (Niro Atomize, Copenhagen, Denmark) equipped with a two fluid nozzle (0.01 " i.d.) employing the following settings
Hot air flow rate- 39.5 CFM
Inlet air temp.. 180°C
Outlet air temperature- 80°C
Atomizer nitrogen flow. 45 L/mιn, 1,800 psi
Liquid feed rate- 33 mL/min
It will be appreciated that unreacted monomers serve as blowing agents, creating the perforated microstructure. The descπbed formulation and conditions yield free flowing porous polymeric particles ranging from 0 1 100μm that may be used in ink formulations In accordance with the teachings herein the microparticles have the advantage of incorporating the pigment directly into the polymeric matrix. The process allows for the production of different particle sizes by modifying the components and the spray drying conditions with the pigment particle diameter largely dictated by the diameter of the copolymer resin particles XV Andersen Impactor Test for Assessing MDI and DPI Performance The MDIs and DPIs were tested using commonly accepted pharmaceutical procedures. The method utilized was compliant with the United State Pharmacopeia (USP) procedure (Pharmacopeia! Previews (1996) 22:3065-3098) incorporated herein by reference. After 5 shots to waste, 20 shots from the test MDI were made into an Andersen Impactor. The number of shots employed for assessing the DPI formulations was dictated by the drug concentration and ranged from 10 to 20 actuations.
Extraction procedure The extraction from all the plates, induction port, and actuator were performed in closed vials with 10 mL of a suitable solvent. The filter was installed but not assayed, because the polyacrylic binder interfered with the analysis. The mass balance and particle size distribution trends indicated that the deposition on the filter was negligibly small. Methanol was used for extraction of beclomethasone dipropionate Deionized water was used for albuterol sulfate, and cromolyn sodium For albuterol MDIs, 0.5 ml of 1 N sodium hydroxide was added to the plate extract, which was used to convert the albuterol into the phenolate form Quantitation procedure. All drugs were quantitated by absorption spectroscopy (Beckman DU640 spectrophotometer) relative to an external standard curve with the extraction solvent as the blank. Beclomethasone dipropionate was quantitated by measuring the absorption of the plate extracts at 238 nm Albuterol MDIs were quantified by measuring the absorption of the extracts at 243 nm, while cromolyn sodium was quantitated using the absorption peak at 326 nm. Calculation procedure. For each MDI, the mass of the drug in the stem (component 3), actuator (
2), induction port ( 1 ) and plates (0 7) were quantified as described above. Stages 3 and 2 were not quantified for the DPI since this device was only a prototype The main interest was to assess the aerodynamic properties of the powder which leaves this device. The Fine Particle Dose and Fine Particle Fraction was calculated according to the USP method referenced above Throat deposition was defined as the mass of drug found in the induction port and on plates 0 and 1. The mean mass aerodynamic diameters
( MAD) and geometric standard diameters (GSD) were evaluated by fitting the experimental cumulative function with log-normal distribution by using two-parameter fitting routine. The results of these experiments are presented in subsequent examples
XVI
Preparation of Metered Dose Inhalers Containing Hollow Porous Particles
A pre weighed amount of the hollow porous particles prepared in Examples I, X, XI, and XII were placed into 10 ml aluminum cans, and dried in a vacuum oven under the flow of nitrogen for 3 4 hours at
40 C The amount of powder filled into the can was determined by the amount of drug required for therapeutic effect. After this, the can was crimp sealed using a DF31/50act 50 I valve (Valois of America, Greenwich, CT) and filled with HFA-134a (DuPont, Wilmington, DE) propellant by overpressure through the stem. The amount of the propellant in the can was determined by weighing the can before and after the fill.
XVII Effect of Powder Porosity on MDI Performance
In order to examine the effect powder porosity has upon the suspension stability and aerodynamic diameter, MDIs were prepared as in Example XVI with various preparations of perforated microstructures comprising gentamicin formulations as described in Example I. MDIs containing 0.48 wt % spray dried powders in HFA 134a were studied. As set forth in Example I, the spray dried powders exhibit varying porosity. The formulations were filled in clear glass vials to allow for visual examination.
A strong dependence of the suspension stability and mean volume weighted aerodynamic diameter was observed as a function of PFC/PC ratio and/or porosity. The volume weighted mean aerodynamic diameter (VMAD) decreased and suspension stability increased with increasing porosity. The powders that appeared solid and smooth by SEM and TEM techniques had the worst suspension stability and largest mean aerodynamic diameter. MDIs which were formulated with highly porous and hollow perforated microstructures had the greatest resistance to creaming and the smallest aerodynamic diameters. The measured VMAD values for the dry powders produced in Example I are shown in Table III immediately below.
Table III
Figure imgf000061_0001
XVIII
Comparison of Creaming Rates in Cromolyn Sodium Formulations A comparison of the creaming rates of the commercial Intal formulation (Rhone-Poulenc Rorer) and spray-dried hollow porous particles formulated in HFA-134a according to Example XII (i.e. see Fig. 3) is shown in Figures. 4A to 4D. In each of the pictures, taken at 0 seconds, 30 seconds, 60 seconds and two hours after shaking, the commercial formulation is on the left and the perforated microstructure dispersion formed accordance with the present invention is on the right. Whereas the commercial Intal formulation shows creaming within 30 seconds of mixing, almost no creaming is noted in the spray-dried particles after 2 hours.
Moreover, there was little creaming in perforated microstructure formulation after 4 hours (not shown). This example clearly illustrates the balance in density which can be achieved when the hollow porous particles are filled with the suspension medium (i.e. in the formation of a homodispersion).
XIX Andersen Cascade Impactor Results for Cromolyn Sodium MDI Formulations
The results of cascade impactor tests for a commercially available product (Inta , Rhone Poulenc
Rorer) and an analogous spray-dried hollow porous powder in HFA-134a prepared according to Examples XII and XVI are shown below in Table IV. The tests were performed using the protocol set forth in Example XV.
Table IV
Figure imgf000062_0001
The MDI formulated with perforated microstructures was found to have superior aerosol performance compared with Intal*. At a comparable fine particle dose, the spray dried cromolyn formulations possessed a substantially higher fine particle fraction (" 67%), and significantly decreased throat deposition (6-fold), along with a smaller MMAD value. It is important to note that the effective delivery provided for by the present invention allowed for a fine particle dose that was approximately the same as the prior art commercial formulation even though the amount of perforated microstructures administered (300 μg) was roughly a third of the Intaf dose administered (800 μg).
XX
Comparison of Andersen Cascade Impactor Results for Albuterol Sulfate Microspheres Delivered From DPIs and MDIs
The in vitro aerodynamic properties of hollow porous albuterol sulfate microspheres as prepared in Example X was characterized using an Andersen Mark II Cascade Impactor (Andersen Sampler, Atlanta, GA) and an Amherst Aerosizer (Amherst Instruments, Amherst, MA).
DPI testing. Approximately, 300mcg of spray dried microspheres was loaded into a proprietary inhalation device. Activation and subsequent plume generation of the dry powder was achieved by the actuation of 50 μl of pressurized HFA 134a through a long induction tube. The pressurized HFA 134a forced air through the induction tube toward the sample chamber, and subsequently aerosolized a plume of dry powder into the air. The dry powder plume was then taken in the cascade impactor by means of the air flow through drawn through the testing device. A single actuation was discharged into the aerosizer sample chamber for particle size analysis. Ten actuations were discharged from the device into the impactor. A 30 second interval was used between each actuation. The results were quantitated as described in Example XV
MDI testing A MDI preparation of albuterol sulfate microspheres was prepared as in Example XVI A single actuation was discharged into the aerosizer sample chamber for particle size analysis. Twenty actuations were discharged from the device into the impactor A 30 second interval was used between each actuation. Again, the results were quantitated as described in Example XV.
The results comparing the particle size analysis of the neat albuterol sulfate powder and the albuterol sulfate powder discharged from either a DPI or MDI are shown in Table V below. The albuterol sulfate powder delivered from the DPI was indistinguishable from the neat powder which indicates that little or no aggregation had occurred during actuation. On the other hand, some aggregation was observed using an MDI as evidenced by the larger aerodynamic diameter of particles delivered from the device
Table V
Figure imgf000063_0001
Similar results were observed when comparing the two dosage forms using an Andersen Cascade Impactor (Figure 5). The spray dried albuterol sulfate powder delivered from the DPI had enhanced deep lung deposition and minimized throat deposition when compared with the MDI The MDI formulation had a fine particle fraction (FPF) of 79% and a fine particle dose (FPD) of 77 μg/actuation, while the DPI had a FPF of 87% and a FPD of 100μg/ actuation.
Figure 5 and the Example above exemplifies the excellent flow and aerodynamic properties of the herein described spray dπed powders delivered from a DPI. Indeed, one of the primary advantages of the present invention is the ability to produce small aerodynamically light particles which aerosolize with ease and which have excellent inhalation properties. These powders have the unique properties which enable them to be effectively and efficiently delivered from either a MDI or DPI This principle is further illustrated in the next Example.
XXI
Comparison of Andersen Cascade Impactor Results for
Beclomethasone Dipropionate Microspheres Delivered From DPIs and MDIs The in vitro aerodynamic properties of hollow porous beclomethasone dipropionate (BDP) microspheres as prepared in Example XI was characterized using an Andersen Mark II Cascade Impactor (Andersen Sampler, Atlanta, GA) and an Amherst Aerosizer (Amherst Instruments, Amherst, MA).
DPI testing. Approximately, 300μg of spray dried microspheres was loaded into a proprietary inhalation device. Activation and subsequent plume generation of the dry powder was achieved by the actuation of 50 μl of pressurized HFA 134a through a long induction tube The pressurized HFA 134a forced air through the induction tube toward the sample chamber, and subsequently aerosolized a plume of dry powder into the air The dry powder plume was then taken in the cascade impactor by means of the air flow through drawn through the testing device. A single actuation was discharged into the aerosizer sample chamber for particle size analysis Twenty actuations were discharged from the device into the impactor A 30 second interval was used between each actuation.
MDI testing A MDI preparation of beclomethasone dipropionate (BDP) microspheres was prepared as in Example XVI. A single actuation was discharged into the aerosizer sample chamber for particle size analysis Twenty actuations were discharged from the device into the impactor A 30 second interval was used between each actuation
The results comparing the particle size analysis of the neat BDP powder and the BDP powder discharged from either a DPI or MDI are shown in Table VI immediately below.
Table VI
Figure imgf000064_0001
As with Example XX, the BDP powder delivered from the DPI was indistinguishable from the neat powder which indicates that little or no aggregation had occurred during actuation. On the other hand, some aggregation was observed using an MDI as evidenced by the larger aerodynamic diameter of particles delivered from the device.
The spray dried BDP powder delivered from the DPI had enhanced deep lung deposition and minimized throat deposition when compared with the MDI. The MDI formulation had a fine particle fraction (FPF) of 79% and a fine particle dose (FPD) of 77 μg/actuation, while the DPI had a FPF of 87% and a FPD of 100μg/ actuation. This foregoing example serves to illustrate the inherent diversity of the present invention as a drug delivery platform capable of effectively incorporating any one of a number of pharmaceutical agents and effectively delivered from various types of delivery devices (here MDI and DPI) currently used in the pharmaceutical arena. The excellent flow and aerodynamic properties of the dry powders shown in the proceeding examples is further exemplified in the next example
XXII
Comparison of Andersen Cascade Impactor Results for Albuterol Sulfate Microspheres and Ventohn Rotacaps from a Rotahaler * Device
The following procedure was followed to compare the inhalation properties of Ventohn Rotocaps (a commercially available formulation) vs. albuterol sulfate hollow porous microspheres formed in accordance with the present invention Both prepartions were discharged from a Rotohaler device into an 8 stage
Andersen Mark II cascade impactor operated at a flow of 60L/mιn. Preparation of the albuterol sulfate microspheres is described in Example X with albuterol sulfate deposition in the cascade impactor analyzed as descπbed in Example XV Approximately 300 μg of albuterol sulfate microspheres were manually loaded into empty Ventohn Rotocap gelatin capsules The procedure described in the package insert for loading and actuating drug capsules with a Rotohaler device was followed. Ten actuations were discharged from the device into the impactor A 30 second interval was used between each actuation
The results comparing the cascade impactor analysis of Ventohn Rotocaps* and hollow porous albuterol sulfate microspheres discharged from a Rotohaler* device are shown in Table VI immediately below
Table VII
Figure imgf000065_0001
The hollow porous albuterol sulfate powder delivered from the Rotohaler device had a significantly higher fine particle fraction (3 fold) and a smaller MMAD value as compared with Ventohn Rotocaps* In this regard, the commercially available Ventohn Rotocap' formulation had a fine particle fraction (FPF) of 20% and a fine particle dose (FPD) of 15μg/actuatιon, whereas the hollow porous albuterol sulfate microspheres had a FPF of 63% and a FPD of 60μg/ actuation.
The example above exemplifies the excellent flow and aerodynamic properties of the spray dried powders delivered from a Rotahaler device Moreover, this example demonstrates that fine powders can be effectively delivered without carrier particles
XXIII Nebulization of Porous Paniculate Structures Compnsing
Phospholipids and Cromolyn sodium in Perfluorooctylethaπe using a MicroMist Nebulizer Forty milligrams of the lipid based microspheres containing 50% cromolyn sodium by weight (as from Example XII) were dispersed in 10 ml perfluorooctylethane (PFOE) by shaking, forming a suspension. The suspension was nebulized until the fluorocarbon liquid was delivered or had evaporated using a MicroMist (DeVilbiss) disposable nebulizer using a PulmoAide* air compressor (DeVilbiss). As described above in Example XV, an Andersen Cascade Impactor was used to measure the resulting particle size distribution. More specifically, cromolyn sodium content was measured by UV adsorption at 326nm. The fine particle fraction is the ratio of particles deposited in stages 2 through 7 to those deposited in all stages of the impactor. The fine particle mass is the weight of material deposited in stages 2 through 7. The deep lung fraction is the ratio of particles deposited in stages 5 through 7 of the impactor (which correlate to the alveoli) to those deposited in all stages. The deep lung mass is the weight of material deposited in stages 5 through 7. Table VIII immediately below provides a summary of the results.
Table VIII
Figure imgf000066_0001
XXIV Nebulization of Porous Paniculate Structures Comprising Phospholipids and Cromolyn Sodium in Perfluorooctylethane using a Raindrop* Nebulizer A quantity of lipid based microspheres containing 50% cromolyn sodium, as from Example XII, weighing 40 mg was dispersed in 10 ml perfluorooctylethane (PFOE) by shaking, thereby forming a suspension. The suspension was nebulized until the fluorocarbon liquid was delivered or had evaporated using a Raindrop" disposable nebulizer (Nellcor Puritan Bennet) connected to a PulmoAide* air compressor (DeVilbiss). An Andersen Cascade Impactor was used to measure the resulting particle size distribution in the manner described in Examples XV and XXIII. Table IX immediately below provides a summary of the results.
Table IX
Figure imgf000066_0002
XXV Nebulization of Agueous Cromolyn Sodium Solution The contents of plastic vial containing a unit dose inhalation solution of 20 mg of cromolyn sodium in 2 ml purified water (Dey Laboratories) was nebulized using a MicroMist disposable nebulizer (DeVilbiss) using a PulmoAide* air compressor (DeVilbiss). The cromolyn sodium solution was nebulized for 30 minutes. An Andersen Cascade Impactor was used to measure the resulting size distribution of the nebulized particles, by the method described above in Example XV. Table X immediately below provides a summary of the results.
Table X
Figure imgf000067_0001
With regard to the instant results, it will be appreciated that, the formulations nebulized from fluorocarbon suspension mediums in Examples XXIll and XXIV provided a greater percentage of deep lung deposition than the aqueous solution. Such high deposition rates deep in the lung is particularly desirable when delivering agents to the systemic circulation of a patient.
Those skilled in the art will further appreciate that the present invention may be embodied in other specific forms without departing from the spirit or central attributes thereof. In that the foregoing description of the present invention discloses only exemplary embodiments thereof, it is to be understood that, other variations are contemplated as being within the scope of the present invention. Accordingly, the present invention is not limited to the particular embodiments which have been described in detail herein. Rather, reference should be made to the appended claims as indicative of the scope and content of the invention.

Claims

WHAT IS CLAIMED:
1. Use of a bioactive agent in the manufacture of a medicament for pulmonary delivery whereby the medicament comprises a plurality of perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament comprising said bioactive agent wherein said aerosolized medicament is in a form for administration to at least a portion of the nasal or pulmonary air passages of a patient in need thereof.
2. The use of claim 1 wherein said inhalation device comprises a metered dose inhaler, a dry powder inhaler or a nebulizer.
3. The use of claim 1 wherein said perforated microstructures are in the form of a dry powder.
4. The use of claim 1 wherein said perforated microstructures are dispersed in a nonaqueous suspension medium.
5. The use of any of claims 1 to 4 wherein said perforated microstructures comprise a surfactant.
6. The use of claim 5 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.
7. The use of claims 5 or 6 wherein said surfactant is a phospholipid.
8. The use of claim 7 wherein said phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, dibehenoylphosphatidyl-choline, diarachidoylpfiosphatidylcholiπe and combinations thereof.
9. The use of any of claims 1 to 8 wherein the mean aerodynamic diameter of the perforated microstructures is between 0.5 and 5 ╬╝m.
10. The use of any of claims 1 to 9 wherein said perforated microstructures have a bulk density of less than about 0.5 g/cm3.
11. The use of any of claims 1 to 10 wherein said perforated microstructures have a mean geometric diameter of less than about 5 ╬╝m.
12. The use of any of claims 1 to 11 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, aπtiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tubercuiars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof.
13. A method for forming a perforated microstructure comprising the steps of: providing a liquid feed stock comprising an active agent; atomizing said liquid feed stock to produce dispersed liquid droplets; drying said liquid droplets under predetermined conditions to form perforated microstructures comprising said active agent; and collecting said perforated microstructures.
14. The method of claim 13 wherein said feed stock comprises a blowing agent.
15. The method of claim 14 wherein said blowing agent comprises a nonfluonnated oil.
16. The method of claim 14 wherein said blowing agent comprises a fluorinated compound.
17. The method of claim 16 wherein said fluorinated blowing agent has a boiling point greater than about 60┬░C.
18. The method of any of claims 13 to 17 wherein said feed stock comprises a colloidal system.
19. The method of any of claims 13 to 18 wherein said feed stock comprises a surfactant.
20. The method of claim 19 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.
21. The method of claim 19 or 20 wherein said surfactant is a phospholipid.
22. The method of claim 21 wherein said phospholipid is selected from the group consisting of dilauroyiphosphatidylcfioline, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholme and combinations thereof.
23. The method of any of claims 13 to 22 wherein said collected perforated microstructures comprise hollow porous microspheres.
24. The method of any of claims 13 to 23 wherein the mean aerodynamic diameter of said collected perforated microstructures is between 0.5 and 5 ╬╝m.
25. The method of any of claims 13 to 24 wherein said perforated microstructures have a mean geometric diameter of less than about 5 ╬╝m.
26. The method of any of claims 13 to 25 wherein said active agent comprises a bioactive agent.
27. The method claim 26 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof.
28. The method of any of claims 13 to 27 wherein said atomization step is accomplished using a spray dryer.
29. A perforated microstructure formed according to any one of claims 13 to 28.
30. A method for increasing the dispersibility of a powder comprising the steps of: providing a liquid feed stock comprising an active agent; and spray drying said liquid feed stock to produce a perforated microstructure powder having a bulk density of less than about 0.5 g/cm3 wherein said powder exhibits reduced van der Waals attractive forces when compared to a relatively non-porous powder of the same composition.
31. The method of claim 30 wherein said liquid feed stock comprises a blowing agent
32. The method of claim 31 wherein said blowing agent comprises a nonfluonnated oil.
33. The method of claim 31 wherein said blowing agent comprises a fluorinated compound.
34. The method of claim 33 wherein said fluorinated compound has a boiling point of greater than about 60┬░C.
35. The method of any of claims 30 to 34 wherein said feed stock comprises a surfactant.
36. The method of claim 35 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.
37. The method of claim 35 or 36 wherein said surfactant is a phospholipid.
38. The method of claim 37 wherein said phospholipid is selected from the group consisting of dilauroyiphosphatidylcfioline, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof.
39. The method of any of claims 30 to 38 wherein said perforated microstructures comprise hollow porous microspheres.
40. The method of any of claims 30 to 39 wherein said active agent comprises a bioactive agent.
41. The method daim 40 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof.
42. A perforated microstructure powder formed according to any one of claims 30 to 41.
43. A powder having increased dispersibility comprising a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder comprises an active agent.
44. The powder of claim 43 wherein said powder comprises hollow porous microspheres.
45. The powder of claims 43 or 44 wherein the mean aerodynamic diameter of said perforated microstructures is between 0.5 and 5╬╝m.
46. The powder of any of claims 43 to 45 wherein said perforated microstructures have a mean geometric diameter of less than about 5 ╬╝m.
47. The powder of any of claims 43 to 46 wherein said perforated microstructures comprise a surfactant.
48. The powder of claim 47 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.
49. The powder of claim 47 or 48 wherein said surfactant is a phospholipid.
50. The powder of claim 49 wherein said phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof.
51. The powder of claim any of claims 43 to 50 wherein said active agent is a bioactive agent.
52. The powder of claim 51 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti- tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof.
53. An inhalation system for the pulmonary administration of a bioactive agent to a patient comprising: an inhalation device comprising a reservoir; and a powder in said reservoir wherein said powder comprises a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder comprises a bioactive agent whereby said inhalation device provides for the aerosolized administration of said powder to at least a portion of the nasal or pulmonary air passages of a patient in need thereof.
54. The system of claim 53 wherein said inhalation device comprises a dry powder inhaler, a metered dose inhaler or a nebulizer.
55. The system of claim 53 wherein said perforated microstructures are dispersed in a nonaqueous suspension medium.
56. The system of claim 55 wherein said nonaqueous suspension medium comprises a fluorinated compound.
57. The system of any of claims 54 to 56 wherein said perforated microstructures comprise a surfactant.
58. The system of claim 57 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.
59. The system of claims 57 or 58 wherein said surfactant is a phospholipid.
60. The system of any of claims 54 to 59 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides and combinations thereof.
61. A method for the pulmonary delivery of one or more bioactive agents comprising the steps of: providing a powder comprising a plurality of perforated microstructures having a bulk density of less than about 0.5 g/cm3 wherein said perforated microstructure powder comprises a bioactive agent; aerosolizing said perforated microstructure powder to provide an aerosolized medicament; and administering a therapeutically effective amount of said aerosolized medicament to at least a portion of the nasal or pulmonary air passages of a patient in need thereof.
PCT/US1998/020602 1997-09-29 1998-09-29 Perforated microparticles and methods of use WO1999016419A1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
EEP200000194A EE04628B1 (en) 1997-09-29 1998-09-29 Powder with Perforated Microstructures and Method for Preparing a Microparticle Composition and Powder with Perforated Microstructures
ES98953220T ES2195408T5 (en) 1997-09-29 1998-09-29 DUST FORMATION PROCEDURE THAT INCLUDES PERFORATED MICROPARTS.
EP98953220A EP1019022B2 (en) 1997-09-29 1998-09-29 Method for forming a powder comprising perforated microparticles
BR9812693-8A BR9812693A (en) 1997-09-29 1998-09-29 Use of a bioactive agent, process to form a perforated microstructure, perforated microstructure, process to increase the dispersibility of a powder, perforated microstructure powder, powder having increased dispersibility, inhalation system for the pulmonary administration of a bioactive agent to a patient, and, process for the pulmonary release of one or more bioactive agents
NZ503464A NZ503464A (en) 1997-09-29 1998-09-29 Perforated microparticles containing a bioactive agent for pulmonary delivery
AT98953220T ATE238035T1 (en) 1997-09-29 1998-09-29 PERFORATED MICROPARTICLES AND USE THEREOF
DK98953220.5T DK1019022T4 (en) 1997-09-29 1998-09-29 Perforated microparticles and their method of use
DE69813853T DE69813853T3 (en) 1997-09-29 1998-09-29 PERFORATED MICROTEILS AND THEIR USE
PL98339732A PL195212B1 (en) 1997-09-29 1998-09-29 Perforated microparticles and method of using them
JP2000513557A JP5372306B2 (en) 1997-09-29 1998-09-29 Porous fine particles and method of use
AU10644/99A AU757337C (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
MEP-2008-41A ME00003B (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
MEP-41/08A MEP4108A (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
EA200000375A EA002562B1 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
SK449-2000A SK285068B6 (en) 1997-09-29 1998-09-29 Powder composition, microspheres, method for forming a particulate composition comprising perforated microstructures by spray drying and method for forming powder comprising perforated microstructures by spray drying
KR1020007003367A KR100589926B1 (en) 1997-09-29 1998-09-29 Perforated microparticles and method of use
IL13512698A IL135126A0 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use and preparation thereof
CA002304819A CA2304819C (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
US09/219,736 US6565885B1 (en) 1997-09-29 1998-12-22 Methods of spray drying pharmaceutical compositions
AU35469/99A AU760537B2 (en) 1998-06-29 1999-03-31 Particulate delivery systems and methods of use
KR1020007015026A KR100796220B1 (en) 1998-06-29 1999-03-31 Particulate delivery systems and methods of use
JP2000556800A JP2003535017A (en) 1998-06-29 1999-03-31 Particulate delivery systems and methods of use
CA002335940A CA2335940A1 (en) 1998-06-29 1999-03-31 Particulate delivery systems and methods of use
EP99917320A EP1091755A1 (en) 1998-06-29 1999-03-31 Particulate delivery systems and methods of use
IL135126A IL135126A (en) 1997-09-29 2000-03-16 Perforated microparticles and methods of use and preparation thereof
IS5415A IS2154B (en) 1997-09-29 2000-03-24 Perforated cleansers and methods for their use
HR20000175A HRP20000175B1 (en) 1997-09-29 2000-03-28 Perforated microparticles and methods of use
NO20001618A NO340149B1 (en) 1997-09-29 2000-03-28 Perforated microparticles and method of use thereof
HK01100524A HK1031680A1 (en) 1997-09-29 2001-01-19 Perforated microparticles and methods of use
US09/886,296 US8168223B1 (en) 1997-09-29 2001-06-21 Engineered particles and methods of use
US10/096,780 US7306787B2 (en) 1997-09-29 2002-03-12 Engineered particles and methods of use
US10/612,393 US20050074498A1 (en) 1997-09-29 2003-07-03 Engineered particles and methods of use
US10/616,448 US20040105820A1 (en) 1997-09-29 2003-07-08 Phospholipid-based powders for inhalation
US11/317,839 US20060165606A1 (en) 1997-09-29 2005-12-22 Pulmonary delivery particles comprising water insoluble or crystalline active agents
US11/317,523 US20060159629A1 (en) 1997-09-29 2005-12-22 Pulmonary delivery particles with phospholipid structural matrix
US12/774,540 US9554993B2 (en) 1997-09-29 2010-05-05 Pulmonary delivery particles comprising an active agent

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6033797P 1997-09-29 1997-09-29
US60/060,337 1997-09-29
US10693298A 1998-06-29 1998-06-29
US09/106,932 1998-06-29
US13384898A 1998-08-14 1998-08-14
US09/133,848 1998-08-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13384898A Continuation-In-Part 1997-09-29 1998-08-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/219,736 Continuation US6565885B1 (en) 1997-09-29 1998-12-22 Methods of spray drying pharmaceutical compositions
US10/096,780 Continuation US7306787B2 (en) 1997-09-29 2002-03-12 Engineered particles and methods of use

Publications (2)

Publication Number Publication Date
WO1999016419A1 WO1999016419A1 (en) 1999-04-08
WO1999016419A9 true WO1999016419A9 (en) 1999-08-19

Family

ID=27369827

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1998/020602 WO1999016419A1 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use
PCT/US1998/020615 WO1999016422A1 (en) 1997-09-29 1998-09-29 Stabilized preparations for use in metered dose inhalers
PCT/US1998/020613 WO1999016421A1 (en) 1997-09-29 1998-09-29 Stabilized bioactive preparations and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US1998/020615 WO1999016422A1 (en) 1997-09-29 1998-09-29 Stabilized preparations for use in metered dose inhalers
PCT/US1998/020613 WO1999016421A1 (en) 1997-09-29 1998-09-29 Stabilized bioactive preparations and methods of use

Country Status (28)

Country Link
EP (4) EP1019020A1 (en)
JP (9) JP4526702B2 (en)
KR (4) KR100572171B1 (en)
CN (1) CN1169520C (en)
AT (3) ATE248583T1 (en)
AU (4) AU757337C (en)
BG (1) BG64816B1 (en)
BR (1) BR9812693A (en)
CA (4) CA2304819C (en)
CZ (1) CZ300758B6 (en)
DE (2) DE69814428T2 (en)
DK (2) DK1019021T4 (en)
EA (2) EA002562B1 (en)
EE (1) EE04628B1 (en)
ES (3) ES2195408T5 (en)
HK (1) HK1031680A1 (en)
HR (1) HRP20000175B1 (en)
IL (2) IL135126A0 (en)
IS (1) IS2154B (en)
ME (1) MEP4108A (en)
NO (1) NO340149B1 (en)
NZ (1) NZ503464A (en)
PL (1) PL195212B1 (en)
PT (1) PT1019022E (en)
RS (1) RS50182B (en)
SK (1) SK285068B6 (en)
TR (1) TR200000819T2 (en)
WO (3) WO1999016419A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US11931374B2 (en) 2016-04-15 2024-03-19 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
EP1019020A1 (en) * 1997-09-29 2000-07-19 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
CA2335940A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
CN1240373C (en) * 1999-05-27 2006-02-08 阿库斯菲尔公司 Porous drug matrices and methods of manufacture thereof
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU763041B2 (en) * 1999-08-25 2003-07-10 Alkermes, Inc. Modulation of release from dry powder formulations
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
EP1242112A4 (en) 1999-12-21 2005-02-09 Rxkinetix Inc Particulate drug-containing products and method of manufacture
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
AU4905601A (en) 2000-02-08 2001-08-20 3M Innovative Properties Company Improved media for cold image transfer
DE60112902T2 (en) 2000-02-08 2006-06-14 3M Innovative Properties Co PROCESS AND KIT FOR PROVIDING A CONSISTENT IMAGE ON A SUBSTRATE
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (en) * 2000-05-10 2004-07-16 Alliance Pharma Phospholipid-based powders for drug delivery.
WO2001087277A2 (en) * 2000-05-15 2001-11-22 Vectura Limited Method of manufacturing particles
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
DE10064219B9 (en) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Novel pharmaceutical composition containing fentanyl and / or its derivatives
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
WO2002087542A1 (en) * 2001-04-26 2002-11-07 Inhale Therapeutic Systems, Inc. Novel methods and compositions for delivering macromolecules to or via the respiratory tract
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
CN1236831C (en) * 2001-05-21 2006-01-18 茵捷特数码浮质有限公司 Compositions for protein delivery via the pulmonary route
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
JP4357842B2 (en) 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ, インコーポレイテッド Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route
TW553752B (en) 2001-06-20 2003-09-21 Inhale Therapeutic Syst Powder aerosolization apparatus and method
EP1487417A4 (en) * 2001-09-17 2010-03-17 Glaxo Group Ltd Dry powder medicament formulations
JP4739672B2 (en) 2001-12-21 2011-08-03 ネクター セラピューティクス Capsule package with moisture barrier
JPWO2003077891A1 (en) * 2002-03-18 2005-07-14 アステラス製薬株式会社 Powder pharmaceutical composition for inhalation and method for producing the same
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
EP1569626A1 (en) * 2002-12-13 2005-09-07 Adagit Pharmaceutical porous particles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
WO2004060351A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
JP4607010B2 (en) 2003-02-28 2011-01-05 中外製薬株式会社 Protein-containing stabilized preparation
US7278982B2 (en) 2003-03-27 2007-10-09 Bioactis Limited Powder medicine applicator for nasal cavity
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
CA2520032C (en) 2003-04-09 2012-10-16 Nektar Therapeutics Aerosolization apparatus with air inlet shield
CA2520265C (en) 2003-04-09 2015-02-17 Nektar Therapeutics Aerosolization apparatus with capsule puncture alignment guide
KR20120080243A (en) 2003-05-28 2012-07-16 노바르티스 아게 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7621299B2 (en) 2003-10-03 2009-11-24 Cabot Corporation Method and apparatus for filling a vessel with particulate matter
AU2004285595A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
CA2562606A1 (en) * 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquids containing suspended glass particles
ITMI20040795A1 (en) 2004-04-23 2004-07-23 Eratech S R L DRY SOLID PHARMACEUTICAL COMPOSITION ON ITS STABLE WATER PREPARATION AND SUSPENSION PROCESS OBTAINED BY ITSELF
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
BRPI0512326A (en) 2004-06-21 2008-02-26 Nektar Therapeutics compositions comprising amphotericin b, methods and systems
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
EP2431026A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN101005830B (en) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006102494A2 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
PA8672101A1 (en) 2005-04-29 2006-12-07 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
PA8675801A1 (en) 2005-05-19 2006-12-07 Centocor Inc ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
ITMI20051999A1 (en) 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
JP5113328B2 (en) * 2005-11-07 2013-01-09 田辺三菱製薬株式会社 Emulsion, method for producing target substance particles using the same, and pharmaceutical product
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
CA2635692C (en) 2005-12-29 2013-06-18 Centocor, Inc. Human anti-il-23 antibodies, compositions, methods and uses
WO2007086039A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101668544B (en) * 2006-12-26 2013-04-24 株式会社新日本科学 Preparation for transnasal application
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
PL220269B1 (en) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Composite carrier of powdered medicines, method of production the medicine carrier and equipment for production of particles of composite carrier
MX2010012452A (en) 2008-05-15 2011-03-15 Novartis Ag Star Pulmonary delivery of a fluoroquinolone.
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
JP5848607B2 (en) 2008-10-31 2016-01-27 ヤンセン バイオテツク,インコーポレーテツド Scaffold compositions, methods and uses based on fibronectin type 3 domains
CN102238939B (en) * 2008-11-04 2015-05-20 希普拉有限公司 Pharmaceutical aerosol composition
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102596992B (en) 2009-02-12 2015-09-09 詹森生物科技公司 Based on the holder combination thing of III type fibronectin domain, method and purposes
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
AU2010226613B2 (en) 2009-03-18 2013-07-25 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP5671001B2 (en) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド Dry powder formulation and method for treating lung disease
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR20100123240A (en) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 Respiratory administering pharmaceutical agent for treating or preventing respiratory inflammatory diseases and method for treating or preventing the same diseases
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
CN102596176B (en) * 2009-05-29 2017-09-19 珍珠治疗公司 Composition and correlation technique and system through breathing delivering activating agent
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
NZ624569A (en) 2009-09-28 2016-01-29 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CN102811715A (en) * 2009-12-08 2012-12-05 悉尼大学 Inhalable Formulations
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
RU2017144619A (en) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. CASES OF SINGLE-VALVE METALS OF DRY POWDERS FOR INHALATIONS
EP2632437A4 (en) 2010-10-29 2014-03-19 Univ Western Health Sciences Ternary mixture formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2827990A1 (en) * 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
EP2709447A4 (en) * 2011-05-17 2014-10-22 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
AU2013246926B2 (en) 2012-04-13 2016-07-21 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
KR101543507B1 (en) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 A continuous process for preparing microspheres and microspheres prepared thereby
CN105377037A (en) * 2013-05-23 2016-03-02 Az治疗公司 Methods for delivering cromolyn
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
JP2016534063A (en) * 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション Cromolyn derivatives and related imaging and treatment methods
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CN106535889A (en) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 Mast cell stabilizers for lung disease treatment
CN112656780A (en) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 Dry powder formulations for inhalation
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
JP6850524B2 (en) 2014-07-31 2021-03-31 オティトピック インク. Dry powder formulation for inhalation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2841933T3 (en) 2014-10-31 2021-07-12 Univ Monash Powder formulation
JP6395216B2 (en) * 2014-11-13 2018-09-26 国立大学法人大阪大学 Method and apparatus for measuring ultrafine bubbles contained in liquid
GB2542064B (en) 2015-01-20 2020-11-18 Univ California Unit aerosol doses for anticoagulation
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
EP3285753A1 (en) 2015-04-22 2018-02-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
MX2017015504A (en) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Implant placement and removal systems.
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
AU2016364650B2 (en) 2015-12-04 2019-04-04 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PT3386997T (en) 2015-12-09 2021-11-04 Univ Wien Med Monomaleimide-functionalized platinum compounds for cancer therapy
EP3402788A1 (en) 2016-01-15 2018-11-21 Universität Hamburg Flavonoide-type compounds bearing an o-rhamnosyl residue
EP3411030A4 (en) 2016-02-01 2019-09-04 InCarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
EP3416947A1 (en) 2016-02-15 2018-12-26 CeMM - Forschungszentrum für Molekulare Medizin GmbH Taf1 inhibitors for the therapy of cancer
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2017296236A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
AU2017296237A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
CN109922800B (en) 2016-08-31 2023-06-13 通用医疗公司 Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
BR112019005168A2 (en) 2016-09-19 2019-06-11 Mexichem Fluor Sa De Cv pharmaceutical composition, sealed container, metered dose inhaler, and methods for treating a patient suffering or likely to suffer from a respiratory disorder, for improving the stability of a pharmaceutical composition and the aerosolization performance of a pharmaceutical composition global warming potential of a pharmaceutical composition
AU2017328908B2 (en) 2016-09-19 2020-04-02 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3515432B1 (en) 2016-09-19 2021-08-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
CN113288869A (en) 2016-09-19 2021-08-24 墨西哥氟石股份公司 Pharmaceutical composition
MX2019003703A (en) 2016-09-30 2020-08-13 Janssen Biotech Inc Safe and effective method of treating psoriasis with anti-il23 specific antibody.
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolyn compositions for treatment of pulmonary fibrosis
MX2019005443A (en) 2016-11-14 2019-11-21 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Combination of a brd4 inhibitor and an antifolate for the therapy of cancer.
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JP2020519628A (en) 2017-05-10 2020-07-02 インカーダ セラピューティクス, インコーポレイテッド Unit doses, aerosols, kits and methods for treating cardiac conditions by pulmonary administration
IL270686B (en) 2017-05-22 2022-09-01 Insmed Inc Glycopeptide derivative compounds and uses thereof
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
US20210130845A1 (en) 2017-09-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019110139A1 (en) 2017-12-05 2019-06-13 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
BR112020012555A2 (en) 2017-12-20 2020-11-24 Poseida Therapeutics, Inc. vcar compositions and methods for use
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2019230192A1 (en) 2018-03-07 2020-10-08 Poseida Therapeutics, Inc. CARTyrin compositions and methods for use
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
KR20200143413A (en) 2018-04-06 2020-12-23 지렌틴 아게 Bumetanide derivatives for the treatment of hyperhidrosis
MA52590A (en) 2018-05-11 2021-03-17 Janssen Biotech Inc METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
US20230067929A1 (en) 2018-12-17 2023-03-02 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
US11390571B2 (en) 2019-01-03 2022-07-19 Aqua Yield Operations LLC PAMAM dendrimers for fertilizer delivery
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
WO2020210672A1 (en) * 2019-04-12 2020-10-15 Aqua Yield Operations LLC Blended nanoparticle fertilizer delivery
CN110051868A (en) * 2019-04-15 2019-07-26 宝盈联华(厦门)生物科技有限公司 A kind of cabinet sterilizer with silicon-carbon rock, Lei mountain flour
JP7404671B2 (en) * 2019-06-25 2023-12-26 株式会社リコー Porous fine particles and their manufacturing method, and pharmaceutical compositions
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR20220079597A (en) 2019-10-02 2022-06-13 톨레모 테라퓨틱스 아게 Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
AU2020366135A1 (en) 2019-10-16 2022-06-02 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
IL297025A (en) 2020-04-14 2022-12-01 Poseida Therapeutics Inc Compositions and methods for use in the treatment of cancer
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
MX2022016497A (en) 2020-06-25 2023-01-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease.
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
CN111700883B (en) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 Salbutamol sulfate sustained-release inhalation preparation and production process thereof
EP3964497A1 (en) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
EP4208154A1 (en) 2020-09-04 2023-07-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
WO2022079290A2 (en) 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
CN112495316B (en) * 2020-10-20 2021-11-19 大连理工大学 Method for preparing micro-nano gel microspheres based on metastable emulsion
TW202237102A (en) * 2020-12-11 2022-10-01 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutical compositions for pulmonary delivery
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20230156764A (en) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
AR125312A1 (en) 2021-04-07 2023-07-05 Tolremo Therapeutics Ag HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR IMPROVEMENT OF CANCER
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023203172A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1410588A (en) 1971-08-10 1975-10-22 Fisons Ltd Composition
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4147766A (en) 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
WO1989005632A1 (en) * 1983-11-14 1989-06-29 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
WO1986006959A1 (en) * 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
US4950477A (en) 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE69005800T2 (en) * 1989-05-01 1994-05-19 Alkermes Inc METHOD FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES.
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5304125A (en) 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
ATE147976T1 (en) * 1991-01-15 1997-02-15 Hemosphere Inc PROTEIN NANOMATRICES AND PROCESS FOR PRODUCTION
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
JP3507486B2 (en) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド Intrapulmonary administration of granulocyte colony-stimulating factor
SE9101090D0 (en) * 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
JPH05500229A (en) * 1991-04-12 1993-01-21 東レ株式会社 Aerosol formulation of solid polypeptide microparticles and its manufacturing method
ES2084360T3 (en) * 1991-06-10 1996-05-01 Schering Corp FORMULATIONS OF CHLOROFLUOROCARBON-FREE AEROSOLS.
PT717987E (en) * 1991-12-18 2001-12-28 Minnesota Mining & Mfg SUSPENSION FORMULATIONS IN AEROSOL
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE4323636A1 (en) * 1993-07-15 1995-01-19 Hoechst Ag Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
DK0711179T3 (en) * 1993-07-30 2005-02-14 Imcor Pharmaceutical Co Stabilized ultrasound microbubble compositions
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
WO1996009814A1 (en) * 1994-09-29 1996-04-04 Andaris Limited Spray-dried microparticles as therapeutic vehicles
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
EP0806940B1 (en) * 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ATE287703T1 (en) * 1995-04-14 2005-02-15 Nektar Therapeutics POWDERED PHARMACEUTICAL FORMULATIONS WITH IMPROVED DISPERSIBILITY
AU709562B2 (en) 1995-06-07 1999-09-02 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
PT954282E (en) 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
EP1019020A1 (en) * 1997-09-29 2000-07-19 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US11931374B2 (en) 2016-04-15 2024-03-19 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders

Also Published As

Publication number Publication date
YU18300A (en) 2003-02-28
AU756693B2 (en) 2003-01-23
AU9677298A (en) 1999-04-23
KR100589926B1 (en) 2006-06-15
JP4526702B2 (en) 2010-08-18
HRP20000175B1 (en) 2004-06-30
CA2304973A1 (en) 1999-04-08
NO20001618D0 (en) 2000-03-28
BG64816B1 (en) 2006-05-31
JP2014169335A (en) 2014-09-18
AU757337C (en) 2005-11-03
JP2003525842A (en) 2003-09-02
DE69814428D1 (en) 2003-06-12
JP2013199497A (en) 2013-10-03
ES2195408T3 (en) 2003-12-01
AU757153B2 (en) 2003-02-06
CN1272058A (en) 2000-11-01
PL195212B1 (en) 2007-08-31
PL339732A1 (en) 2001-01-02
CA2304973C (en) 2009-11-17
EE04628B1 (en) 2006-06-15
EA200000375A1 (en) 2000-12-25
EA003665B1 (en) 2003-08-28
DK1019022T4 (en) 2010-11-08
JP2001517691A (en) 2001-10-09
ATE238035T1 (en) 2003-05-15
EP1019021A1 (en) 2000-07-19
JP2011116788A (en) 2011-06-16
EA002562B1 (en) 2002-06-27
CZ20001115A3 (en) 2000-09-13
TR200000819T2 (en) 2001-06-21
AU750567B2 (en) 2002-07-25
WO1999016422A1 (en) 1999-04-08
CZ300758B6 (en) 2009-08-05
NO340149B1 (en) 2017-03-13
KR20010030810A (en) 2001-04-16
DE69814428T2 (en) 2004-05-13
IL135126A0 (en) 2001-05-20
EP1019021B2 (en) 2012-12-26
AU1064499A (en) 1999-04-23
KR100575070B1 (en) 2006-05-03
KR20010030787A (en) 2001-04-16
DK1019022T3 (en) 2003-07-28
KR100599634B1 (en) 2006-07-12
JP6100114B2 (en) 2017-03-22
AU1185799A (en) 1999-04-23
DE69813853T3 (en) 2011-05-12
ES2195415T3 (en) 2003-12-01
AU757337B2 (en) 2003-02-20
SK285068B6 (en) 2006-05-04
RS50182B (en) 2009-05-06
NO20001618L (en) 2000-05-19
IS2154B (en) 2006-10-13
EP1019021B1 (en) 2003-09-03
CA2304820A1 (en) 1999-04-08
JP5739197B2 (en) 2015-06-24
NZ503464A (en) 2002-05-31
ATE248583T1 (en) 2003-09-15
EE200000194A (en) 2001-04-16
ES2205560T5 (en) 2013-04-16
PT1019022E (en) 2003-08-29
CA2304975C (en) 2009-06-16
EA200200036A1 (en) 2002-04-25
EP1019022A1 (en) 2000-07-19
HK1031680A1 (en) 2001-06-22
AU9677098A (en) 1999-04-23
CA2304819A1 (en) 1999-04-08
KR100572171B1 (en) 2006-04-19
JP6078498B2 (en) 2017-02-08
CN1169520C (en) 2004-10-06
EP1019022B1 (en) 2003-04-23
DE69813853D1 (en) 2003-05-28
DK1019021T4 (en) 2013-01-07
IL135126A (en) 2006-04-10
EP1019020A1 (en) 2000-07-19
ES2205560T3 (en) 2004-05-01
CA2304819C (en) 2008-04-08
BG104253A (en) 2000-11-30
JP2013216688A (en) 2013-10-24
WO1999016421A1 (en) 1999-04-08
CA2304975A1 (en) 1999-04-08
JP2001517692A (en) 2001-10-09
DE69813853T2 (en) 2004-01-29
HRP20000175A2 (en) 2001-06-30
WO1999016419A1 (en) 1999-04-08
JP2010047615A (en) 2010-03-04
EP1019022B2 (en) 2010-07-28
MEP4108A (en) 2010-02-10
ES2195408T5 (en) 2010-11-25
ATE239447T1 (en) 2003-05-15
IS5415A (en) 2000-03-24
KR20010030801A (en) 2001-04-16
DK1019021T3 (en) 2003-11-10
CA2304820C (en) 2009-06-23
EP1019023B1 (en) 2003-05-07
EP1019023A1 (en) 2000-07-19
KR20010030788A (en) 2001-04-16
SK4492000A3 (en) 2000-09-12
JP2003525841A (en) 2003-09-02
BR9812693A (en) 2000-08-22
JP5372306B2 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
AU757337C (en) Perforated microparticles and methods of use
US7306787B2 (en) Engineered particles and methods of use
US9554993B2 (en) Pulmonary delivery particles comprising an active agent
US7628978B2 (en) Stabilized preparations for use in metered dose inhalers
AU2006200277B2 (en) Perforated microparticles and methods of use
MXPA00003105A (en) Perforated microparticles and methods of use
MXPA00003096A (en) Stabilized preparations for use in metered dose inhalers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135126

Country of ref document: IL

Ref document number: P-183/00

Country of ref document: YU

Ref document number: 98809603.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 09219736

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY A NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 503464

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 10644/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2304819

Country of ref document: CA

Ref document number: 2304819

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4492000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2000-1115

Country of ref document: CZ

Ref document number: P20000175A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2000 513557

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/003105

Country of ref document: MX

Ref document number: 1020007003367

Country of ref document: KR

Ref document number: 2000/00819

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1998953220

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200000396

Country of ref document: VN

Ref document number: 200000375

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998953220

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-1115

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007003367

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998953220

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020007003367

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 10644/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2009-244

Country of ref document: CZ